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We have characterised two biologically important protein complexes. Firstly, we 
have captured and analysed a complex of the biotin protein ligase (BPL) and the 
biotinylation domain (BCCPA67) of acetyl-CoA carboxylase (ACC) from the 
hyperthermophile Aquifex aeolicus. The genes encoding both BPL and BCCPA67 
were overexpressed in E. coli and purified to homogeneity. Isolation of milligram 
amounts of both recombinant proteins allowed us to perform kinetic analysis of the 
BPL enzyme with its substrates using steady-state techniques. Furthermore, a 
chemically crosslinked complex of BPL and BCCPA67 was isolated and a 
comprehensive mutational study has identified a salt bridge between the two proteins 
which is important for heterodimerisation. The role of a conserved 'thumb-like' 
motif in BCCPA67 was also investigated by mutagenesis. Our results suggest an 
interaction between the biotin moiety and the 'thumb' reduces the propensity of BPL 
and holo-BCCPA67 to heterodimerise. 
In a separate project we have investigated the relationship between the tertiary 
structure and biological activity of a novel 13-defensin related peptide (Defri). 
Defensins are cationic antimicrobial peptides which have a characteristic six cysteine 
motif and are important components of the innate immune system. Defri is a 
polymorphism of mouse f-defensin 8 and contains only 5 cysteines. Against a panel 
of pathogens, we found that oxidised synthetic Defri had significantly higher activity 
than its reduced form, and the oxidised and reduced forms of its six-cysteine 
containing analogue (Defri Y5C). Using non-denaturing gel electrophoresis and high 
iv 
Abstract 
resolution Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR 
MS) we observed Defri and Defri Y5C dimers. Two complementary fragmentation 
techniques- collision induced dissociation (CD) and electron capture dissociation 
(ECD) - revealed that Defri Y5C dimers form by non-covalent, weak association of 
monomers which contain three intramolecular disulfide bonds. In contrast, Defri 
dimerisation is mediated by an intermolecular disulfide bond. Proteolysis and peptide 
mass-mapping revealed that Defri Y5C monomers fold with the canonical 3-
defensin disulfide bond connectivity whereas oxidised Defri is a complex mixture of 
dimeric isoforms with as yet unknown inter and intramolecular connectivities. We 
conclude that, compared with its six-cysteine analogue, the enhanced activity and 
stability of this mixture of Defri dimeric isoforms is due to the presence of an 
intermolecular disulfide bond. 
In a related project, we have developed a method for the recombinant expression of 
defensins in E. coli. This method has been successfully used to express and purify 
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Modification 
Chapter 1: Biotinylation 
1.1 	The structure and properties of biotin 
Biotin (Vitamin H, Co-enzyme R) is a water-soluble B vitamin produced in small 
quantities by microorganisms and plants. Unlike bacteria, mammals are unable to 
synthesise the cofactor and thus rely on dietary intake to satisfy their biotin 
requirements. 
Biotin was first isolated by Kogl and Tönnis in 1936 (1), who isolated 1.1 mg 
of the vitamin as its methyl ester from more than 500 pounds of egg yolk and its 
structure was later deduced by du Vigneaud et al. (2). X-ray analysis revealed that 
the molecule consists of an imidazolidone ring fused to a tetrahydrothiophene ring 
with a valeryl side chain. Of the eight optical active forms only one, D-(+)-biotin, is 
biologically active (Fig 1.1). 
Today, biotin is widely used along with avidin and streptavidin, the specific 
biotin binding proteins, in the analysis biochemical phenomena. The chemical or 
enzymatic biotinylation of biomolecules allows easy detection/purification from 
complex mixtures using avidin affinity, and has great utility in many areas of 
scientific research. A structural and mechanistic understanding of the enzymes which 
carry out the post-translational addition of biotin to proteins may aid in the design of 
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Figure I.I. D-(+)-biotin. The biologically active isoform of biotin. 
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1.2 	Biotin-dependant enzymes - The biotin enzyme family 
In vivo biotin is utilised as a coenzyme in numerous essential enzymatic 
carboxylation reactions (3). The cofactor is covalently bound to these enzymes via an 
amide linkage between its valerate side chain and the F--amino group on a specific 
lysine residue of the enzyme (4). The biotin prosthetic group then acts as a 'swinging 
arm" and is used to transfer activated CO2 between active sites within the enzyme 
The small group of biotin dependant enzymes share a remarkably similar 
catalytic mechanism. The first step involves fixation of CO2 by biotin, which occurs 
specifically at FN to form a carboxybiotin complex. This is followed by 
decarboxylation of carboxybiotin and proton transfer to different acceptor substrates 
 
Biotin dependant enzymes are involved in a diverse range of biochemical 
processes and can be divided into three classes (Table 1.1). Class I enzymes are 
ATP-dependant carboxylases which transfer CO2 from hydrogen carbonate to 
specific acceptors, and are exemplified by acetyl-00A carboxylase (ACC, see section 
1.3). Class II and III enzymes are transcarboxylases and decarboxylases respectively, 
and do not require ATP. In these enzymes the CO2 unit is transferred from either an 
acyl derivative or keto-ester to the enzyme before being transferred to either an 
acceptor or released as free CO2. To date, decarboxylases have only been found in 
anaerobic bacteria and employ the free energy of decarboxylation to pump Na 
across a membrane. The resulting Na gradient is then utilised for the synthesis of 
ATP (7,8). 
Class Enzyme Reaction Biochemical Role 
Carboxylases Pyruvate Carboxylase Pyruvate to Oxaloacetate Gluconeogenesis, lipogenesis 
Acetyl-CoA Carboxylase Acetyl-CoA to Malonyl-CoA Fatty acid biosynthesis 




methylglutaconyl-CoA Catabolism of leucine 
Geranyl-CoA Carboxylase Geranyl-00A to Carboxygeranyl-CoA Catabolism of isoprenoids (microbial) 




Methylmalonyl-CoA and Pyruvate to 
oxaloacetate and Propionyl-CoA 





Methylmalonyl-CoA to Propionyl-CoA and 
CO2 Lactate fermentation (Micrococcus lactis) 
Oxaloacetate Decarboxylase Oxaloacetate to Pyruvate and CO2 
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1.3 	Acetyl-00A Carboxylase (ACC) 
1.3.1 The Biological Role of Acetyl-CoA Carboxylase 
Acetyl-00A carboxylase (ACC) catalyses the conversion of acetyl-00A to malonyl-
CoA, the first committed step of fatty acid synthesis (see Fig. 1.2) (9). The malonyl-
CoA is then used as a unit for repeated rounds of condensation by fatty acid 
synthases (FAS). 







Figure 1.2. The carboxylation of acetyl-CoA. This key metabolic process is 
catalysed by AAC. 
Two physically distinct types of enzyme are found in nature. Heterodimeric ACCs, 
usually composed of four subunits, are found in prokaryotes; and homomeric ACCs 
consisting of a single large polypeptide are found in eukaryotes. The majority of 
plants express both types of ACC (10). Heterodimeric ACC is expressed in the 
plastid and is used in de novo fatty acid biosynthesis, whereas the ACC expressed in 
the plant cytosol is a homomeric and is required for fatty acid elongation and the 
biosynthesis of several secondary metabolites- examples include flavonoids and 
anthocyanins (11). In mammals, ACC exists in two isoforms, ACC I and ACC2, 
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which are encoded by different genes. ACC1 is a cytosolic enzyme and regulates fat 
synthesis in lipogenic tissues, whereas ACC2 is associated to the mitochondrial 
membrane and controls the rate of lipid oxidation (12,13). In addition to fatty acid 
production, the malonyl-CoA produced by bacterial ACCs is also the building block 
for a variety of natural products - such as the vitamins, biotin and lipoic acid (14,15); 
polyketide antibiotics (16); and the acylated homoserine lactone pheromones used as 
quorum sensors (17). Furthermore, malonyl-CoA has been shown to play major roles 
in regulating the expression of other FAS enzymes (18). 
Since ACCs play critical roles in the synthesis and regulation of fatty acid 
biosynthesis they have become attractive target areas for the development of novel 
therapeutics treatments for obesity, metabolic syndrome, type 2 diabetes, and 
antibiotic treatment of bacterial infection (19-23); and the first report of a potent 
bacterial ACC inhibitor was published this year (24). 
1.3.2 Heterodimeric Acetyl-CoA Carboxylases 
Heterodimeric ACCs found in bacteria and plant plastids are multi-subunit enzymes 
consisting of a biotin carboxylase (BC), a carboxyltransferase (CT), and a biotin 
carrier protein (BCCP). They are exemplified by the ACC from the bacterium E. coli 
(Table 1.2) (25). The enzyme complex readily dissociates in solution, however each 
subunit retains the ability to catalyse distinct partial reactions (9), and it is clear that 
the overall ACC reaction proceeds via two steps (Fig. 1.3). The first step involves the 
carboxylation of biotin prosthetic group which is attached to the BCCP subunit and is 
catalysed at the active site of the BC subunit. The activated CO2 is then transferred to 
the active site of the CT subunit which catalyses the transfer of CO2 to acetyl-00A. 
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Hence, ACC catalyses the formation of a new carbon-carbon bond and the energy 
required for this new bond is derived from the hydrolysis of ATP (6). 
Subunit Encoding gene Monomeric Solution Form 
Protein MW (Da) 
Biotin Carboxylase (BC) accC 49.4 Dirtier 
Carboxyltransferase, a subunit accA 35.1 Dimer plus dimer 
(CT-(X) of CT-0 
Carboxyltransferase, b subunit accD 33.2 Dimer plus dimer 
(CT-13) of CT-a 
Biotin Carboxyl Carrier Protein accB 16.7 Tetramer 
(BCCP) 
Table 1.2. Subunits of E. coli ACC. The above table outlines the subunit 
constituents of E. co/i ACC. Together the homodimeric BC, the heterodimeric CT 
and the tetrameric BCCP would constitute an enzyme with an overall mass of 
>300kDa. However, isolation of such a complex has not been achieved. 
ATP * KCO3 	 ADP • P1 








- BCCP BCCP 	 S 
Biotin Cntbooyl Carrier Protein BCCP (o*.B)J 
Cnrbooykr.nofnroon(CT- 	(o**A) nnd CT- 
liCoA 
Molooyl.CoA 	 AotyI.CoA 
COOH 
Figure 1.3. The two-step reaction mechanism of AAC. The covalently bound 
biotin of BCCP was as a carrier of CO2 and shuttles the carboxylate moiety between 
the BC and CT subunits. 
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1.3.3 The E. coil Biotin Carboxyl Carrier Protein 
The biotin carboxyl carrier protein (BCCP) subunit of ACC has been extensively 
studied. The full-length protein is 156aa long and was found to be difficult to work 
with, so most studies have been carried out using an 82aa C-terminal fragment of the 
protein (which contains the biotin domain). Consequently very little is known of the 
structure and function of N-terminus. It is thought to mediate dimerisation and 
interact with the other subunits of ACC. 
A. 










Figure 1.4. The NMR structures of both apo- (A) and holo (B) E. ccli BCCP. The 
biotinyl-domain of E.coli BCCP consists of a 3-barrel with the biotin moiety exposed 
on a tight 3—turn. Notice the characteristic thumb region of BCCP which is close in 
space to the active site. (PBD codes 2BDO and 3BDO). 
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The structure of the biotin domain has been studied by both NMR and X-ray 
crystallography and is a remarkably symmetrical structure consisting of two sets of 
four antiparallel 13 sheets that form a flattened 13-barrel (Fig. 1.4) (26-28). The biotin 
cofactor is covalently attached to Lys122 which is exposed on a tight 3-turn at one 
end of the molecule, with the N- and C-terminals close together at the other. The 
active lysine residue is situated in a highly conserved biotinylation motif (Ala-Met-
Lys-Met) (29,30). The biotin domain of BCCP shows striking similarity to the lipoic 
acid-modified domains of pyruvate dehydrogenases. Elegant studies by Reche and 
Perham have demonstrated that specific BCCP mutants can be lipoylated in vitro, 
suggesting these two carrier proteins share a common evolutionary origin (31). 
However, E. coli BCCP contains a "thumb-like" protrusion, comprising residues 94-
101, which is not found in the lipoyl domain. It has been demonstrated that residues 
in the "thumb" interact with the biotin ring, and the "thumb" region becomes less 
mobile upon biotinylation of the protein, suggesting the thumb plays a role in 
orientating the biotin moiety in space (32). Indeed, the "thumb' is required for the 
acetyl-CoA carboxylation reaction in vivo (33). 
Heteronuclear NMR studies of the apo- and holo-forms of the E. coli BCCP 
domain indicate that there are no major conformation changes accompanying post 
translational modification. However, dynamic changes have been noted, with some 
tightening of the structure around the "thumb" and more favourable side-chain 
packing (27,28,34). This change in dynamics explains why Cys 116 can react with 
thiol reagents in the apo- but not the holo-form of biotinyl domain and why apo-
BCCP is more susceptible to limited proteolysis (35). 
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1.3.4 Biotin Carboxylase (BC) 
1.34.1 BC Structure 
The biotin carboxylase (BC) subunit of ACC catalyses the carboxylation of the biotin 
uriedo ring, a reaction obligatory in all biotin-dependant carboxylases (6). The 
crystal structure of the BC subunit of ACC from E. coli has been solved to 1.9 A and 
consists of dimers containing three domains (Fig. 1.5) (36,37). The N-terminal 
domain forms a dinucleotide binding motif consisting of five strands of parallel P-
sheets flanked on either side by a-helices. The"B-domain" extends from the main 
body of the subunit where it folds into two alpha-helical regions and three strands of 
f3-sheet. The C-terminal domain forms part of the globular portion of the protein and 
contains an eight-stranded antiparallel 3-sheet, a small three stranded antiparallel f3-
sheet and seven a-helices. The proposed active site pocket is located between the B-
and C-domains and is enclosed by the residues His 209-Glu 211, His 236-Glu 241, 
Glu 276, Ile 287-Glu 296, and Arg 338. The active sites are located away from the 
dimer interface and are separated by 62 A. However, it has been found that the BC 
catalytic activity is dependant on the presence both subunits and the two subunits 
must be in communication during catalysis (38). More recently the structure of a BC 
mutant with ATP bound within the active site has been published, revealing the 
subunit belongs to the ATP-grasp superfamily (39,40). The crystal structure reveals 
that upon ATP binding the enzyme undergoes a large conformational change and the 
"B-domain" rotates by approximately 45° to cover the active site. Residues Lys-1 16, 
His-236 and Glu-201 are highlighted as important for nucleotide binding, consistent 
with site directed mutagenesis data (41). Modelling studies superimposing structures 
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of the BC domain with biotin and ATP bound separately have revealed the relative 
orientation of biotin and ATP within the active site. The 'y-phosphate of ATP was 
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C. Figure 1.5. The crystal structure of E. coli 
p 	 BC subunit. A. Apo-BC. The BC subunit is 
His 236 'N dimeric and each monomer contains 3 
domains. One monomer is shaded grey, 
while the second monomer is coloured to 
	
, I 	 highlight the 3 distinct domains. The N- 
ATP 	
terminal domain is shaded green, the B- 
domain is shaded blue, and the C-terminal 
domain is shaded gold (PBD code 1DV1). B. 
A BC mutant (E288K) with ATP bound. 
Notice the large rotation of the B-domain 
Lys 116 	upon ATP binding (PBD code 1DV2). C. 
Glu 201 	
" 	Residues involved in ATP binding. 
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1.3.4.2 BC Mechanism 
Inhibition studies were performed in 1999 to probe the mechanism of BC, using an 
inhibitor of BC which incorporated structural aspects of all three substrates: ATP, 
biotin and bicarbonate (42). Results suggest that the reaction proceeds via an 
ordered addition of substrates, with ATP binding first followed by bicarbonate and 
biotin (43). Product release was shown to proceed with carboxybiotin released first, 
followed by ADP and then phosphate. 
	
O 	0 
HCO3 + MgATP 	 HO/OLOH 
0 	0 	 HO 
11 
HO/O 	OH 
HO 	 0 
-02C" J,  
NH 
BCCP 	 H 	 BCCF 
Figure 1.6. The chemical mechanism of BC. The carboxylation of biotin proceeds 
via the formation of carboxyphosphate. This is followed by direct attack on the 
carbon of carboxyphosphate by the IN of biotin. 
The chemical mechanism of BC is thought to begin with the production of 
carboxyphosphate intermediate (Fig. 1.6)- labelling studies have demonstrated that 
one oxygen atom from bicarbonate is channelled to the phosphate product, indicating 
that bicarbonate and ATP are involved in a covalent interaction (44). This is also 
consistent with the observation that the catalytic cleavage of ATP by BC only 
requires bicarbonate (i.e. BC has bicarbonate dependent ATPase activity) (45). To 
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date however, the carboxyphosphate intermediate has not been trapped and 
characterised. Very little is known about the reaction of carboxyphosphate with 
biotin, but by comparison with other members of the ATP-grasp superfamily it is 
believed that there is direct attack on the carbon of carboxyphosphate by the IN of 
biotin (Fig 1.6). For this to occur, the carboxylation of biotin requires two key 
structural elements: a base for the abstraction of the proton from IN of the ureido 
ring; and an amino acid to stabilise the negative charge of the enolate anion. 
However, exhaustive mutational analysis of BC and other ATP-grasp enzymes have 
been unable to identify amino acid residues which fulfil these roles (41,46-48). It 
may be possible that the process involves substrate-assisted catalysis. It is known that 
the transfer of CO2  to biotin only occurs if one of the phosphate oxygen atoms is 
protonated, which suggests that the phosphate oxygen atom could acts as a catalytic 
base to abstract the IN proton. Interestingly, BC will accept both biotinylated-BCCP 
and free biotin as substrates. 
Furthermore, the bicarbonate dependent ATPase activity displayed by BC is 
dramatically increased by the presence of both biotin or holo-BCCP (47,49). Thus, 
the hydrolysis of ATP is synergistic with the binding of another substrate (biotin) - a 
phenomenon known as substrate-induced synergism (50). 
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1.3.5 Carboxyltransf erase (CT) 
1.3.5.1 CT Structure 
Carboxyltransferase (CT) catalyses the transfer of CO2 from carboxybiotin to acetyl-
CoA. Little is known about the structure of E. co/i CT; however, the structure of the 
CT domain from the yeast ACC has recently been determined to 2.7 A resolution, 
and is dimeric (Fig. 1.7) (51). The crystal structure shows that each CT domain 
molecule comprises two subdomains (N and C domains) that are intimately 
associated with each other. It is interesting to note that the N- and C- terminal halves 
show significant sequence homology to the f3 and a subunits of bacterial CTs. The N 
and C-domains of yeast CT have little sequence identity yet display similar folds, 
with a central 13-3—a superhelix. The fold is characteristic of the crotonase/CIpP 
superfamily, many members of which are acyl-CoA-dependant enzymes that catalyse 
various reactions involved in fatty acid 3-oxidation (52-55). Co-crystallisation of the 
enzyme with CoA has allowed the identification of the active site, which is at the 
interface of the dimer and contains residues from the N- and C-domains of both 
monomers. The CoA molecule associates with the N-domain and the Ni and N6 
atoms of the adenine base are recognised by hydrogen bonds to the polypeptide 
chain. The phosphate groups are located near three conserved basic cationic residues 
(Arg'733, Lys 2034"  Arg2036 ). It is postulated that biotin binds at a small 3-sheet in the 
C-domain of the other monomer in the active site. 
Further structural studies of yeast CT domain have revealed the molecular 
details of inhibitor binding. The herbicide haloxyfop has been captured in the active 
site (56). Unexpectedly, haloxyfop binding requires large conformational changes 
within the active site, forming a large hydrophobic pocket in the enzyme. Residues 
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known to affect herbicide sensitivity are located in the effected region. The Pfizer 
lead compound, CP-640186 (an inhibitor of mammalian ACC) has also been co-
crystallised with yeast CT (57). This inhibitor displays a distinct mechanism of 
inhibition and it is thought that it binds at the putative biotin-binding site. 
COOH 
Figure 1.7. The crystal structure of the CT domain of yeast ACC including 
bound CoA. The yeast CT is dimeric, with each of the monomers split into two 
distinct subdomains. One CT monomer is shaded in grey, while the other monomer is 
shaded to highlight the N-terminal (blue) and C-terminal (gold) subdomains. The 
binding pocket is highlighted by the presence of CoA in the crystal structure (PBD 
code 10132). 
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1.3.5.2 CT Mechanism 
The chemical mechanism of CT was originally probed by determining the pH rate 
profile of the reverse reaction (58). Initial velocity patterns and inhibition studies 
have revealed an ordered kinetic mechanism of CT, with maionyl-00A binding 
before carboxybiotin (25). Acid-base catalysis is required in this process because the 
proton on the Ni' of biotin must be removed to allow for carboxyl transfer from 
malonyl-00A. This study demonstrated that a single ionising group on the enzyme, 
with a pKa of 7.5, must be unprotonated for catalysis. It was postulated that this 
group was a cysteine residue which acts as the base to remove the proton from the 
Ni' of biotin. However, the recent structural evidence shows no cysteine in the active 
site. Furthermore, mutational analysis of the active site has revealed that no residue 
acts as a general base and it is now thought that the Ni' atom of biotin itself 
functions as the general base (51). This is in direct contrast with the crotonases, 
where an acidic sidechain of the enzyme is required for catalysis. 
The transfer of the carboxyl from carboxybiotin to acetyl-00A can occur by 
either a stepwise mechanism (protein abstraction from the methyl group of acetyl-
CoA occurs before carboxyl transfer) or by a concerted mechanism (proton removal 
is simultaneous to carboxyl transfer). To date, studies to distinguish between the two 
mechanisms have not been performed with CT. However, results using pyruvate 
carboxylase suggest that the mechanism is stepwise (59). 
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1.3.6 A Working Model of an ACC complex 
Extensive structural and biochemical studies of the ACC subunits have allowed a 
working model for the ACC complex to be proposed. Investigation of BC revealed 
that dimer formation is required for activity, even though the active sites for from the 
dimer interface (38). This observation suggested a model in which the two subunits 
of BC are mechanistically linked in a fixed cycle and can not catalyse carboxylation 
simultaneously. Instead, the two subunits alternate catalytic reactions, with one site 
performing catalysis while the second is releasing product. This mechanism would 
require two BCCP molecules to be well separated from each other, as each would 
interact with a different BC active site. However, a separate study of BCCP implied 
that at least two biotinyl-domains interact during catalysis (33). It is now believed 
that the ACC complex contains 2 BC and 4 BCCP subunits, with a BCCP dimer 
interacting with each BC molecule. Indeed, a recent analysis of the BC-BCCP 
complex has shown this stoichiometry to be correct (60). 
The structural interactions of the BC-BCCP complex are still unknown but 
have been shown to involve the N-terminal residues of BCCP (60). Future studies 
will no doubt concentrate on elucidating these interactions and analysing the CT-
BCCP complex in the hope of building a clearer picture of the mechanism of the full 
ACC complex. 
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1.4 	Biotin Protein Ligase (BPL) 
1.4.1 The Biotinylation Reaction 
The enzyme biotin protein ligase (BPL), also known as holocarboxylase synthase 
(HCS), is responsible for attaching biotin to the specific lysine residue at the active 
site of newly synthesised biotin dependant enzymes. This is a post-translational 
modification of exceptional specificity (61), In E. coli, only a single lysine within the 
BCCP subunit of ACC is recognised and biotinylated by endogenous BPL. 
Enzymatic biotinylation is an ATP-dependant two-step reaction resulting in the 
formation of an amide linkage between the carboxyl group of biotin and the E-aminO 
group of lysine (Fig. 1.8). In the first step, the carboxyl group of biotin is activated 
by the formation of an adenylate. This is subsequently subjected to nucleophilic 
attack by the active lysine residue of the biotinyl domain forming the biotinylated-
species. This reaction is closely related to that of the activation of the amino acyl-
tRNA synthetases (62). 
E. coli BCCP is 156-amino acids in length, with only the C-terminal 82, the 
biotin binding domain, required for efficient enzymatic biotinylation (63). Similarly 
sized domains are recognised by BPLs in carboxylases from other bacteria (64), 
yeast (65), and mammals (66). Primary structure analysis of these biotin binding 
domains reveals a very high degree of similarity, with the active lysine residue 
located in a highly conserved (AIV)MKM motif. Furthermore, biotin-accepting 
enzymes can be recognised and biotinylated by BPL derived from widely divergent 
species (64,67-69), indicative of a process highly conserved throughout evolution. 
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HN 'J~ NH 
_( S 
Biotin 	 ATP 
HN )~ NH 
Biotinyl-5'-AMP 







Figure 1.8. The biotinylation of BCCP. This two-step reaction is catalysed by BPL. 
Firstly, the carboxyl group of biotin is activated by the formation of an adenylate. 
This is subsequently subjected to nucleophilic attack by the active lysine residue of 
the BCCP biotinyl domain forming the biotinylated-species. 
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1.4.2 Enzyme Classification 
Genetic analyses indicate that each organism has a single BPL-encoding gene, which 
is responsible for processing all biotin-dependant enzymes. The enzyme is required 
for health growth and deletion of the bpl gene has been shown to be lethal. BPL/ 
HCSs have been grouped into four classes which all share a highly conserved central 
catalytic domain but differ at each termini (Fig. 1.9). Class I and II enzymes are 
derived from bacteria. They both have a C-terminal domain of unknown function but 
differ at the N-terminus, with class II enzymes displaying an N-terminal DNA 
binding domain. Eukaryotic BPLs fall into Classes III and IV, they vary in size from 
the prokaryotic enzymes, often having larger N-terminal domains which have little or 
no similarity to bacterial enzymes. None of the eukaryotic proteins contains 
sequences that suggest any DNA binding activity. The role of this N-terminus is 
unclear, but an N-terminally truncated BPL from the yeast Saccharomyces cerevisiae 
shows a dramatic reduction in enzyme activity (65). It has been speculated recently 
that this domain my play a part in acceptor-substrate recognition (70). 
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Figure 1.9. Biotin Protein Ligase Classification. BPL enzymes can be divided into 
four separate classes based on there tertiary structure. Bacterial BPLs are members of 
classes I and II, whereas classes III and IV are eukaryotic BPLs. 
1.4.3 E. coil Biotin Protein Ligase (BirA) 
1.4.3.1 The Bifunctional Nature of BirA - Controlling Biotin Biosynthesis 
Genetic and biochemical studies have been performed on BPLs from several species, 
of which the best characterised is the BPL from E. co/i, BirA (BC 6.3.4.15). This 
35.3 kDa class II BPL is bifunctional, acting both as a biotin ligase and as a DNA-
binding repressor of the biotin operon (71-73). The biotin operon of E. co/i (bio) 
contains five genes that are involved in biotin biosynthesis, with the operator located 
between bioA and bioB (74). This repressor function is triggered by the formation of 
the intermediate biotinyl-AMP, which acts as the corepressor, with the BirA-
biotinyl-AMP complex binding to the bio operator as a dimer. Although biotinyl-
AMP is the corepressor, intracellular biotin levels influence gene expression due to 
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the ordered addition of substrates to BirA, with biotin binding first. The BirA-
biotinyl-AMP complex is thermodynamically very stable which results in very low 
concentrations of both unligated BirA and biotin within the cell (75). The switch 
from biotin ligase to a repressor reflects competition between apo-BCCP and 
operator DNA for the BirA-biotinyl-AMP complex. Thus, biotin synthesis is 
intimately linked to both biotin and apo-BCCP concentrations in vivo. This elegant 
biochemical control system ensures that when all apo-BCCP has been biotinylated 
the stable BirA-biotinyl-AMP complex will bind to the bio operator and turn off the 
transcription of the biotin biosynthetic genes (since no additional biotin biosynthesis 
is required). 
Studies of a second class II BPL from the bacterium Bacillus subtillis have 
revealed a similar role for BPL in regulating biotin biosynthesis (76,77). 
Furthermore, comparative genomics suggests that the existence of class II BPL 
within a genome strictly correlates with the presence of putative BPL-binding sites 
upstream of biotin operons (78). 
1.4.3.2 Structure of BirA 
Despite their importance in all living cells, the structure of only a single BPL, BirA 
from E. co/i, has been determined. The crystal structure of BirA has been resolved to 
2.3 A in both the monomeric form and the DNA binding holo-dimeric form (79-8 1). 
The monomer consists of three distinct domains and typifies class II BPLs (Fig 1.10). 
The N-terminal domain has a helix-turn-helix fold characteristic of major groove 
DNA binding proteins, used in bio repression to bind to the operator of the bio 
operon. The central catalytic domain has been shown to contact biotin, with the 
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complete loop encompassing residues 110-128 enclosing the cofactor. Located 
within this loop is a highly conserved glycine rich sequence "5GRGRXG'2° which 
was first proposed as the ATP binding site, however recent characterisation of single-
site mutants suggest that the motif functions in biotin and biotinyl-AMP binding 
(82). In a recent study, a single mutation within this conserved sequence was shown 
to have a dramatic effect on the activity of BirA. An RI 18G BirA mutant had non-
specific activity, displaying a high level of promiscuous protein biotinylation (83). In 
effect, the removal of Arg 118 led to the loss of the specificity of the enzyme for 
BCCP. The authors explained this phenomenon by postulating that the mutant 
releases biotinyl-AMP from the active site; and the increased non-specific activity is 
non-enzymatic, but results from chemical acylation from the released active 
intermediate. Thus, Arg 118 is linked with the binding of biotinyl-AMP. 
Little is known about the function of the small C-terminal domain, although 
recently residues within this domain have been shown to interact with BCCP. 
Perhaps more interestingly, an arginine residue in the C-terminus (R317) has been 
proposed to contribute to the interaction with ATP even though it is some distance 
from the proposed catalytic domain (84). 
Binding of the intermediate by the BirA monomer results in ordering of 
flexible loops of the central domain, resulting in more favourable energetics of 
dimerisation (85,86). However, the resulting interactions are only weak and dimer 
formation may only occurs on the DNA surface (81). Recent studies have revealed 
the half life of this DNA-protein complex to be approximately 400 seconds (87). In 
the dimeric structure the 3-sheets in the central domain of each monomer are 
arranged side by side, forming a single, seamless antiparallel n-sheet. The protruding 
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N-terminal DNA binding domains of the holo-dimer are then thought to contact two 
12 bp sequences at the termini of the operator sequence (88). 
V, 
Figure 1.10. The structure of the E. coli BirA dimer with biotin bound at each 
active site. One subunit is highlighted as follows- N-terminal DNA-binding domain 
(pink), catalytic domain (gold), and C-terminal domain (blue). (PDB codes 1HXD) 
1.4.3.3 The BirA-BCCP Complex 
The elucidation of the three-dimensional structures E. coli BirA (79-81) and E. coli 
BCCP (26-28) has allowed a model to be constructed of the BirA/BCCP complex 
(89). The key feature of this proposed interaction is that it utilises the same surface 
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loop in BirA necessary for homo-dimerisation. The proposed model suggests that the 
complex is formed by hydrogen bonding of 3-strands from each protein, creating an 
extended 13-sheet (Fig. 1.11). The difference between the two interactions is the 
relational orientation of the two domains. In the homodimer, strand Va! 1 89-Lys 194 
from the first BirA subunit forms an antipara!lel 13-sheet interaction with the same 
residues in the second subunit. In contrast, in the heterodimer the same stand of BirA 
participates, but the resulting 13-sheet interaction is parallel. This resulting mutually 
exclusive protein-protein interaction is used to explain the regulation of biotin 
biosynthesis by in vivo concentrations of apo-BCCP (89). 
Figure 1.11. A model of the E. cvii BirA:BCCP complex. BirA is shown in silver 
with biotin bound at the active site. BCCP is shown in gold. Notice the parallel 
sheet interactions between BirA and BCCP (PDB code 1K67). 
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1.5 Aims 
To gain further insight into the detailed protein-protein interactions that control 
biotin transfer we have analysed the reaction between BPL and apo-BCCP from the 
hyperthermophilic organism Aquifex aeolicus (90). This bacterium grows optimally 
at 95 °C on hydrogen, oxygen, carbon dioxide and mineral salts. Enzymes from 
extremophiles (extremozymes) are offering new opportunities for biocatalysis as a 
result of their extreme stability (91-93). Analysis of the A. aeolicus genome 
identified bpl and accB homologues; the predicted BPL is from the group I class 
(which also includes M. tuberculosis) which lack the N-terminal DNA-binding 
domain found in E. coli BirA (94). In E. coli, we have expressed active A. aeolicus 
BPL, the biotin-binding domain of BCCP as a six histidine N-terminal fusion 
(BCCPM7) as well as a series of BCCP mutants. Biotinylation of apo-BCCPA67 by 
BPL was most efficient at 70 °C and we have carried out kinetic analyses and 
proteolysis experiments at this temperature. Furthermore, we describe the isolation 
and characterisation of a chemically crosslinked BPL:BCCPM7 complex for the first 
time. This study is the first detailed characterisation of a class I BPL and the first 
investigation of a post-translational modification complex from a hyperthermophilic 
organism. 
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aeo!icus. 
Chapter 2: Aquifex aeolicus BPL 
2.1 	Analysis of the A. aeolicus genome 
The complete genome sequence of Aqufex aeolicus consists of 1512 predicted open 
reading frames (90). We performed a BLAST search on the complete genome and 
identified two ORFs of 233aa and 154aa with high sequence homology to E. coli 
BirA (20.9% identity, 35.2% similarity) and BCCP (33.8% identity, 46.9% 
similarity) respectively. The pairwise sequence alignments generated by CLUSTAL 
W are shown in figure 2.1 and these enabled us to design PCR primers to clone the 
A. aeolicus BPL and BCCP genes (95). We noted from this initial analysis that the A. 
aeolicus BPL differs from the E. coli BirA in that it lacks an N-terminal DNA-
binding domain which places it in the group I class of BPLs along with those from 
M. tuberculosis and T. maritima (94). 
Previous studies on full-length E. coli BCCP (156 aa) revealed that the 
protein forms a tight complex with a second acetyl-00A carboxylase subunit in 
solution and complicates biochemical studies (96). In most cases, the biotin carrier 
domain of biotin-containing enzymes is located at the C-terminal end of the 
carboxylase, with the biotinyl-lysine about 35 residues from the C-terminus. Deletion 
studies revealed that a minimum of 75-80 residues of the BCCP is recognised by E. 
coli BirA. The truncated form of the E. coli BCCP containing 87aa has been used in 
biochemical and structural studies (BCCP-87) and here we expressed A. aeolicus 
BCCP lacking 67 residues from the N-terminus (BCCPM7, Fig. 2.1) with an N-
terminal six histidine-tag (total length 96aa). The homology scores between the A. 
aeolicus BCCPL67 and E. coli BCCP-87 domains are 51.9% identity and 69.6% 
similarity (Fig. 2.1). 
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Figure 2.1. Sequence alignments of BCCP (A) and BPL (B) from E. coli and A. 
aeolicus. Pairwise alignment was prepared using CLUSTAL W. 
The (1) shows the start residue of BCCP-87 domain used in previous studies. 
The (1') shows the start codon of the BCCPA67 domain. The biotinylated lysine 
residue is highlighted in blue. Residues highlighted in red were suspected 
crosslinking residues (see section 3.2). Secondary structural elements of the BCCP-
87 domain are indicated and the (*) indicates the "thumb" region. 
The (-) and (+) indicate the pairs of disordered surface loops which are close in 
space in the E. coli BirA structure. The ($) indicates the trypsin cleavage sites of A. 




Chapter 2: Aquifex aeolicus BPL 
2.2 	Cloning, expression and purification of BPL 
The A. aeolicus bpl gene was amplified by PCR using the primers BPLfor, BPLrev 
and A. aeolicus genomic DNA as a template. The resulting product was cloned into 
the plasmid pCR2.1 (Invitrogen). DNA sequencing confirmed the previously 
published gene sequence, with the exception of a single base change at position 325 
(1 —C), which results in the substitution of a cysteine residue with an arginine. 
Subsequently the bpl gene was cloned into a pET-28a expression vector (Novagen) 
using the restrictions enzymes NcoI and BamHI; the resulting plasmid was named 
pET-28albpl (Fig. 2.2). Expression was performed in various E. coli cells (DE3 
lysogens); we found optimum recovery of protein using the BL21(DE3) strain. Cells 
were grown in shake flasks at 37°C and expression induced with 1mM isopropyl-1-
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Figure 2.2 - Expression Vector pET28aIbpl. Aqufex bpl gene cloned using NcoI 
and BarnHI restriction sites. 
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The predicted p1 of the A. aeolicus BPL is 9.1 and contains a high proportion 
of positively charged residues and so cation-exchange chromatography was used to 
purify the enzyme in a single step (See Fig. 2.3). Initially the crude lysate was 
incubated at 60°C which resulted in the precipitation of a significant quantity of E. 
coli proteins. It was then necessary to dialyse the sample overnight (20°C) against 
10mM HEPES (pH 7.5) as immediate loading of an untreated extract onto a 
ResourceS column resulted in very poor binding (<5%). It is unclear why this step 
was necessary, but after dialysis binding to the cation exchange column approached 
100%. BPL eluted from the column at 200mM NaCl (Fig. 5) and we obtained the 
enzyme with a purity of greater than 95% (as determined by SDS-PAGE). 
Electrospray mass spectrometry analysis gave the molecular weight of the protein as 
26636.83 ± 2.34 Da, consistent with the post-translational removal of the N-terminal 
methionine residue, and accurate to within experimental error of the predicted value 
of 26634.57 Da. The final yield of BPL using this method was >10mg per litre of cell 
culture and this protein was used for all subsequent kinetic and cross linking 
analysis. 
Figure 2.3. Purification of A. aeolicus BPL 
Protein purification was analysed by SDS-
PAGE under reducing conditions. Lane 1, 
low molecular weight marker. Lane 2, BPL 
cell lysate. Lane 3, BPL cell lysate after heat 
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2.3 	Cloning, expression and purification of BCCPA67 
We designed primers to clone a truncated domain of the A. aeolicus bccp gene 
missing the first 201 base pairs which encode the N-terminal 67 amino acids of A. 
aeolicus BCCP (ACCBi67for and ACCBrev). The truncated gene was amplified 
from genomic DNA using PCR and cloned into the pCR2. 1 vector (Invitrogen) using 
the restriction enzymes NcoI and BamHI. DNA sequencing confirmed the expected 
gene sequence, and the bccpzi67 gene was subsequently cloned into a pET-derived 
expression vector with an N-terminal hexahistidine tag. The final construct was 





acrb D67 	 AMP 
  








Figure 2.4. Expression Vector pET6HIaccbM7. Aqufex accbzi67 gene cloned 
using Ncol and BarnHI restriction sites. The resulting construct encodes an N-
terminal hexahistidine tag. 
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E. coli BL21(DE3) competent cells were used for recombinant expression 
(described under "Materials and Methods") and the BCCPA67 cell lysate was first 
purified by nickel-affinity chromatography (see Fig. 2.5). The protein eluted with 
200mM imidazole and, as precipitation had been observed at high concentrations of 
this eluant, it was immediately diluted 1:1 with 10 mM HEPES (pH 7.5) and dialysed 
against this buffer. SDS-PAGE analysis indicated BCCPA67 to be >90% pure but 
electrospray mass spectrometry revealed the presence of two distinct species - the 
first of molecular weight 10740.11 ±1.112 Da, corresponded to the predicted mass of 
apo-BCCPA67 (10739.63 Da); the second corresponding to the holo-form 
(biotinylated), with a mass increase of 226Da (10965.41 Da; predicted mass 10965.6 
Da), This confirmed that the A. aeolicus BCCPA67 domain folded correctly, was 
recognised and biotinylated by the host E. co/i BirA. To separate the apo- and holo-
forms of BCCPA67 we employed anion exchange chromatography in a similar way 
to that used for E. co/i BCCP-87 (97). Fractions from the column were analysed by 
electrospray mass spectrometry and the apo-protein eluted at a slightly lower salt 
concentration than the holo-form (160-240 mM NaCl vs. 240-320 mM NaCl). 
Approximately 80% of the apo-BCCPA67 was resolved from the holo-form by 
collecting only the leading fractions of the protein peak. The final yield of apo-
BCCPA67 was —5- 10 mg per litre of cell culture and - 1mg per litre of the holo-form. 
kDa 
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2.4 	Biological properties of BPL 
Activity assays were performed with BPL by measuring the incorporation of 
['4C]biotin into the purified apo-BCCPA67 biotin-accepting domain (98). In initial 
experiments we observed optimal enzyme activity at pH 8.5 (Fig. 2.6a), and 
magnesium ions, ATP, biotin and apo-BCCPA67 were all required for activity. The 
activity of the enzyme was also measured at varying temperatures, with optimal 
activity at 70°C. Increasing the temperature above 70°C resulted in enzyme 
precipitation, together with a dramatic loss in activity (Fig 2.6b). BPLs tolerance of 
other nucleotide sources was measured by replacing ATP with UTP, GTP, or CTP. 
No BPL activity was detected for any of these three substrates-suggesting the 
enzyme is completely dependent on ATP for its nucleotide supply (data not shown). 
In assays performed with the mutant BCCPL67 K! 17L as the biotin acceptor 
no biotinylation was observed, verifying K! 17 as the active residue and 
demonstrating the specificity of the BPL catalysed reaction. 
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Figure 2.6. Biological Properties of A. aeolicus BPL. A. Relative activity of BPL 
with changing pH. B. Relative activity of BPL with changing temperature. 
2.5 	Kinetic Analysis of BPL 
The kinetic constants for D-biotin, MgATP, and apo-BCCPA67 were determined 
using steady-state kinetics (Fig. 2.7) The Km  for D-biotin was determined to be 439.6 
± 69.2 nM. The KmS for BPLs from other species range from low nanomolar to low 
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micromolar; 67 ± 1mM (S. cerevisiae BPL), 300nM (E. coli BirA), 130nM (A. 
thialiana HCS) and 3.3mM (chicken liver HCSI) (65,84,99,100). The Km for 
MgATP was 15.14 ± 1.52 jiM, which is similar to that determined for the S. 
cerevisiae BPL (20.9 ± 3j.tM) and A. thaliana HCS (4.4 tM). In contrast, the Km for 
MgATP for E. coli BirA is around 300tM. Finally, the Km for apo-BCCPz67 was 
160.43 ± 32.43 jiM. A range of biotinylation substrates have been used in assays of 
BPL activity with cross-species reactivity frequently observed e.g. S. cerevisiae BPL 
has a Km  of 11.1 ± 1mM for E. coli BCCP-87. However, we could not test E. coli 
BCCP-87 as a substrate for BPL since the rate of biotinylation at 37°C was outwith 
the lower limit of detection in our assay. 
As discussed in chapter 1, the first step in all biotinylation reactions studied 
thus far involves the synthesis of a biotinyl-5'-AMP intermediate and the release of 
inorganic pyrophosphate (PPi). This molecule is the substrate for biotin transfer to 
BCCP and is also the co-repressor of E. coli BirA. To prove that BPL also 
synthesises biotinyl-5'-AMP we incubated BPL, biotin and ['4C] MgATP (the ATP 
was labelled in the 8 position). We observed the synthesis of [14C] biotinyl-5'-AMP 
by the use of an avidin binding assay (Clarke, D. J.; MChem research project). 
Moreover, we carried out inhibition studies with PPi and found that it acted as a 
competitive inhibitor relative to ATP and as a non-competitive inhibitor relative to 
biotin (Clarke, D. J.; MChem research project). This implies that MgATP binds to 
BPL prior to biotin, in contrast to E. coli BirA where the order is reversed (75). 
Similar orders of binding have been observed in other BPLs such as S. cerevisiae and 
A. thaliana, which like A. aeo/icus BPL, have no DNA-binding domain (65,99,101). 
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We also noted that biotinylation was inhibited by the addition of NaCl in 
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Figure 2.7. Steady-state kinetic analysis of BPL substrate binding. The activity of 
A. aeolicus BPL was measured under steady-state conditions at 70 °C. Two 
substrates were kept at constant saturating levels while the concentration of the third 
substrate was varied over the ranges shown above in the graphs. From the curves, Km 
values for biotin (A), MgATP (B), and apo-BCCPM7 (C) were determined (see 
Materials and Methods). 
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2.6 	Limited Proteolysis of BPL 
We subjected BPL to limited proteolysis in the presence and absence of biotin and 
MgATP (Fig. 2.8). Digestion with both trypsin and chymotrypsin resulted in 
formation of a fragment of —21 kDa. Chymotrypsin digestion also produced an array 
of smaller peptide fragments. Preincubation of BPL with saturating amounts of biotin 
or MgATP had little effect on the protein's susceptibility to digestion. However, 
preincubation with both substrates dramatically increased the resistance of BPL to 
proteolysis, suggesting that the binding of the substrates and/or the formation of the 
intermediate, biotinyl-5'-AMP, plays a role in protecting the protease cleavage site. 
LC-MS analysis of the peptide fragment produced from BPL after treatment with 
trypsin revealed the presence of two distinct species of mass 215549.54 ± 2.57 Da 
and 21678.62 ± 5.93 Da. Primary structure analysis of BPL established these masses 
corresponded to trypsin cleavage between R44 and K45, and K45 and W46 adjacent 
to the proposed catalytic centre and biotinyl-5'-AMP binding site. 
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Figure 2.8. Proteolysis of BPL. A. aeolicus BPL was treated with trypsin or 
chymotrypsin either with or without equilibrating the enzyme with ImM MgATP 
and/or 50tM biotin. Lanes 1-4, Trypsin digest; lane] BPL; lane 2, BPL + MgATP; 
lane 3, BPL + biotin; lane 4, BPL + MgATP and biotin. Lanes 5-8 Chymotrypsin 
digest; lane 5, BPL; lane 6, BPL + MgATP; lane 7, BPL + biotin; lane 8, BPL + 
MgATP and biotin. 
2.7 Discussion 
Analysis of the complete genome of the hyperthermophile A. aeolicus revealed the 
presence of BPL and BCCP homologues (see Fig. 2.1). The A. aeolicus BPL enzyme 
belongs to the class I group of BPLs since it lacks the DNA-binding domain found in 
E. coli BirA and is the smallest characterised thus far. Eukaryotic BPLs also lack 
predicted DNA-binding domains but have large N-terminal extensions with unknown 
functions (102). The full-length A. aeolicus BCCP has a C-terminus showing high 
sequence homology to the biotin domains of biotin-carboxylases and contains the 
eight amino acid 'thumb' motif found in E. coil BCCP (33,102,103). The N-terminus 
has a large proportion of charged residues, and displays little similarity to any other 
BCCPs. 
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Using recombinant proteins isolated from E. co/i we have characterised the 
full-length BPL and BCCP biotinylation domain BCCPL.67 from a 
hyperthermophile, and we have gained insight into this extremely specific post-
translational modification reaction at high temperatures. We found A. aeolicus BPL 
to be monomeric and so competing homo-dimerisation interactions found in E. coli 
BirA are not present. We isolated a mixture of apo- and holo-forms of A. aeolicus 
BCCPL67 and so conclude that it must be a substrate for E. co/i BPL in vivo. 
Biotinylation in hyperthermophiles proceeds via the two-step reaction sequence 
found in other organisms (Fig 1.2). Isolated A. aeolicus BPL could biotinylate apo-
BCCPA67 at temperatures up to 70°C albeit at a slow rate. It is interesting to 
compare the A. aeolicus BPL:BCCPA67 biotinylation reaction with that of a mutant 
E. co/i BirA lacking the N-terminal DNA binding domain (BirA65-321) and E. co/i 
BCCP-87. The BirA65-321 mutant could synthesise biotinyl-5'-AMP and transfer 
biotin to apo-BCCP-87 at the same rate as wild-type BirA. However, the affinity of 
BirA65-321 mutant for biotin and biotinyl-5'-AMP was decreased 100-fold and 
1000-fold respectively (104). This suggested that in BirA, the N-terminal domain is 
somehow involved in tight-binding of the two ligands. In future, it would be 
interesting to study a BPL:BirA chimera by fusing the DNA-binding domain at the 
N-terminus of A. aeolicus BPL. 
Substrate Km values for BPLs from a number of species have been shown to 
range from the low nanomolar to low millimolar. In steady-state kinetic assays at 
70°C, the A. aeolicus BPL bound biotin, MgATP and apo-BCCPA67 with affinities 
of 439.6 nM, 15.14 tM and 160.43 .tM respectively. The kinetic constant for 
MgATP suggests that A. aeolicus BPL resembles those from eukaryotic biotin 
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auxotrophs (low micromolar). In contrast, E. coli BirA binds MgATP with a Km in 
the low millimolar range which reflects its dual function as both repressor of biotin 
biosynthesis and biotin ligase. It is interesting to note that A. aeolicus contains all the 
genes required to convert pimelate to biotin (bioW, bioF, bioA, bioD and bioB) 
suggesting it can synthesise this vitamin but the in vivo concentration of biotin within 
A. aeolicus cells is unknown. The K 1 for the apo-BCCP67 domain used in this 
study is high compared to others but this may reflect the fact that the first 67 amino 
acid residues, which contain a high number of charged residues, could play an 
important role in tight binding to BPL. Most biochemical studies use these truncated 
BCCP domains and future work using full length BCCPs should elucidate the role of 
the N-terminal interaction with BPL. The calculated 	for biotin of 1.7 ± 0.1 X 
104 M' s 1 is 300-, 100- and 35-fold smaller than the E. coli BirA, yeast and A. 
thaliana BPL enzymes respectively but reflects the fact that the A. aeolicus BPL kcat 
is low at 70 °C (cf A. aeolicus grows optimally at 95 °C) (65,99,105). 
To analyse the domain structure of BPL, we investigated its susceptibility to 
limited proteolysis and found that treatment with trypsin produced two -20kDa 
fragments differing in length by only one residue. Mass spectrometry revealed that 
cleavage had occurred after residues R44 and K45 which, by comparison with E. coli 
BirA, are predicted to lie near the putative intermediate binding site (Fig. 2.1). 
Treatment of BPL with trypsin and chymotrypsin in the presence of biotin did not 
protect the enzyme from either protease and similarly, MgATP alone failed to block 
proteolysis. However, incubation of the enzyme in the presence of both substrates 
rendered A. aeolicus BPL protease resistant. The same region is protease sensitive in 
S. cerevisiae BPL and is also protected by incubation with biotin and MgATP (65). 
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The E. coli BirA structure contains five surface loops, four of which are in the central 
domain with loop regions [110-128, 212-233] and [140-146, 193-199] close together 
in three dimensional space (61). The region containing [110-128] in E. coli BirA is 
highly conserved to residues [32-50] in A. aeolicus BPL whereas the other loop 
regions have low pairwise sequence homology. A protease-sensitive site has been 
reported between residues 217 and 218 of BirA. In contrast, A. aeolicus BPL is not 
cleaved at this site but is cleaved in the adjacent loop region [32-50]. This suggests 
that this highly-conserved region forms an exposed loop near the biotinyl-5'-AMP 
binding site (Fig. 2.1). These flexible, unstructured regions are also involved in 
BCCP binding and are believed to become more rigid upon substrate binding 
(61,106). 
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3.1 	Chemical crosslinking of BPL and BCCP 
Although structures of E. coli BirA and both apo-and holo-BCCP-87 have been 
determined, our goal was to isolate a BPL:BCCP complex for biochemical and 
structural studies. Previous work in our laboratory used the chemical crosslinking 
agent 1-ethyl-3-(dimethylamino-propyl)-carbodiimide (EDC) to isolate an E. coli 
flavodoxin/flavodoxin reductase complex, so we used this reagent to crosslink BPL 
and various forms of BCCPiX67 (107). 
Initially we incubated BPL and apo-BCCPi67 in the presence of excess 
EDC at room temperature with and without saturating amounts of biotin and 
MgATP, but we did not observe any crosslinked species of predicted molecular 
weight -36kDa on SDS-PAGE. However, a species was observed when the 
incubation was carried out at elevated temperatures, with 60°C being the optimum 
(see Fig. 3.1 A). The presence of the substrates had no observable effect on 
crosslinking. Interestingly, when BPL was incubated with holo-BCCPA67 and EDC 
the amount of crosslinked species generated was significantly reduced compared to 
the apo- form (Fig. 3.1 B); suggesting that the active lysine residue (El17) in 
BCCPL67 may be involved in chemical crosslinking. 
Purification of the BPL:BCCPz67 complex from unreacted proteins was 
achieved using size exclusion chromatography on Sephadex 75, which resolved the 
mixture into three peaks (Fig. 3.2). Analysis by SDS-PAGE revealed the 
BPL:BCCPA67 complex had a molecular weight of 37 kDa (Fig. 3.2, inset). 
Electrospray analysis of the complex gave a molecular weight of 37,221 ± 200 Da 
which agrees well with the predicted mass of a 1:1 heterodimer. 
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Figure 3.1. SDS-PAGE analysis of chemical crosslinking assays. Gel A, 
crosslinking of BPL and apo-BCCPz67. Gel B, crosslinking of BPL and holo-
BCCPL67. Both Gels lanes 1-5, assay after 0, 5, 10, 15, and 30 minutes respectively. 
Gel A lanes 6 and 7, control assays with BCCPA67 alone and BPL alone. 
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Figure 3.2. Purification of the chemically crosslinked BPL:apo-BCCPA67 
complex by size exclusion chromatography. The chromatogram above was 
obtained when the cross-linking reaction was applied to a Superdex 75 column. The 
three peaks correspond to the crosslinked complex (7-8ml), BPL (lOml) and 
BCCPL67 (11-12m1). Insert. SDS-PAGE analysis of the column fractions. Lane 1, 
cross-linking reaction before purification. Lane 2-11, 1 ml fractions eluting between 
6-15m1. 
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32 	Identification of Potential Residues Involved in BPL:BCCPA67 
Crossi inking 
The recently proposed model of the E. coli BirA:BCCP-87 complex, described in 
section 1.4.3.3 (Fig. 1.11), was obtained using data from structural studies, sequence 
analysis, mutagenesis and limited proteolysis experiments (89). The model (PDB 
code I K67) was built using the coordinates of the BirA dimer in the presence of 
biotin (PDB code IHXD) and BCCP-87 (PDB 1BIA) and it suggests that regions 
119-128 and 87-90 of BCCP (also identified by NMR studies) interact directly with 
BirA. We have mapped the A. aeolicus BPL/E. coli BirA sequence alignment (Fig. 
2.1) onto the E. coli BirA:BCCP-87 structure to allow identification of candidate 
residues that may be cross-linked by EDC in our isolated BPL:BCCPA67 complex. 
The proposed model suggests that the complex is formed by hydrogen 
bonding of f3-strands from each protein, creating an extended n-sheet (Fig. 1.10). The 
3D model has several pairs of charged residues (R or K and D or E) that are between 
1.9 and 5.7 A apart (see Fig. 3.3). The side chains of the closest pair, BirA 
R119/BCCP-87 E119 are 1.92 A apart and are located close to the bound biotin and 
active lysine (K122) residue. Two other pairs, BirA K283/BCCP-87 E147 and BirA 
K194/BCCP-87 E128, are separated by 5-6 A in the model. However, computer-
aided re-alignment of these side chains reduced the separation to 3.5 and 1.0 A 
respectively. It is interesting to note that all these residues are conserved between the 
A. aeolicus and E. coli proteins (Fig. 2.1, highlighted in red). The residues L95 on 
BirA and Q126 on BCCP-87 are 4.3 A apart but are not conserved. These are 
substituted by K19 on BPL and E121 in BCCPL\67 and furthermore, computer- 
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modelled substitutions of BPL L95K and BCCP-87 Q126E reduce the distance 
between these two residues to 1.8A, suggesting they could form a potential ion-pair 
in the A. aeolicus BPL:BCCPA67 complex. 
These four ions pairs in the A. aeolicus proteins were subject to mutational 
studies to identify what role, if any, they played in mediating protein crosslinking. 
Single amino-acid mutations of BCCPL67 were prepared, selectively removing each 
glutamate residue, and their ability to crosslink wild-type BPL monitored. A fifth 
BCCPL67 mutant, KI 17L, was also prepared; this BCCP mutant lacks the active 
lysine. 
Figure 3.3. A model of the E. coli BirA:BCCP-87 complex. Four amino-acid pairs 
at the protein:protein interface are highlighted. Residues in red are situated on BCCP 
and residues in blue are situated on BPL (BirA). These pairs correspond to potential 
ion pairs in the A. aeolicus complex (see text). 
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3.2.1 Cloning, Expression and Purification of E114A, E121A, E123A, 
El 42A, and K1 17L AccBzl67Mutants. 
A series of truncated bccpzl67 mutant genes, with glutamate residues replaced by 
alanine residues, were produced using the megaprimer method (108). The mutations 
were confirmed by DNA sequencing and the genes were subsequently cloned into a 
pET-derived expression vector with an N-terminal hexahistidine tag. The resulting 
constructs were then transformed into E. coli BL21 (DE3) cells for expression (as 
described in "Materials and Methods"). In addition, a further mutant was 
constructed, accbzi67 Ki 17L, which contains a mutation removing the active lysine 
residue (see Appendix 1). 
All of the mutant proteins were purified in a similar manner to the wild type 
BCCPA67 protein (see section 2.3). Nickel-affinity chromatography was employed, 
followed by anion exchange. The purification procedure was monitored by SDS-
PAGE and LC-MS (see Fig. 3.4, Table 3.1). Pure apo-protein was obtained for each 
mutant expressed. 






Figure 3.4. SDS-PAGE analysis of purified BCCPA67 mutants. Lane 1, 
BCCPA67 El 14A; lane 2, BCCPA67 E121A; lane 3, BCCPA67 E123A; lane 4, 
BCCPA67 E142A. All proteins were 1 mg/ml concentration. 
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Modification (Da)  
Suggested Modifications 
BCCPA67 10739.6 10740.1 +226(10%) Biotinylation 
BCCPM7EII4A 10681.6 10679.0 None 
BCCPA67 El 21 A 10681.6 10682.0 -2116(15%) Proteolysis (M1 -V77)? 
BCCPA67 E123A 10681.6 10680.0 +126(10%), Octanylation? 
+189(20%) Lipoic Acid? 
BCCPA67EI42A 10681.6 10681.0 None 
BCCPA67 K  17L 10724.6 10724.8 None 
Table 3.1. Analysis of BCCPA67 mutants by LC-MS. All mutants were analysed 
by LC-MS using a C5 reverse-phase HPLC column attached directly to a Platform-
MS. The masses of all mutants were consistent with their theoretical masses. Post-
translational modifications observed were noted. 
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3.2.2 Crosslin king BCCPA67 Mutants with BPL 
The purified apo-BCCPA67 mutants were assayed for their ability to crosslink to 
wild-type BPL using EDC. The assays were essentially the same as described in 
"Materials and Methods" and section 3.1. The crosslinking was monitored by SDS-













Figure 3.5. Chemical crosslinking of BPL with BCCPA67 mutants. All gels lane 
1, low molecular weight marker. All gels lanes 2-6, assay after 0, 5, 15, 30 and 60 
minutes respectively. Gel A, BCCPA67 wild-type. Gel B, BCCPA67 Ki 17L. Gel C, 
BCCPA67 E1 14A. Gel D, BCCPA67 E121A. Gel E, BCCPA67 E123A. Gel F, 
BCCPA67 E142A. 
Under identical conditions, the BCCPA67 Ki 17L mutant crosslinked to BPL in 
comparable amount to wild-type BCCP; indicating that the active lysine residue of 
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BCCP is not directly involved in crosslinking within the BCCPz67:BPL complex. 
One of the four glutamic acid mutants, BCCPL67 EI2IA, showed a significant 
reduction in crosslinking potential; suggesting that this residue plays an important 
role in crosslinking BCCPt67 to BPL. 
3.2.3 Cloning, Expression and Purification of a bpi K19A mutant. 
Analysis of the E. coli BCCP:BirA model revealed that the E121 residue of aquifex 
BCCPA67 is in close proximity to K19 of Aquifex BPL. In order to test if K19 does 
indeed have a role in crosslinking the Aqufex BCCPt67:BPL complex a BPL K19A 
mutant was prepared, and it's ability to crosslink with wild-type BCCPz67 was 
monitored. 
A bpl K19A mutant gene was produced using the megaprimer method (108). 
The mutation was confirmed by DNA sequencing and the gene subsequently cloned 
into the pET-28a expression vector. The resulting construct was then transformed 
into E. co/i BL21 (DE3) cells for expression (as described in "Materials and 
Methods"). 
The expressed protein was purified in an identical manner to wild-type BPL, 
using cation exchange chromatography. However, the resulting yield of pure protein 
was significantly less than wild-type (-4mg / litre of cell culture). Analysis of the 
pure protein by LC-MS revealed that a single species of mass 26585.98 ± 10.82 Da, 
which is in agreement with the predicted mass of 26577.5 Da. 
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3.2.4 Chemical crosslinking BPL K19A with BCCPA67. 
The purified BPL K19A was assayed for its ability to crosslink to wild-type 
BCCPA67. The assays were essentially the same as described in 'Materials and 
Methods" and section 3.1. The crosslinking was monitored by SDS-PAGE and the 
results are displayed in Figure 3.5. 
By direct comparison with wild-type BPL it is clear that the BPL mutant has 
a reduced ability to crosslink with BCCPA67 (Fig. 3.6). This result suggests that the 
K19A residue is involved in the formation of the BPL:BCCPM7 complex. However, 
a small quantity of the crosslinked species is observed after treatment of BPL K19A 
and BCCPA67 with EDC. This may be due to non-specific crosslinking, i.e. the E121 
residue of BCCPA67 may crosslink to another basic residue on BPL K19A which is 
close in space. 





Figure 3.6. Chemical crosslinking of BPL K19A with BCCPA67. Both gels lane 
1, low molecular weight marker; lanes 2-6, assay after 0, 5, 15, 30 and 60 minutes 
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3.3 	The Role of the "Thumb" Region of BCCPz67 in BPL:BCCPz67 
Crosslinking. 
Extensive X-ray crystallographic and NMR studies have been performed on both the 
apo- and holo-BCCP biotinylation domain (see section 1.3.3). In the first reported 
structure, Athappilly and Hendrickson showed that the domain is a remarkably 
symmetrical structure consisting of two sets of four antiparallel 3-sheets (26). 
However the symmetry of the molecule is disrupted by a protruding eight residue 
structure known as the "thumb', which has been shown to interact with the biotin 
moiety in holo-BCCP. This structural motif is not found in all other biotinylated 
proteins. For example, the P. shermanii 13S biotinoyl domain lacks the 8 amino 
acid motif and the structure of this domain has been shown to display a folding 
pattern essentially identical to E. coli BCCP biotinoyl domain lacking the "thumb" 
(109). However, primary structure alignments suggest that the "thumb" is present in 
A. aeolicus BCCP (see figure 2.1). 
Studies by Reche and co-workers showed that an E.coli BCCP biotinoyl 
domain mutants lacking the "thumb" motif was efficiently biotinylated in both in 
vitro and in vivo experiments (31). These results suggest that it is unlikely that the 
"thumb" moiety has a role in biotinylation of the BCCP by cognate BirA. However, 
the observation that the expression of an E. coli BCCP "thumbless" mutant fails to 
restore both growth and fatty acid biosynthesis to a temperature sensitive mutant 
strain of E. coli lacking a BCCP, suggests the thumb plays a critical role in the ACC 
reaction (33). 
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Although structural studies have revealed that biotinylation of BCCP has no 
significant effect on the overall structure of the protein domain, biochemical studies 
have highlighted significant differences in the susceptibly of the two protein forms to 
both chemical modification and proteolysis, indicating a difference in protein 
dynamics (35). More recently, this increased stability of holo-BCCP has been 
attributed to the interaction of the biotin moiety with the "thumb' region of the 
BCCP (32). Elegant experiments performed by Solbiati and co-workers 
demonstrated that a chemically biotinylated BCCP biotinoyl domain "thumbless" 
mutant displayed sensitivities to trypsin and chemical modification similar to that of 
wild-type apo-BCCP, and was significantly more susceptible to modification than 
wild type holo-BCCP. 
In our initial experiments chemically crosslinking A. aeolicus BPL and 
BCCPA67 we noticed a significant difference in the propensity to crosslink to BPL 
between the apo- and holo-forms of BCCPA67 (section 3.1). Experiments using the 
holo-BCCPA67 produced significantly less of the chemically crosslinked 
protein:protein complex. This result suggested that the active lysine residue (Ki 17) 
of BCCPA67 may be participating in chemical crosslinking to BPL. However, further 
experiments revealed that a KI 17L BCCPA67 mutant crosslinked to BPL in 
comparable amounts to wild type apo-BCCPA67 (section 3.2). This latter result 
demonstrates that our first hypothesis was incorrect; that the active lysine plays no 
significant role in crosslinking BCCPA67 and BPL. To test if the interaction between 
the biotin moiety and the "thumb" region of A. aeolicus BCCPA67 has an effect on 
reducing protein crosslinking both apo and holo- BCCPA67 "thumbless" mutants 
were prepared and chemically analysed. 
55 
Chapter 3: The Aquifex aeolicus BPL:BCCP Complex 
3.3.1 Cloning, expression and purification of A. aeolicus AccB,J67 
"thumbless" mutants. 
Initially, a thumbless' BCCPA67 mutant, with the replacement of residues 89-
SPAPGA 94 with an AAA linker sequence, was produced using the megaprimer 
method (108). The mutations were confirmed by DNA sequencing and the gene was 
subsequently cloned into a pET-derived expression vector with an N-terminal 
hexahistidine tag (see Appendix 1). The resulting construct, named 
pET6H/Accbzi67JTh, was then transformed into E. coli BL2I (DE3) cells for 
expression (as described in "Materials and Methods"). 
The mutant protein was purified in a similar manner to the wild-type 
BCCPA67 protein (see section 2.3). Nickel-affinity chromatography was employed, 
followed by anion exchange. The purification procedure was monitored by SDS-
PAGE and LC-MS. Interestingly, the expressed protein was only isolated in the apo-
form; suggesting that the mutant was not efficiently biotinylated by BirA in vivo. 
LC-MS analysis of the protein detected a single species of mass 10472.0 Da, which 
is in agreement with the predicted mass of 10472.4 Da. 
To produce the holo- form of the thumbless' BCCPA67, chemical 
biotinylation of the protein was attempted using biotinoyl-N-hydroxysuccinimide. 
Unfortunately, this reaction was not specific for the active lysine (Ki 17), and 
resulted in multiple sites of biotinylation, presumable at each of the five lysine 
residues within the protein as well as the amino-terminus. In order to overcome this 
problem we produced a second 'thumbless' mutant, in which the KI 17 was the sole 
lysine residue within the protein. 
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The production of the "sole-lysine thumbless' BCCPA67 mutant was 
undertaken in two stages using the megaprimer method. The procedure involved 
substituting four lysine residues with arginines (see Appendix 1). Fortunately, three 
of the lysine residues were close in the primary sequence and could be changed using 
the same mutant primer. The final lysine was mutated separately. After the 
introduction of the mutations, the sequence was verified by DNA-sequencing and the 
resulting gene, named AccBzi67zlTh 4KR, was cloned, expressed, and purified as 
described previously. Analysis of the resulting protein, named BCCPA67LTh4KR, 
by LC-MS revealed a single species of mass 10583.0 Da, consistent with the 
predicted mass of 10584.4Da. 
3.3.2 Chemical biotinylation and purification of BCCPá67ATh 4KR 
Chemical biotinylation of the "thumbless" BCCP mutant, BCCPz67LTh4KR, was 
achieved used a previously described method (32). The protein was incubated with 
activated biotin (biotinyol-hydroxy-succinimide) for four hours. After optimisation 
the final yield of biotinylated protein was approximately 25%. Furthermore, analysis 
by LC-MS revealed the presence of a small amount of protein (3%) modified with 
covalent attachment of two biotin moieties. Presumably, the amino terminus of the 
protein is slightly susceptible to biotinylation under the conditions used. 
Separation of the apo- and holo-BCCPA67 mutant was achieved by RP-
HPLC using a CS column, and holo-BCCPA67ATh4KR was isolated in 98% purity. 
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3.3.3 Chemical crosslinking BPL and apo- and holo- BCCPi67ATh 
4KR 
The purified apo- and holo- forms of BCCPL67LTh 4KR were assayed for their 
ability to crosslink to wild-type BPL. The assays were essentially the same as 
described in "Materials and Methods" and section 3.1. The crosslinking was 
monitored by SDS-PAGE and the results are displayed in Fig. 3.7. 
Under identical conditions, both the apo- and holo-BCCP 'thumbless' 
mutants crosslinked to BPL in comparable amounts. This is in stark contrast to the 
results of crosslinking apo- and holo-BCCPM7 to BPL, where there is a significant 
decrease in the propensity of the holo-form to crosslink to BPL. Therefore, removing 
the "thumb" region of BCCP has an effect similar to lack of biotinylation and these 
results suggest that the interaction between the biotin moiety and the protruding 
thumb region of BCCP is responsible for the decrease in the ability of the BCCP to 
recognise BPL. 
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Fig. 3.7. Chemical crosslinking of BPL with apo- and holo-BCCPi67ATh4KR 
mutants. All gels lane 1, low molecular weight marker. All gels lanes 2-6, assay 
after 0, 5, 15, 30 and 60 minutes respectively. Gel A, apo-BCCPM7zTh4KR. Gel B, 
holo-BCCPA67Th4KR. 
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3.4 Discussion 
There is evidence that ion pair networks are important for the recognition of BCCP 
by BirA in E. coli. A recent combined mutagenesis/biological selection approach 
identified two single glutamate residues E119 and E147 of E. coli BCCP-87 that 
appear to interact with BPL (98). A BCCP-87 El 19K mutant was inactive as a 
substrate for BirA, whereas the E147K protein could be biotinylated, albeit poorly. It 
is presumed that these acidic BCCP-87 residues interact with basic BirA counterparts 
and mutation of BirA residues K277 and R317 were found to effect biotinylation and 
ATP binding respectively. This surprising result suggested that the C-terminal 
domain of BirA, which had been ascribed no biochemical function, also plays a 
significant role in apo-BCCP and substrate recognition (84). 
It has been shown that ion pair networks are a common feature in heat-
resistant proteins and are believed to play important roles in their increased thermal 
stability (92,110). Since both the A. aeolicus BPL and BCCP contain a large number 
of charged residues, and we observed inhibition of biotinylation at high salt 
concentrations we presume that ionic interactions are involved in the formation of 
the hyperthermophilic BPL:BCCPA67 complex. To investigate the formation of the 
BPL:BCCPz67 heterodimer we used the chemical cross-linking agent EDC to 
capture a BPL:BCCP complex for the first time. The zero-length EDC reagent 
activates acidic residues on one protein to form an unstable urea derivative (111). 
This derivative then reacts with a nucleophile (such as lysine) on another protein to 
form an amide link between the two proteins. Incubation of BPL and apo-BCCP67 
in the presence of EDC led to the time-dependent appearance of a species of -37kDa 
on SDS-PAGE gels (Fig. 3. 1), which is in agreement with the predicted mass of a 1:1 
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complex of BPL and apo-BCCPA67. We observed that BPL, BCCPA67 and the 
complex eluted earlier than predicted from the size exclusion column. Nevertheless, 
the complex was easily separated from the unreacted proteins using this procedure 
(Fig. 3.2) and allowed us to confirm its mass by electrospray mass spectrometry. 
Overlaying the primary sequence of the A. aeolicus BCCP and BPL proteins 
onto the model of the E. coli BCCP-87:BirA protein interface assembled by Weaver 
and co-workers (89), allowed us to identify four ion-pairs which may be involved in 
crosslinking BCCPA67 and BPL. We then recombinantly produced a series of four 
BCCPA67 mutants, with single mutations of the glutamic acid residues thought to be 
present at the protein-protein interface. Analysis of the ability of each member of the 
mutant library to crosslink to wild-type BPL allowed us to identify a single glutamic 
acid residue on BCCPA67, E121, which is involved in crosslinking (Fig. 3.4). The 
proposed ion-pair partner to BCCPA67 E121 was BPL K19, and a BPL KI9A 
mutant did indeed show a reduced ability to crosslink to wild-type BCCPD67; 
verifying it's role in crosslinking. 
Interestingly, in our initial crosslinking experiments, we noticed the 
formation of the complex was significant reduced between BPL and holo-BCCPA67 
(Fig. 3. 1B). Initially, we hypothesised that this was because the active lysine residue 
of BCCP, Ki 17, was involved in crosslinking to BPL; therefore the amino sidechain 
of Ki 17 would be effectively blocked from crosslinking upon biotinylation. 
However, this hypothesis was rejected when a BCCPA67 K1 17L mutant was shown 
to crosslink to BPL in comparable amount to wild-type apo-BCCPA67-
demonstrating that the active lysine residue is not required for crosslinked complex 
formation. 
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Although the published 3D structures of the apo- and holo- forms of BCCP-
87 show no major structural differences, some structural studies (both NMR and x-
ray) have concluded that the lack of any major differences between them might not 
be wholly reflected in their behaviour in solution (28). NMR titration experiments 
were carried out with BirA and apo-BCCP-87 and, in light of our data, it would be 
interesting to repeat this work with BirA and holo-BCCP-87 to determine if any 
differences arise. Recent elegant studies by Cronan and Solbiati, described in chapter 
3.3, highlight a difference in the stability of apo-BCCP-87 and holo-BCCP-87 to 
proteolysis and they propose the majority of this increased stability is due to an 
interaction between the biotin moiety and the "thumb" domain of E. coli BCCP (32). 
The authors attribute this increased stability of the holo-BCCP to a reduction in the 
dynamics of the protein upon biotinylation. 
Primary sequence analysis revealed that the A. aeolicus BCCPL67 also 
contains a well-conserved thumb domain located between residues 89 SPAPGA 94. 
Production of apo- and holo-BCCPA67 mutants lacking the "thumb" region allowed 
us to analysis the effect of the "thumb" upon crosslinking to BPL. We found that 
apo-BCCPA67zTh crosslinked to BPL in comparable amounts to wild-type apo-
BCCPA67- demonstrating that the "thumb" region is not required for the recognition 
of BCCP by BPL. This result is strengthen by previous research which shows that an 
E. coli BCCP "thumbless" mutant is efficiently biotinylated in vivo and in vitro (31). 
More interestingly, holo-BCCPA67ATh is also chemically crosslinked to BPL in 
significant amounts. It seems that the 'thumb' region of BCCP is required for BPL to 
distinguish between the apo- and holo- forms of its protein substrate. We hypothesise 
that a biotin-thumb interaction exists in holo-BCCPA67, similar to that found in 
61 
Chapter 3: The Aquifex aeolicus BPL:BCCP Complex 
E.coli BCCP. If this hypothesis is correct it is easy to imagine that the reduction in 
the dynamics of the protein, which are a consequence of this interaction, hampers the 
formation of the ion pair network at the BPL:BCCP heterodimer interface, thus 
reducing chemical crosslinking. This hypothesis allows us to speculate on a 
mechanism of biotinylation in which, upon attachment of biotin, the reduction in 
dynamics of BCCP aid the dissociation of the ligase-ho10BCCP complex. 
In light of these results, future work should concentrate on measuring the 
dynamics of the apo- and holo- forms of both wild-type BCCP167 and its 
'thumbless' mutant. Indirect evidence for any difference in the dynamics of the two 
forms of the proteins could be established by testing the susceptibility of the proteins 
to proteolysis, in a similar manner as performed by Cronan and Solbiati (32). 
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4.1 	The Diversity and Classification of Antimicrobial Peptides 
Antimicrobial peptides (AMPs) are gene encoded polypeptides of fewer than 100 
amino acids (112,113). They are widespread throughout the plant and animal 
kingdom and typically display broad-spectrum antimicrobial activity at physiological 
concentrations. The diversity of AMPs is so great that it is difficult to categorise 
them except broadly on the basis of their secondary structure (all reported AMPs are 
catalogued online at www.bbcm.univ.trieste.iti—tossi/amsdb.html). However, the 
fundamental structural trait shared by the majority of AMPs is the ability of the 
molecule to adopt a shape in which clusters of hydrophobic and cationic residues are 
spatially organised in discrete patches- known as amphipathic design. In some 
classes, such as defensins and bactenecins, this amphipathic nature is constrained by 
a rigid framework of antiparallel 3-sheets held together by disulfide bridges 
(114,115). In contrast, linear peptides, such as magainin, only adopt an amphipathic 
structure when they enter a membrane and become predominantly (X-helical in nature 
(116). Members of a third class of AMPs are characterised by the predominance of 
one or two amino acids within their primary structure. These linear peptides, 
examples include the tryptophan-rich indolicidin, the histidine-rich histatins, and the 
proline/ arginine-rich PR39, separate hydrophobic and cationic sidechains around an 
extended peptide scaffold (117-119). Examples of the various classes of AMPs are 
given in table 4.1. 
It is interesting to note that anionic AMPs have been discovered and 
characterised. However, these peptides are restricted to a few animal species and 
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tissues (120). In recent years there has been growing interest in these fascinating 
molecules for development of novel therapeutics (121-125). 
Class Sequence Origin 
Linear, a-helical 
Cathelicidin (LL-37) LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES Human 
Buforin II TRSSGAGLQFPVGRVFIRLLRK Vertebrate 
Magainin 2 GIGKFLHSAKKFGKAFVGEIMNS Frog 
One Disulfide Bond 
Bactenecin 1 RLCRIVVIRVCR Cow 
Two 	Disufide 
Bonds 
Protegrin 1 RGGRLC I YC2RRRFC2 VC J VGR Pig 
Three 	Disulfide 
Bonds 
c-defensin (HNP3) DC1 YC2RIPAC3IAGERRYGTC2IYQGRLWAFC3C1 Human 
13-defensin (HBD2) GIGDPVTC J LKSGAIC,HPVFC3PRRYKQIGTC,GLPGTKC1 C3KK Human 
P 
9-defensin (Resistin) GFC1 RC2LCRRGVC3RC2IC TR Monkey 
Four 	Disulfide 
Bonds 
Hepci din DTFIFPIC I IFC2C3GC4C1 HRSKC2GMC3C4KT Human 
Linear, 	not 	a- 
helical 
PR-39 RRRPRPPYLPRPRPPPFFPPRLPPR1PPGFPPRFPPRFP Pig 
Histatin 5 DSHAKRHHGYKRKFHEKHHSHRGY Human 
Table 4.1. Overview of antimicrobial peptides - Representatives from each class. 
Cysteines paired in disulfide bonds are noted. C-terminal amides are noted by a. For 
a comprehensive inventory see www.bbcm.univ.trieste.it/-tossi/amsdb.html.  
4.2 	Vertebrate Defensins 
4.2.1 Classification 
The defensins are a diverse class of vertebrate antimicrobial peptides, which are 
characterised by a common triple 3-sheet fold held together by six disulfide linked 
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cysteine residues. These evolutionary related molecules were first classified in 1985 
(114,126), and have recently been the focus of several review papers (127-129). The 
two main defensin subfamilies, a— and 3-defensins, differ in cysteine spacing and 
connectivity of the disulfide bonds (Fig. 4.1). More recently, a third defensin 
subfamily of 9-defensins has been isolated from the rhesus macaque monkey (130). 
The 8-defensins are cyclic peptides, formed by splicing two nine amino acid peptide 
precursors. This subfamily is thought to have evolved in primates but has been 
inactivated in humans by mutations which incorporate premature stop codons (131). 
Antimicrobial peptides found in invertebrates and plants which contain six 
(or eight) cysteines have also been classified as defensins (132-136). However, their 
evolutionary relationship to vertebrate defensins is unclear (137), and this 




Figure e 4.1. The disulfide bridging connectivity in a, 3, and 8-defensins. a-
defensins are characterised by C1-C6, C2-C4 and C3-05 disulfide bridging. 3 - 
defensins are characterised by C1-05, C2-C4 and C3-C6 disulfide connectivity. 0-
defensins are characterised by an amide-linked backbone that forms a cyclic structure 
with three disulfide bonds. 
M. 
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4.2.2 Biological Role of Mammalian Antimicrobial Defensins - The 
Innate Immune system. 
Although mammals are constantly exposed to a myriad of microbes, very few 
succeed in causing systemic infection. This is predominantly due to the barrier 
function of the skin and mucous membranes which form a mechanical obstruction, 
and the presence of antimicrobial substances. If this barrier is breached, invading 
microbes are contained and eliminated by the host immune system. Innate immunity 
is the first line of constitutively pre-existing host defence that is rapidly mobilised 
following pathogen detection, and consists of two major components (138,139). 
Firstly, invading microbes are challenged with resident macrophages and various 
humoral protectants, including 3-defensins, lectins and complement. In humans, four 
3-defensins (H13D1-HBD4) have been described in detail, and many more 3-defensin 
genes have been identified within the genome (140-145). The expression of these 3-
defensin genes in barrier and secretory epithelial cells is constitutive in some cases 
(HBDI), whereas in others the gene is expressed in response to infection, such as 
HBD2-4 (146,147). Similar epithelial 3-defensins derived from other mammals have 
been characterised and are reviewed in ref. (148). 
The second arm of innate immunity involves the production of chemokines 
for the recruitment and activation of polymorphonuclear leukocytes (PMNs). Half a 
century ago, a crude protein fraction of PMNs displaying antimicrobial activity was 
isolated and named "phagocytin" (149-151). Subsequent investigation of 
"phagocytin" revealed a complex mixture of antimicrobial proteins and peptides. 
Antimicrobial proteins found in PMNs include: lactoferrin, lysozyme, cathepsin G, 
azurocidin, caiprotectin and bactericidal/permeability-increasing protein (BPI) (152). 
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The peptide fraction of "phagocytin consists of cationic antimicrobial peptides that 
belong to the cx-defensin (126-129) and cathelicidin (153-156) families. The a-
defensins are stored in primary (azurophil) granules (157,158). When PMNs ingest 
microorganisms into phagocytic vacuoles, these granules fuse to the vacuoles and 
deliver their contents onto the microorganism. Consequently, the local concentration 
of a-defensin can be very high (>10 mg/ml). In contrast, cathelicidins are stored in 
secondary (specific) granules of the PMNs and are mainly delivered extracellularly 
(159). 
Human PMNs contain four a-defensins (HNP1-4) and one cathelicidin (LL-
37IhCAP-18) (126,159-161). However, the type and number of AMPs in mammalian 
PMNs varies between species. Bovine PMN do not contain a-defensins, but express 
many -defensins and cathelicidins (156,162,163). Porcine and ovine PMNs contain 
no defensins and only express cathelicidins (155,156,164), whereas murine PMNs 
contain only a single cathelicidin (165). Interestingly, the PMNs of Old World 
monkeys have been shown to contain 0-defensins (circular peptides, known as 
lectins, with effective antiviral activity) in addition to their a-defensins and 
cathelicidin (131,166-170). The antimicrobial arsenal of PMNs is further enhanced 
by the production of a variety of toxic oxidants. These are formed by reactions 
between superoxide anions produced by NADPH oxidase and myeloperoxidase. 
Additionally, the PMNs from some species contain oxidants that are derived from a 
type H inducible nitric oxide synthase (NOS) (171). 
In addition to expression in PMNs, a-defensins are also found in Paneth cells 
in humans (HD5-6), mice and rhesus monkeys (172-176). These secretory cells are 
located in the basal regions of the Lieberkuhn crypts, tiny pits throughout the small 
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intestine. The release of a-defensins and other antimicrobial substances from these 
cells is stimulated by the LPS of invading intraluminal bacteria. Paneth cell a-
defensins, also known as cryptdins, are reviewed in refs. (177,178). 
The complex nature and number of host defence molecules indicate that no 
single mechanism is adequate to control and fight the threat of microbial infection. 
Furthermore, it is clear that defensins play a critical role in the innate immune 
response. 
4.2.3 Defensin Genes, Biosynthetic Pathways, and Posttranslational 
Processing 
In humans, the genes encoding a- and 13-defensins are located in a cluster on 
chromosome 8p23 (179-183). This defensin cluster is incompletely mapped, and is 
highly polymorphic- the copy-number of specific defensin genes are variable 
between individuals (184). Recently, four additional defensin gene clusters have 
been discovered, which contain transcribed genes. However, their protein products 
have not yet been fully characterised (145). Analogous defensin gene clusters have 
been identified in mice (145,185-187). 
Defensin genes are initially expressed as a pre-propeptide, containing an N-
terminal endoplasmic reticulumlgolgi targeting sequence (signal pre-sequence), the 
adjacent anionic precursor sequence (propeptide sequence) and the cationic mature 
peptide at the C-terminus (Fig. 4.2). In a-defensins, the charge on the propeptide and 
mature peptide balance (188). In 1999, a paper by Wilson et al. reported the cellular 
processing of a murine Paneth cell a-defensin (189). The metalloprotease 
matrilysin (MMP7) was shown to cleave the propeptide sequence to produce the 
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mature peptide, and the interaction of these two molecules has been the subject of a 
further study (190). More recently, the protease trypsin was shown to be the 
processing enzyme of human a-defensin HP-5 (191,192). To date, no detailed 
analysis regarding the processing of 3-defensins has been published. 
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Figure 4.2. Structure of prototypical defensin gene and peptide. The gene 
product is a prepropeptide. The pre-sequence encodes a signal sequence. The pro-
sequence is removed by a specific protease either before or after secretion (see text). 
The mature peptide is antimicrobial. 
4.2.4 Genetic Regulation of Defensins 
Defensin biosynthesis can be regulated by microbial signals, development signals, or 
cytokine response and has been described in detail for human, bovine and murine 
molecules. Human PMN a-defensins are synthesised constitutively by the bone-
marrow precursors of PMNs during specific differentiation stages of the cells 
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development (neutrophil maturation) (193). The defensins are processed into the 
mature form before packaging into primary (azurophil) granules. Once matured, 
PMNs do not express a-defensins and cease granular synthesis. They are then 
released into the bloodstream and are free to enter tissues. Paneth cell a-defensins 
are also thought to be synthesised constitutively. However, they are only released 
into the lumen after exposure to bacteria or cholinergic stimuli (194). This release 
has recently been shown to be moderated by a Ca 2'-activatedK(+) channel mIKCal 
(195). Once released, the a-defensins are processed by their specific proteases, such 
as matrilysin or trypsin. 
The expression of HBD- 1, which is produced predominantly in the urinary 
tract, has been found to be constitutive, as has its murine homologue mBD-1 (196). 
In contrast, HBD-2 expression is upregulated by infection and inflammatory stimuli 
in human studies (197). In cell culture experiments, HBD-2 expression was 
stimulated by interleukin (IL)- 1 a, IL-1p, tumour necrosis factor-a (TNF-(x), 
microorganisms, and lipopolysaccharide (LPS) (196). This upregulation mechanism 
is dependant on a specific nuclear factor-KB (NF-1d3) binding site upstream of the 
I-{BD-2 gene. The upregulation of several murine and bovine 3-defensins by the NF-
KB pathway has also been demonstrated (185,198). Both HBD-3 and HBD-4 are 
upregulated during infection (143,199). In vitro, the production of HBD-3 by 
keratinocytes and airway epithelial cells is stimulated by TNF-a or bacteria. 
However, the genetic control is mediated by an NF-KB independent pathway which 
is not fully understood. There is also evidence of upregulation of HBD-2 and HBD-3 
in epithelia by Rhinovirus-16 and HIV-1 (200,20 1). 
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In some cases, the synthesis of defensins is regulated developmentally. For 
example, rabbit alveolar macrophages have been shown to synthesise and accumulate 
a-defensins during the first postnatal month (202). 
4.2.5 Defensin Structure 
Although purified in 1985, the first structural characterisation of a defensin was not 
published until 1991 (203). This crystallographic study elucidated the structure of a-
defensin HNP-3 to a resolution of 1.9 A. HNP-3 folded to form a triple stranded f3-
sheet held together by 3 disulfide bonds. This novel fold has also been shown to be 
adopted by human HNP-1 and rabbit NP-2 and NP-5, despite very little sequence 
identity between the molecules (204-207). Recently, the structures of human 3-
defensins have been extensively investigated and both crystallographic and NMR 
structures of HBD-1, -2, and -3 have been determined (208-211). In addition NMR 
structures of several murine and bovine defensins have also been published (212). 
The secondary structures of these 3-defensins are similar; and essentially the same as 
the a-defensins (Fig 4.3 and 4.4). Although the two subfamilies display different 
disulfide connectivity and spacing both display the same triple-stranded 3-sheet fold. 
There is no hydrophobic core in these small molecules, which suggests the fold is 
stabilized by the disulfide bonds. The presence of a small N-terminal (X-helical 
segment has been observed in several f3-defensins (HBD-2, mBD-8), however it is 
unclear what, if any, significant role this feature has (210,212). The quaternary 
structure of defensins seems to vary between molecules. For example HNP-1 was 
dimeric in its crystalline form, whereas other a-defensins are predominantly 
monomeric. Furthermore, native gel electrophoresis suggests that HBD-1 is 
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monomeric, while HBD-2 and HBD3 are dimeric. However, NMR analysis of 
HBD-2 and HBD-3 show no indication of dimerisation, while crystallographic data 
suggests oligomerisation of HBD-2. It maybe that the more dynamic environment of 
NMR is responsible for the lack of higher order structure observed using this 
method. It has been postulated that higher order oligomerisation is essential for 
antimicrobial activity and further analysis of defensin oligomerisation, both in 
solution and in the presence of membranes, is required. 
(1) 1 	10 	20 	30 	 45 
HBD1 (1) -----jH'Njj QCLYS IFT IQ CYRGKAKC
HBD2 (1) ---CIPVT 	
ICHJCLPJ 
CGLP TKCC F- 
HBD3 (1) GIINTLQ1YCRVR RCA EE GKCST RKC KK 
Consensus (1) 	D Y CL SGG C LACP K KQIGTC 	G KCCKK 
Figure 4.3. Sequence alignment of human -defensins HBD1-3. Notice the 
conserved cysteine residues which form disulfides between Cys 1 and 5, 2 and 4, and 
3 and 6. Apart from the cysteine residues and two conserved glycine residue, there is 
very little sequence homology between the peptides. 
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Figure 4.4. The crystal structures of representatives of a- and J3-defensins. A. 
The structure of a-defensin HNP-3. The molecule is dimeric, one monomer is 
coloured gold and the disulfide bonds are highlighted in red. Notice the characteristic 
triple stranded 3-sheet fold. B. A space-fill model of HNP-3, residues are highlighted 
by charge. Notice the aliphatic nature of the molecule. C. The structure of 3-defensin 
HBD- 1. Again, the molecule is dimeric within the unit cell and one monomer is 
highlighted. The characteristic triple stranded 3-sheet is adopted; also notice the 
small N-terminal cc-helix, which is displayed by some 3-defensins. D. A space-fill 
representation of HBD-1 which again highlights the aliphatic nature of defensins. 
74 
Chapter 4: Defensins 
4.2.6 Antimicrobial Activity of Defensins 
Most defensins exhibit broad spectrum antimicrobial activity against both bacteria 
and fungi (199,213-217). Furthermore, many show impressive in vitro activity 
against microorganisms resistant to conventional antibiotics. However, antimicrobial 
activity is sensitive to the ionic strength and the concentration of divalent cations. 
Under optimal conditions (low salt concentration), activity is observed at 
concentrations as low as 1-10 jig/ml (nM to jiM range). Increasing the concentrations 
of salts and plasma proteins competitively inhibits defensin activity. There is 
evidence that some enveloping viruses, including HIV, are also inactivated by 
defensins (218-220). Indeed, human a-defensins have been implicated among the 
molecules that are responsible for the antiviral activity secreted by CD8+ T cells of 
HIV-non-progressors; although these results have recently been questioned 
(221,222). 
At higher concentrations, some defensins have cytotoxic effects against 
mammalian cells (223-225). Furthermore, cells exposed to high concentrations of 
defensins generate pro-inflammatory signals suggesting that defensins could be 
responsible for some tissue injury- especially in the lung (226,227). 
A recent seminal study by Salzman et al. has described the potent in vivo 
activity of a human a-defensin (HD-5) in protecting mice from oral administration of 
virulent Salmonella typhimuriurn (228). Using transgenic mice expressing HD-5, the 
authors demonstrated that this defensin protected animals from an infection that was 
fatal for wild-type mice. Protection was achieved quickly upon administration of 
bacteria, and lower counts of S. typhimurium were observed in the intestinal lumen, 
with less dissemination to other organs. Interestingly, protection was only observed 
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if the dose of S. typhimurium was given orally, not intraperitoneally, supporting the 
hypothesis that defensins act as "locally secreted antibiotics". 
From early studies of defensin peptides, it was thought that the strictly 
conserved cysteines residues, and the resulting characteristic disulfide bridges, were 
essential for antimicrobial activity. Indeed, the disulfide bridging had been shown to 
be integral for maintaining the triple-stranded n-sheet tertiary structure, and it was 
assumed this tertiary structure governed antimicrobial activity. However, in 2002 
Nagaraj and co-workers showed peptide fragments of bovine neutrophil 3-defensin 
BNBD-2 had antibacterial activities which were independent of the number and 
location of the disulfide bridges (229). To my knowledge, this is the first study to 
analyse the direct effects of the disulfide bonds on activity. Recently, this has been 
followed by studies showing that the antimicrobial activity of HBD-3 is independent 
of disulfide bridging (230). Furthermore, analysis of the murine a-defensin, Cryp4, 
and disulfide variants revealed a similar relationship (231). 
So, what biological role does this invariant structural feature perform? It has 
been demonstrated that the chemotactic properties (see section 4.2.9) of HBD-3 are 
dependant on disulfide-bond formation (230). There is also evidence that disulfide 
crosslinking protects defensins from proteolysis by proteases (231). 
4.2.7 Mechanism of Antimicrobial Activity 
Defensins, like all cationic AMPs, exploit a fundamental difference between the 
microbial and host's cell membrane. Bacterial membranes tend to be rich in 
hydroxylated phospholipids (such as phosphatidylglycerol and cardiolipin) and 
contain lipoteichoic acid or lipopolysaccharide (LPS) moieties in their outer 
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membrane (Fig. 4.6). These constituents are anionic and consequently they generate 
a negative charge on the outer membrane of the bacterium. In contrast, eukaryotic 
membranes are principally composed of zwitterionic phospholipids, such as 
phosphatidyicholine and phosphatidylethanolamine. Thus, the outer leaflet of 
eukaryotic membrane has very little net charge. In the model proposed by Shai, 
Matsuzaki and Huang, the first step of cationic AMP action involves an electrostatic 
interaction between the peptide and the anionic bacterial membrane (232,233). This 
theory is supported by experimental data, using artificial membranes, which clearly 
implies electrostatic interactions are crucial for targeting defensins to the bacterial 
cell wall (234-237). What happens once the defensin molecule has located the 
bacterial membrane is less certain. The theories proposed to date can be split into two 
camps- those that propose that higher order structures are formed inside the 
membrane and those that do not (238). 
In the first case, the 'barrel-stave' model, there is evidence for the formation 
of defensin multimers following initial interaction with the membrane. The observed 
leakage of dye markers from liposomes implies that pores are formed, at least 
transiently, within the membrane (236). It is proposed that after the initial interaction 
with the membrane, and upon reaching a threshold concentration, the defensins start 
to self-aggregate and insert deeper into the membrane core. Aggregation allows for a 
minimal exposure of the peptide hydrophilic residues to the hydrophobic membrane 
interior, as the peptides adopt a transmembrane configuration. Lipids may also 
intercalate with the peptides within these channels. These pores then allow the 
leakage of intracellular components out of the cell and/or defensins into the cell. 
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In the second case, 'the carpet model', the defensin molecules act against 
microorganisms though a relatively diffuse manner, often equated with detergents 
(238). A high density of peptides accumulates on the membrane surface. 
Phospholipid displacement, changes in membrane fluidity and/or reduction in 
membrane barrier properties subsequently lead to membrane disruption. This theory 
requires the defensin to adopt no specific quaternary structure. Thus, when a 
threshold concentration of peptide is reached, the membrane is subject to 
unfavourable energetics and membrane integrity is lost. In this theory defensin 
molecules do not need to enter the hydrophobic environment of the membrane core 
(Fig. 4.5). 
In both theories, it seems that disruption of the cell wall and rapid membrane 
depolarisation is the primary action resulting in cell death. However, there is 
evidence that defensins may have intracellular targets, since they have been shown to 
bind to both glycoproteins, and DNA (166,239). Therefore, secondary defensin 
targets may exist. Early studies by Lehrer et al. demonstrated that defensins act on 
both the outer and inner membranes of Gram-negative bacteria independently, and 
the lethal consequences of defensin exposure are correlated specifically to the 
disruption of the inner membrane (240). 
Chapter 4: Detensins 
A. 	 B. 
Figure 4.5. The proposed mechanisms of the antibacterial activity of defensins. 
Hydrophilic regions of the peptides are coloured red, hydrophobic regions of the 
peptides are coloured blue. A. The 'barrel-stave' model. The attached peptides 
aggregate and insert into the membrane bilayer so that the hydrophobic peptide 
regions align with the lipid core region and the hydrophilic peptide regions form the 
interior region of the pore. B. The 'carpet' model. The peptides disrupt the 
membrane by orienting parallel to the surface of the lipid bilayer, carpeting the 
membrane. 
4.2.8 AMP Resistance - Bacterial Countermeasures 
Although AMPs display broad spectrum activity, both constitutive and inducible 
resistance has been documented in bacteria (238). These 'bacterial countermeasures' 
include, reducing the net negative charge of the bacterial cell envelope; expelling 
AMPs through energy dependant pumps; and digestion of AMPs with proteases 
(241). These resistance mechanisms have been noted as key virulence factors in 
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Figure 4.6. Examples of lipid A from the Gram-negative bacterium Salmonella 
enteritica (A) and Lipoteichoic acid from the Gram-positive bacterium 
Staphylococcus aureus (B). Modifications of the bacterial cell envelope components 
involved in defensin resistance. The cationic modifications are highlighted in red. In 
A, addition of both amino-arabinose and C1 6 fatty acids have been documented. In B, 
addition of aniline. 
Reducing the negative charge of the cell wall appears to be the most common 
mechanism of resistance, and has been achieved by both Gram-positive and Gram-
negative bacteria (Fig. 4.6). Gram-positive bacteria have a characteristic thick cell 
wall composed of peptidoglycan and teichoic acid polymers. Teichoic acid consists 
of alternating phosphate and alditol groups, and the phosphate groups confer an 
overall negative charge to the molecule. Partial neutralisation of teichoic acid, by 
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modifying the phosphate group with D-alanine, has been achieved in many Gram-
positive defensin resistant bacteria (staphylococci, streptococci, enterococci, listeriae 
and bacilli) (242). Addition of D-alanine requires four proteins (D1tA, -B, -C and -D) 
which are encoded in an operon. Experimental evidence has demonstrated that 
disruption of this dlt operon in S. aureus abolishes defensin resistance (243). 
Furthermore, it is also believed that another strain of S. aureus modifies 
phosphatidylglycerol with L-lysine, producing lysyiphosphatidyiglycerol (LPG), as a 
means of resisting AMPs (244). The two free amino groups of the lysine moiety of 
lysyiphosphatidyiglycerol result in a net positive charge on the molecule. The gene 
mprF encodes a lysine transferase (using lysine-t-RNA as a substrate) and is required 
for the biosynthesis of this unusual phospholipid and EmprF S. aureus mutants are 
more susceptible to defensins (244). 
In Gram-negative bacteria a similar resistance mechanism exists (Fig. 4.4). 
One of the major components of the outer membranes of these bacteria is 
lipopolysaccharide (LPS), and reduction in the anionic charge of LPS has been well 
documented. The anionic component of LPS, lipid A, is composed of a glucosamine 
dimer flanked by phosphate groups and linked to five or more fatty acids (245). 
Modification of the lipid A moiety with aminoarabinose has been documented in 
Salmonella enterica, Pseudoinonas aeruginosa and Burkholderia cepacia (246-249). 
The free amino group of aminoarabinose leads to the reduction in the net charge of 
lipid A, and confers resistance to defensins and other cationic AMPs (Fig. 4.4). The 
pmrE and pmrHFIJKL genes are responsible for the biosynthesis of aminoarabinose 
and its addition to lipid A, and S. enterica pmrF mutants have been shown to be 
virulence attenuated in mice (250). Modification of lipid A with 
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phosphoethanolamine is also found in cationic AMP resistant S. enterica and is 
thought to alter the net charge of lipid A in a similar way (251). 
These genes which confer resistance to defensins and other cationic AMPs in 
Gram-positive bacteria are under the control of the PhoP-PhoQ regulon (246). This 
two-component master-regulatory' system controls many virulence factors in 
response to changes in magnesium and calcium ion concentrations (252). 
Bacterial efflux pumps, which are proton-motive-force dependent, have long 
been known to confer resistance to organic dyes and disinfectants. Recently, 
however, they have been linked with increased resistance to cationic AMPs. The 
MtrCDE exporter has been shown to increase resistance to the mammalian AMPs 
protegrin and cathelicidin in Neisseria gonorrhoeae and similar mechanisms have 
been demonstrated in some clinical strains of S. aureus (253,254). 
Finally, in a recent publication by Islam et al. a novel concept of resistance to 
HBD-1 and LL-37 was documented in the Shigella species (255). The mechanism 
involves inhibiting the production of these peptides in human rectal epithelial cells. 
The event involves Shigella plasmid DNA but is not fully understood. 
4.2.9 Other Biological Roles of Defensins 
In addition to their broad spectrum antimicrobial properties, there is growing 
evidence that defensins have additional biological activity and act as important signal 
molecules in the immunological repertoire; see review ref (129,256). Recent reports 
suggest that defensins act as chemokines, and thus serve as a bridge between the 
innate and adaptive immune systems. Over fifteen years ago, HNP-1 and -2 were 
shown to be chemotactic for human monocytes, and more recently they have been 
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shown to induce migration of human T lymphocytes and dendritic cells (DCs) 
(257,258). Similar activity has been observed for -defensins- for example, HBD-2 
is chemotactic for immature DCs, 1-cells and neutrophils treated with TNF-
cx (259,260). In each case, HBD-2 acts by binding to the CCR6, a member of a large 
family of G-protein coupled receptors (GPCR). Mouse 13-defensin-2 also triggers 
maturation of DCs though an interaction with Toll-like receptor 4 (TLR4) (261,262). 
Finally, HBD-2 also induces mast-cell migration via chemotaxis through an, as yet, 
unknown pathway (263). 
Neutrophil derived a-defensins from humans, rats, guinea pigs and rabbits 
cause peritoneal mast cells to release histamine (264). This process is triggered at nM 
concentrations of defensin, and acts through a G-protein-dependant process. A 
similar activity has also been observed using HBD-2, but not HBD-1 (265). 
Histamine, as well as being a mediator of inflammation, is an important bioactive 
marker for mast-cell degranulation. As the granules of human and mouse mast-cells 
contain both 3-defensins and cathelicidins (some of which are chemotactic for 
neutrophils), as well as a range of serine proteases, this process can be viewed as a 
communication circuit between the bodies neutrophils and mast-cells (266,267). 
In 1994, human a-defensins were shown to interact with complement (268). 
Purified HNP-1-3 from human neutrophils were immobilised and subsequently 
shown to bind Clq and trigger the classic pathway of complement activation (269). 
However, more recent work has cast doubt on these early findings, as van den Berg 
et al. demonstrated that HNP-1 in solution inhibited activation of the classical 
pathway (270). To date the exact effect of defensinl complement interactions remain 
unclear. In addition, there is evidence that some rabbit neutrophil defensins are 
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opsonins, aiding the ingestion of Kiebsiella pneumoniae by macrophages (271); (X-
defensins have also shown to have both cytotoxic and growth promoting effects 
under controlled conditions (225,272-276). 
Finally, recent evidence suggests that many defensins are lectins - they 
recognise and bind carbohydrates (166,169,170). The antiviral activity of some 
defensins has been attributed to this property. HNP-1-3 and retrocyclin (a 8-defensin) 
have been shown to bind to glycoprotein B2 (gB2) of herpes simplex virus type 2 
(HSV-2) - gB2 has an essential role in allowing HSV-2 to attach and enter the target 
cell (169,277,278). 
4.3 	Defensins in human health 
Current and rapidly expanding information on defensin expression, structure, and 
biological activity has established a firm foundation for further study of the role that 
these peptides may have in human health and disease (279). However, to date, only 
limited work has been performed exploring the direct relationship between 
defensin/AMP function and disease pathogenesis. 
4.3.1 Lung Disease - Cystic Fibrosis 
One possible example of inactivation of defensin and other AIVIPs causing human 
disease has been proposed for cystic fibrosis (CF). CF is the most common 
autosomal recessive genetic disease caused by the mutation in the cystic fibrosis 
transmembrane regulator (CFTR) gene. The CFTR gene encodes a regulated chloride 
channel that also functions as a regulator of other ion channels, and mutation of this 
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gene leads to an imbalance in the airway surface liquid. The main cause of morbidity 
and mortality in CF is respiratory failure due to the progressive destruction of the 
airway and lungs by a cycle of recurring infection and inflammation. These 
infections are typified in early childhood by S. aureus and Hemophilus influenzae, 
but eventually these are succeeded by Pseudomonas aeruginosa and this infection 
indicates the onset of progressive lung disease. 
These events indicate a local defect in epithelial host defence, as the infection 
is strictly limited to the lungs and does not spread elsewhere (280). In 1996, Smith et 
al. proposed that this impairment was due to inhibition of defensin and cathelicidin 
activity by an abnormally high ionic environment in the CF lung (281). This theory is 
supported by evidence that HBD-1 is inactivated in CF, and that overexpression of 
cathelicidin in a CF xenograft model restores bacterial killing (217,282). According 
to this theory, the thin layer of fluid that coats the respiratory epithelia, known as the 
airway surface liquid (ASL), normally has a low salt concentration relative to blood 
plasma- conditions which favour the activity of cationic AMPs. In CF, the ability to 
absorb salt from the epithelial cell fluid is compromised which leads to an increased 
salt concentration in the ASL, and consequently a loss in AMP activity. However, 
measuring the salt concentration of ASL has proved problematic and very little direct 
evidence supports this theory. Alternative hypotheses have been proposed, and the 
role of defensins in CF pathogenesis remains speculative (283,284). 
4.3.2 Dermatological Diseases - Psoriasis and Atopic Dermatitis 
As outlined in section 4.2.2-4.2.4, defensin genes in epithelial cells are upregulated 
during infection and injury. However, a similar but much longer-lasting increase in 
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defensin and cathelicidin expression has been observed in some inflammatory 
conditions, such as psoriasis (141,147,285,286). Evidence suggests that patients with 
psoriasis have a decreased incidence of several types of infection (287). This 
resistance has been proposed to be due increased epithelial AMP expression in these 
patients. 
In contrast, recent studies have extended these association by demonstrating 
that patients with atopic dermatitis have insufficient amounts of LL-37 and HBD-2 
expressed at the skin surface (288). These patients are frequently subjected to skin 
infections by several microorganisms. 
Finally, another dermatological example of the effect of defensins is seen in 
burn wounds. The concentration of defensins and cathelicidins is reduced in bum 
wound fluid in comparison with incision wounds (289). Bacterial infection of bum 
wound is a common problem, particularly with P. aeruginosa, a bacterium 
particularly sensitive to the AMPs down-regulated. Thus, a relative deficiency of 
AMPs in the burn environment might contribute to local and systemic 
immunosuppression. 
4.3.3 Inflammatory Bowel Diseases 
Increased AMP expression has been observed in association with several diseases of 
the gut (290). HD-5 is expressed from Paneth cells in the colon in inflammatory 
bowel disease but is not present in normal colonic mucosa, HD-6 and HBD-2 has 
also been linked to this disorder (291-293). 
Surface intestinal epithelial cells induce the expression of five defensins in 
active ulcerative colitis but not in normal or inactive disease (294). In contrast, 
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Crohn's disease is characterised by the down-regulation of HBD-2 and -3 in the 
colon (295). This disease, which involves inflammation and frequent infection of the 
bowel, may be a 'defensin deficiency syndrome' (296). 
Gastrointestinal infections are also associated with defensin expression. H. 
pylori infection has been shown to induce HBD-2 expression in the human gastric 
epithelium (297). Finally, in a startling example, the expression of both LL-37 and 
HBD-1 is turned off in early Shigella infections in humans (255). This down-
regulation has been proposed as a virulence factor in the development of the disease. 
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4.4 	Defensin-Related Peptide - Defrl 
The dogma that all defensins contain the conserved six-cysteine motif was recently 
challenged by a report by our collaborators, who recently described a murine 3-
defensin gene in C571316 mice that encoded a 34 amino acid peptide with only five 
cysteine residues (Defrl, accession no. AJ344114, Fig. 4.5) (298). This gene is a 
variant allele of Defb8, a classical defensin which encodes six cysteines and is found 
in all other inbred murine strains tested (299). Defrl was shown to be expressed 
mainly in the heart and testis, and a synthetic Defrl peptide displayed potent 
antimicrobial activity against both Gram-positive and Gram-negative bacteria. 
In the work reported here we have performed both structural and functional 
analysis of Defrl and its six-cysteine analogue (Defrl Y5C) and report a novel 
relationship between the tertiary structure and antimicrobial activity of this unique 
defensin. 
1 2 3 	 4 56 
Defb8 	EPVSCIRNGGICQYRCI GLRHKI GTCGSPFKCCK 
Defrl DPVTYIRNGGICQYRCI GLRHKI GTCGSPFKCCK 
Defrl Y5C DPVTCIRNGGICQYRCIGLRHKIGTCGSPFKCCK 
Figure 4.7. Sequence of Defb8, Defri and Defrl Y5C. Numbering corresponds to 
the six conserved cysteines found in 3-defensins. Notice the loss of Cysi in Defrl. 
The overall charge of each sequence is +5. 
Chapter 5: Structural and functional characterisation of detensin related 
peptide-1 (Defri). 
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5.1 	Antimicrobial Properties of Defri and Defri Y5C 
5.1.1 Antimicrobial Activity of Defrl and Defri Y5C 
In a previous study, Dorin and coworkers demonstrated that, despite having only five 
cysteine residues, murine Defri displayed antimicrobial activity at nanomolar 
concentrations (298). Here we analysed synthetic Defri and its six cysteine 
analogue, Defri Y5C, and have determined the minimum bactericidal concentrations 
(MBCs) of the oxidised and reduced forms of both peptides against a diverse panel 
of clinically relevant microbes (Table 5.1). Numerous methods have been used in 
various laboratories to determine the antimicrobial activities of defensins 
(229,231,300). Typically, the test organism is exposed to the peptide (0 - 24 hours), 
followed by growth on liquid or solid media and subsequent determination of optical 
densities and/or counting of surviving colonies relative to a control. Antimicrobial 
activities (ig/ml) are quoted as MICs, MBCs, LD50s or LD90s (dose required to kill 
50% or 90% bacteria). 
At the outset we incubated P. aeruginosa PAO1 with peptides for 0, 1, 4 and 
24 hours and noted that the MBCs (99.99% bacteria killed) were the same for each 
time point indicating that the peptides killed within an hour of administration (Fig. 
5.1). We therefore carried all the reported broth dilution assays with a 1 hour 
incubation time (see Materials and Methods). 
The test peptides were assayed against a panel of multiresistant, clinically 
relevant pathogens which included highly transmissible P. aeruginosa strains 
responsible for outbreaks in CF clinics in Manchester (C3425), Liverpool (H183), 
Brisbane (C4269), and Melbourne (C3781); B. cepacia complex isolates (ATCC 
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25416 and J2315); Sten. maltophilia isolates (C1980, C3625, C3626, C3627); 
Raistonia pickettii (C3079) and Raistonia eutropha (C3081); Bordetella 
bronchoseptica J3083; MRSA S113; and Candida albicans J2922. Other bacteria 
investigated were laboratory reference stains of E. coli (ATCC 25922), P. 
aeruginosa (PAO1), S. aureus (ATCC 25923), and E. faecalis (ATCC 29212). 
Time (Minutes) 
Figure 5.1. Time-Kill Assay. A defensin killing assay (including PAUl and Defri 
at 5 x MBC: 25 .tg/ml) was prepared and a bacterial sample was removed at 30-
minute intervals, and plated to determine the viable count (CFU/ml). The data shows 
that bacterial viability was reduced significantly within the first 30 minutes, and 
completely abolished by 60 minutes. 
Defri exhibited broad spectrum antimicrobial activity, with MBCs ranging 
from 3-12.5 ig/ml against all organisms tested, with the exception of the two B. 
cepacia complex isolates. Defri also displayed antifungal activity against Candida 
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albicans. The high-resistance to Defri displayed by the B. cepacia complex isolates 
(MBC>lOOj.xg/ml) is in agreement with well documented evidence that these bacteria 
are highly resistant to cationic AMPs (301,302). 
In contrast, the six cysteine analogue Defri Y5C displayed MBCs in the 
range 50-100 Lg/mI against Gram-negative bacteria, ~!100 tg/ml against Gram-
positive bacteria, and 25 tg/ml antifungal activity. The increased MBCs of Defri 
Y5C compared with Defri highlight a significant increase in potency for the 5 
cysteine variant. Recent work by Wu et al. has demonstrated that the activity of 
human f-defensin 3 (HBD3) is independent of the number and connectivity of 
disulfide bridges within the molecule (230). To test this hypothesis we repeated the 
antimicrobial assays with both peptides after complete reduction with excess DTT. 
Reduced Defri Y5C had similar MBCs to its oxidised form, supporting the 
hypothesis that its activity is independent of the presence of disulfide bonds. 
However, the MBCs of reduced Defri were significantly higher than its oxidised 
form and similar to the MIBCs for Defri Y5C. Thus, in this instance, it appears that 
the presence of disulfide bonds does influence the antimicrobial activity of the 5 
cysteine containing peptide. 
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Organism Strain Description MBCa (ImI) 
Defri Defri Detri Y5C 
Detri Y5C Red Red 
Gram-negative 
P. aeruginosa PAOI Lab Strain 6 50 50 100 
C3425 Manchester 6 50 100 100 
1-1183 Liverpool 6 100 100 >100 
C4269 Brisbane 6 >100 100 >100 
C3781 Melbourne 6 100 100 >100 
P235 LPS Rough Mutant 6 >100 50 >100 
ATCC 
E. co/i 25922 Culture Collection 8 >100 >100 50 
ATCC 
B. cepacia 25416 Culture Collection - GI >100 >100 NDb ND  
J2315 Clinical Isolate - Gill >100 >100 ND" ND" 
S. maltophilia C1980 Clinical Isolate 12.5 >100 >100 >100 
C3625 Clinical Isolate 6 >100 50 >100 
C3626 Clinical Isolate 3 >100 >100 >100 
C3627 Clinical Isolate 6 >100 >100 >100 
C3642 Clinical Isolate 12.5 >100 >100 >100 
B. bronchoseptica J3083 Clinical Isolate 6 >100 >100 >100 
picketti C3079 Clinical Isolate 3 >100 >100 >100 
R. eutrooha C3081 Clinical Isolate 3 >100 >100 >100 
Gram-positive 
ATCC 
E.faecalis 	29212 	Culture Collection 
ATCC 
aureus 	25923 	Culture Collection 
S  l3/J29l8 Clinical Isolate - MRSA 
6 	100 	>100 	ND" 
10 	>100 	>100 	>100 
6 >100 25 >100 
Fungi 
C. albicans 	J2922 	Clinical Isolate 	3 	25 	25 	50 
Table 5.1 Antimicrobial activity of Defri and Defri Y5C. aI\4BC  values are the 
minimum concentration required to kill 99.99% of initial inoculum. "ND, not determined. 
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5.1.2 Salt Sensitivity of Defri and Defri Y5C 
For further comparison we also analyzed the effect of high salt concentrations on the 
antimicrobial activities of Defri and Defri Y5C against P. aeruginosa (Fig. 5.2). 
The activity of Defrl Y5C was extremely salt sensitive, killing only 10% of 1 x 1 
05  
bacteria in the presence of 25 mM NaCl and being completely inactive at 50 mM 
NaCl. In contrast, Defri displayed 100% killing at 25 and 50 mM NaCl, 84% killing 
at 150 mM NaC1 and 28% killing even at 300 mlvi NaCl. These salt sensitivity 
results further highlight the significant differences between the antimicrobial activity 
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Figure 5.2. The effect of NaC1 concentration on the antimicrobial activity of 
Defri and Defri Y5C. P. aeruginosa PAO1 cells (1 x 105 CPU in 100 111) were 
resuspended in 10 mM sodium phosphate buffer, 0.1% ISB, pH 7.4 containing 0, 25 
50, 150 and 300 mlvi NaCl. Bacteria were challenged with defensin at 4 x MBC (24 
.ig/m1 for Defri and 200 Jig/ml Defri Y5C) for 1 hour at 37 °C before serial 
dilutions of the assay mixture were plated on ISA plates and grown overnight at 37 
°C. CPUs were counted and the percentage bacteria killed determined. 
MA 
Chapter 5: Defensin related peptide 1 
5.2 	Structural properties of Defri and Defri Y5C 
To rationalise the striking differences observed in antimicrobial activity between 
Defri and Defri Y5C, the structure of the two peptides was investigated. This was 
undertaken using a combination of native gel electrophoresis, reverse-phase 
chromatography, and high-resolution mass spectrometry using Fourier transform ion 
cyclotron resonance (FT-ICR-MS). In contrast to both NMR and x-ray 
crystallography, FT-ICR-MS requires only microgram amounts of each peptide for 
analysis. 
5.2.1 Native Gel Electrophoresis 
To analyse the structure of Defri and Defri Y5C they were subjected to non-
denaturing electrophoresis on 16% Tricine gels (Fig. 5.3). In their oxidised states, the 
predominant forms of both peptides migrated with apparent molecular weights of 
—7kDa which suggests that both defensins can dimerise under these conditions. 
Reduction of both peptides with excess DTT increased their apparent mobility to 
—4kDa which indicates they are present as monomers and that disulfide bonds are 
involved in maintaining their tertiary structure. It is interesting to note the 
observation of significant amounts of Defri dimer even after incubation with DTT 
which suggests increased stability of the Defri dimer over the Defri Y5C dimer 
under reducing conditions. 
Previous studies on various antimicrobial peptides have revealed that some, 
but not all, can dimerise. For example, HBD3 is a potent antimicrobial peptide 
isolated from human skin which has been the subject of intensive structural and 
functional studies (142). By native gel electrophoresis dimeric HBD3 was observed 
under oxidising conditions whereas monomeric HBD3 was detected after reduction 
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(211). Modeling studies predict that the dimer is formed through a combination of 
electrostatic salt bridges and H-bonding between amino side chains. Octomers, 
formed by amide backbone interactions, have also been observed in the crystal lattice 
of HBD2 (209). The formation of higher order aggregates of antimicrobial peptides 
has been proposed as one factor which contributes to their ability to disrupt bacterial 
membranes (303). Since oxidised Defri and Defri Y5C behave in a similar manner 
by gel electrophoresis, dimerisation alone cannot explain the significant differences 




Figure 5.3. Colloidal Coomassie-stained non-denaturing 16% Tricine gel of 
oxidised and reduced Defri and Defri Y5C. lane 1, Defri reduced; lane 2, Defri 
oxidised; lane 3, Defri Y5C reduced; lane 4, Defri Y5C oxidised. Mass markers in 
kDa are indicated. 
5.2.2 Characterization of the nature of dimerisation of Defri and Defri 
Y5C using FT-ICR mass spectrometry 
To identify the structural differences between Defri and Defri Y5C, which could 
account for the difference in antimicrobial activity, high-resolution FT-ICR mass 
spectrometry was employed. The resolving power and accuracy of this instrument 
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allows the determination of the mass and isotopic distribution of large biomolecules. 
A comparison of experimentally observed values to those predicted based on the 
empirical formula for the oxidised and reduced forms of both defensins can then be 
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Figure 5.4. Defri Y5C FT-ICR isotopic envelope. The deconvoluted isotopic 
envelope from FT-ICR nanospray analysis of oxidised Defri Y5C. (A), Triangles 
correspond to the isotopic envelope expected from a Defri Y5C monomer with all 
cysteines oxidised i.e. contains 3 disulfides. (B), shows the equivalent spectra for the 
dimeric form of Defri Y5C. Again the triangles represent the isotopic envelope 
expected from a dimer with all cysteines oxidised i.e. 6 disulfide bonds. The 
elemental composition of oxidised Defri Y5C monomer with 3 disulfides is 
C157H754N50043S6, average mass 3722.4490 Da and a Defri Y5C dimer with 6 
disulfide bonds is C314H508N100086S12, average mass 7444.898 Da. 
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Analysis of the ion envelope and deconvolution for Defrl Y5C suggested the 
presence of two species (Fig. 5.4 A and B). The isotopic distributions and masses fit 
very well to those predicted for a Defri Y5C monomer containing 3 disulfide bonds 
(elemental composition C157H254N50043S6, average mass 3722.4490 Da, Fig. 5.4A) 
and to a dimeric Defri Y5C with 6 disulfide bonds (C314H508N1 086S12, average 
mass 7444.898 Da, Fig. 5.413). Artificial dimerisation and formation of higher order 
aggregates has been observed for proteins under the conditions used in electrospray 
ionisation (ESI). However, we do not believe the dimer to be an artifact since it was 
also observed by native-gel electrophoresis in a 6-fold excess over the monomer. 
Nevertheless, since the dimer peak displays 16% relative abundance compared to the 
monomer, it is clear that the dimer is not stable to the electrospray process suggesting 
dimer formation by weak, non-covalent interactions. 
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Figure 5.5. Defri FT-ICR isotopic envelope. High resolution mass spectrum of 
oxidised Defri dimeric isoforms. The triangles correspond to the isotopic envelope 
calculated from the Defri amino acid sequence containing five disulfide bonds. The 
elemental composition for Defri dimer is C326H518N100088S10, average mass 
7566.9761 Da. 
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FT-ICR analysis on oxidised Defrl produced the mass spectrum which upon 
denconvolution gave rise to one major species (Figure 5.5) whose isotopic 
distribution matched that expected for a fully oxidised dimer containing 5 disulfide 
bonds (elemental composition for Defrl dimer C326H518N1 00088S1 0, average mass 
7566.9761 Da). Interestingly, there was no peak corresponding to Defrl monomer. In 
contrast to that observed for Defrl Y5C, the Defri dimer remains intact under 
electrospray conditions, which implies a strong interaction between monomers. Since 
a Defrl dimer contains 10 cysteine residues, and a fully oxidised isoform has 5 
disulfide bonds, dimerisation can only occur through formation of at least one 
intermolecular disulfide bridge. 
5.2.3 Dissociation of defensin dimers 
Collision induced dissociation (CID) and electron capture dissociation (ECD) are 
powerful mass spectrometry techniques used for analysing protein structure which 
complement traditional methods (304,305). These fragmentation techniques were 
employed to characterize the protein-protein interactions mediating dimerisation in 
Defri Y5C and Defrl. 
For CID analysis of the Defrl Y5C dimer, a peak corresponding exclusively 
to the +5 charge state of the dimer (nilz 1490) was isolated and subjected to 
dissociation (Figure 5.6). The +5 ion readily dissociates into two monomers with +3 
(m/z 1242) and +2 (m/z 1862) charge states (Fig. 5.6 - inset). Dissociation of the 
dimer occurs without fragmentation of the peptide backbone demonstrating that the 
Defrl Y5C dimer is unstable thereby supporting our hypothesis that dimerisation is 
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Figure 5.6. Collision-induced dissociation (CID) spectra of Defri Y5C. The ion 
envelope for nanospray FT-ICR analysis of Defri Y5C is shown with each ion 
annotated as monomeric [M], or dimeric [D]. Inset - the dimer D 51 ion with m/z 
1488.905 (monoisotopic mass) was subjected to CID and gave rise to monomeric 
fragment ions with +3 and +2 charge states. 
In stark contrast, the Defri dimer was stable to the same CID conditions used 
for Defri Y5C. When the stable dimeric ion corresponding to the +7 charge state 
(m/z 1082) was isolated and subjected to dissociation no significant monomeric 
daughter' fragments were observed (Fig. 5.7). Increasing the amount of gas into the 
collision cell still did not dissociate the dimer, but did allow us to partially sequence 
the peptide since it gave rise to a distinct b-type fragment series from the N-termini 
up to the location of the first cysteine (b2-blO) and a y-type fragment resulting from 
the loss of a C-terminal lysine (Fig. 5.7 - inset). Such stability under CID conditions 
indicates the Defri dimer is held together by covalent bonding. 
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Figure 5.7. Collision-induced dissociation (CID) spectra of Defri. The +7 charge 
state (m/z 108 1.401, monoisotopic mass) generated by nanospray FT-ICR MS was 
isolated and subjected to collisional activation with argon for 40ms prior to detection. 
Fragments arising from activation are labeled. The Defri species remains intact but 
CID produces b and y ions arising from the cleavage of the amide backbone. Inset, 
magnification of the y ions at m/z 1200-1300. 
These observations are complimented by ECD, where cleavage of Cys-Cys disulfide 
bridges is known to be a favored process (306). When the isolated +7 charge state of 
the Defri dimer was subjected to ECD, the molecule readily dissociated into 
monomers with charge states +2, +3 and +4 (rn/z 1893, 1262, and 949 respectively 
(Fig. 5.8). On closer inspection (Fig. 5.8, inset), we observed low intensity species 
with masses +1- 16 Da either side of the +2 monomer peak, which indicate the 
gain/loss of a sulfur atom. We can explain the appearance of these species only if the 
Defri dimer is formed by a covalent intermolecular disulfide bond. Here, the ECD 
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process has cleaved the dimer into monomers by two mechanisms. Firstly, symmetric 
cleavage of the S-S bond to give a monomer signal with m/z 1892.5. The alternative 
pathway involves asymmetric cleavage of the C-S bond of the intermolecular 
disulfide bridge to give rise to two monomers; one with a persulfide SH at in/z 1909 
and its corresponding partner having lost S at in/z 1876.5. The mechanisms of the 
cleavage of the S-S and S-C bonds are analogous to those previously observed by 
CID (307). 
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Figure 5.8. Electron capture dissociation (ECD) of Defri. Defri was subjected to 
nanospray FT-ICR MS and the [D]7 dimer ion (m/z 108 1.401) was isolated and 
irradiated with electrons for SOms. This caused the +7 ion to fragment into +5, +4, +3 
and +2 monomers. The magnification of the +2 monomer ion series is, which results 
from both symmetric and asymmetric cleavage of the intermolecular S-S bond, is 
shown. 
The use of high-resolution FT-ICR, coupled with two dissociation techniques 
has revealed structural differences between Defrl Y5C and Defrl and for the first 
time identified a defensin dimer containing an intermolecular disulfide bond. 
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5.2.4 Reverse-phase high-pressure liquid chromatography 
High-pressure liquid chromatography (HPLC) on a C1 8 reverse-phase column was 
used to investigate structural differences between the oxidised and reduced forms of 
both peptides. Oxidised Defri Y5C eluted as a single, sharp peak at 26.8 mins on a 
20-35% acetonitsile gradient. This species had a mass of 3722.0 Da by ESI-MS in 
good agreement with the predicted value of 3722.3 Da for Defrl Y5C with the loss 
of six hydrogens. Upon incubation with excess DTT the single peak eluted earlier in 
the gradient at 23.6 mins and this shift in retention time suggested that reduction of 
the disulfide bonds caused a change in the structure of the defensin (the mass of this 
species is 3728.1 Da). It is thus apparent that Defri Y5C folds to give a single 
species. Upon refolding from a denatured state we would normally expect a shift to 
shorter retention time on a reverse-phase column resulting from burial of 
hydrophobic residues. The refolding mechanism of defensins is not well understood 
but appeal's to be governed by the formation of the disulfide bonds. Since defensins 
are amphipathic and contain surface-exposed hydrophobic and cationic patches, 
these properties can be postulated to explain this unusual chromatographic behavior, 
which has also been observed for the oxidative folding of HBD2 (230) 
In contrast, oxidised Defri eluted as a broad peak between 22 and 24 mins 
which we were unable to resolve despite trying a range of conditions (under ESI 
conditions Defri 7566.0 Da in agreement with a dimer with the loss of 10 protons). 
Upon reduction with excess DTT Defri eluted as a single, sharp peak at 21.8 mins 
(mass 3788.0 Da, predicted mass for fully-reduced 3788.2 Da). This data suggests 
that during oxidative refolding Defri has formed a number of different species all of 
which are dimeric. This phenomenon has been observed for HBD3 which was shown 
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to form several different oxidised isoforms from a single reduced precursor (230). 
The differences in the chromatographic behavior of Defri and Defri Y5C again 
suggest that their structures are dissimilar. 





Figure 5.9. HPLC analysis of the oxidised and reduced forms of Defri and 
Defri Y5C. Analysis was performed on a Cl 8 reverse phase HPLC column using a 
15-40% acetonitrile gradient over 40 minutes. (A). Analysis of Defri Y5C, the red 
trace corresponds to oxidised Defri Y5C and the blue trace corresponds to reduced 
Defrl Y5C. (B). Analysis of Defri, the red trace corresponds to oxidised Defri and 
the blue trace corresponds to reduced DefrI. 
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5.2.5 Determination of Disulfide Connectivity of Defri and Defri Y5C 
To determine their S-S connectivities, both defensins were subjected to protease 
cleavage and analysis of the resulting peptide fragments by MALDI-TOF and Q-
TOF mass spectrometry. Trypsin cleavage of Defri Y5C produced two major 
fragments which were easily separated by HPLC (Table 5.2). Fragment 1 had a mass 
of 1711.87 Da and was unmodified by treatment with chymotrypsin, consistent with 
the species (D1-R7) + (C16-R20) + (C32-K34) containing 2 disulfide bonds 
(calculated mass 1711.84 Da). Because (C32-K34) contains two adjacent cysteines 
(Cys5 and Cys6) this data alone cannot be used to assign the absolute connectivity. 
However, from the mass of the first fragment we can assign the connectivity as either 
Cysl-Cys5 and Cys3-Cys6 or Cysl-Cys6 and Cys3-Cys5. The second tryptic 
fragment had a mass of 1817.54 Da, and was susceptible to chymotrypsin producing 
a species with mass 1532.70 Da. These results are consistent with the second tryptic 
fragment being (N8-R15) + (123-K31) containing 1 disulfide bond (calculated mass 
1816.86 Da), and its chymotrypsin derivative being (N8-Y14) + (123-F30) 
(calculated mass 1532.66 Da), allowing the assignment of a disulfide bond between 
Cys2-Cys4 (Fig. 5.10). 
105 
Chapter 5: Detensin related peptide 1 
Cale. Mass 	Obs 	Cale. Mass Obs. Mass 
Assignment 	 (+1) Massa Chymo (1)b 	Chymo" 	Disulfide Bridge 
Fragment 1 	(D1-R7) + (C16-R20) + (C32-K34) 	1711.84 	1711.87 	1711.84 	1711.55 	C1-05 C3-C6 or 
C1-C6 C3-05' 
Fragment 2 	(N8-R15) + (123-K31) 	1816.86 	1817.54 	1532.66 	1532.70 	C2-C4 
Table 5.2. Determination of the disulfide bond connectivity of oxidised Defri 
Y5C. Trypsin digest of the peptide produced two fragments. The purified peptides 
(Fragment 1 and Fragment 2) were analyzed by MALDI-Tof. Each fragment was 
also digested separately with chymotrypsin before assignment. 
'Calculated and observed masses of tryptic fragments (Da) 
bCalculated and observed masses of fragments after treatment with chymotrypsin 
(Da) 
'Assignment of S-S connectivity for fragment 1 was determined to be C1-05 C3-C6 
using CID (see text). 
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C3-C6 
DPVT IRNGGI QYR IGLRHKIGT GSPFK K 
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Figure 5.10. Proteolysis of Defri Y5C. Defri was first digested with trypsin which 
produced two fragments, consistent with f3-defensin topology. A chymotrypsin 
digestion of each fragment was used to verify assignment. 
To distinguish between CysS and Cys6 in fragment I we used a Q-TOF 
tandem mass spectrometer and CID to sequence the peptides. Dissociation of the +3 
charge state of fragment 1 resulted predominantly in the sequential loss of residues 
from the N-terminus of the fragment (DI-R7). However, a +2 species was observed 
with in/z 405.48 Da (deconvoluted mass 808.96 Da), which we attribute to (C16-
R20) + (C33-K34) (calculated mass 808.41 Da), which allows the assignment of the 
disulfide bridge between Cys3-Cys6 and thus, by elimination, Cysl-Cys5. In 
summary, oxidised Defri Y5C monomers contain the typical 3-defensin S-S 
connectivity (Cysl-Cys5, Cys2-Cys4, Cys3-Cys6). It is worth noting that the NMIR 
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structure of mBD-8 (NEPVSCIRNGGICQYRCIGLRHKIGTCGSPFKCCK) has 
been determined (PDB accession code IE4R) (212). This defensin is very similar to 
Defrl Y5C, the only differences being at the N-terminus (NEPVS of mBD-8 replaces 
DPVT of Defri Y5C). Since the sequences of mBD-8 and Defrl Y5C are highly 
similar and they both display 3-defensin connectivities we suggest that mBD-8 is a 
good model for the 3D structure of Defrl Y5C. 
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Figure 5.11. Cifi Spectrum of Defrl Y5C tryptic fragment 1. The 3+ charge state 
(mlz 572.22) was isolated and subject to CID. This led predominantly to sequential 
loss of N-terminal residues, yielding a series of y-ions (Main diagram, loss of 
residues highlighted. Inset B, cleavages shown in red). However, a 2+ species with 
m/z 405.48 was observed which was attributed to cleavage between Cys5 and Cys6 
(Inset A and Inset B, highlighted in purple). This species allowed the assignment of 
Cys3-Cys6 and Cysl-Cys5). 
In contrast to its six cysteine analogue, cleavage of oxidised Defri with a 
combination of trypsin and chymotrypsin produced a complex mixture of peptide 
products which proved impractical to separate by HPLC. Instead, the unfractionated 
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mixture was analyzed by MALDI-TOF MS. The mass spectra obtained from analysis 
of the reduced peptide products revealed that proteolysis had been incomplete, and 
many peptides were present which contained uncleaved, internal proteolysis sites 
(see table 5.3A). Analysis of the oxidised tryptic digest peptide products enabled the 
assignment of disulfide connectivities (see table 5.313). Peaks were observed with 
masses consistent with peptide fragments with Cys2-Cys3, Cys2-Cys4, Cys3-Cys4, 
and Cys4-Cys4 disulfide bonds. To confirm the initial assignment of these masses 
and identify potential disulfide bonds we again carried out N-terminal sequencing of 
selected peptides by CID. This allowed us to confirm the identity of the N-terminal 
fragment (Dl-R7), and peptides containing disulfide bridges between Cys2-Cys3 and 
Cys2-Cys4. 
Our analysis revealed Defrl has S-S connectivities not typical of either a or 
defensins. It appears form our proteolysis/mass mapping data that certain cysteine 
residues (e.g. Cys2) can form disulfide bonds with more than one other cysteine. 
This can only be explained if Defril is a mixture of topologically different dimeric 
isoforms, rather than a single species with a defined connectivity. The HPLC 
analysis also supports the unusual nature of Defri. The broad peak resulting from 
RP-HPLC analysis of oxidised Defri again suggests that Defri is heterogeneous. 
The high-resolution FT-ICR data prove that all of these isoforms are dimeric 
connected by an intermolecular disulfide bridge. However, it appears that the 
intermolecular disulfide bond is not formed exclusively between two equivalent 
cysteine residues from each monomer e.g. Cys5'-Cys5 or Cys4'-Cys4. Rather, our 
proteolysis and chromatography data suggest that the Defri dimer can be formed via 
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any two cysteine residues from each monomer from a possible 15 combinations e.g. 
Cys2'-Cys3. 
Recent work on synthetic HBD3 led to the surprising discovery that it did not 
fold into a single isoform with typical 3-defensin disulfide connectivity in vitro 
(230). Instead, at least 7 topologically distinct isoforms were isolated with unusual 
intramolecular connectivities, all of which displayed similar antimicrobial activity. It 
is noteworthy that the S-S connectivity of native, HBD3 purified from human skin 
has not been determined (142). Interestingly, none of these isoforms contained an 
intermolecular disulfide bond. The authors were unable to determine the individual 
connectivity of these isoforms, so devised a synthetic protocol which allowed the 
control of disulfide bond formation. We are currently exploring whether this, or a 
similar, strategy can be used to control the formation of a specific intermolecular 
disulfide bond in Defri. 
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Relative 
Assignment 	CaIc. Mass (+1) 	Obs. Mass 	Abundance 
(D1-R7) 863.46 863.71 72 
(16-Y14) 1023.50 1023.98 91 
(16-1115) 1179.60 1179.92 11 
(H21-F30) 1046.50 1046.95 67 
(N8-R20) 1452.71 1452.72 26 
(06-F30) 1588.80 1588.67 20 
(1115-F30) 1744.90 1744.54 100 
(06-K34) 2051.01 2051.21 13 
 
Caic. Mass 	 Relative 	N-terminal 
Assignment 	(+1) Obs. Mass 	Abundance Sequencing' 	Disulfide Bridge 
(D1-R7) 863.46 863.36 72 	DPVTY 
(N8-R20) 1450.70 1450.83 100 NGGI C2-C3 
(16-R20) 1719.88 1719.66 58 C2-C3 
(R15-R20) + (H21-F30) 1760.90 1760.61 87 	 HKI C3-C4 
(16-Y14) + (123-F30) 1801.83 1801.50 47 C2-C4 
(16-Y14) + (H21-F30) 2066.98 2067.31 48 C2-C4 
(H21-F30) + (H21-F30) 2089.99 2090.28 6 C4-C4 
(16-Y14) + (H21-K34) 2527.18 2526.82 11 
Table 5.3 Determination of the disulfide bond connectivity of oxidised Defri. 
Oxidised Defri was digested with trypsin and chymotrypsin and the peptide 
fragments analyzed by MALDI-TOF. (A) The peptide mixture from the digest was 
reduced with TCEP and masses assigned accordingly. (B) MALDI-TOF analysis of 
the peptide digest without reduction and assignment of disulfide bonds. Assignments 
were confirmed by N-terminal sequencing by CID peptide mass mapping where 
indicated. 
a N-terminal sequencing data was collected using CID to resolve peptides which 
could not be unambiguously assigned (see text). 
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5.3 	Discussion 
-Defensins are characterized by having six conserved cysteines which are oxidised 
to form three disulfide bonds. It was assumed that these were required for 
antimicrobial activity but several recent studies have begun to explore their structural 
and functional roles. Analogues of bovine -defensin BNBD-12 containing one, two 
and three disulfide bridges, synthetic peptides corresponding to the carboxy-terminal 
segment of bovine f3-defensin BNBD-2 and a cysteine-free, full-length analogue of 
HBD3 all displayed antimicrobial activity suggesting that the three disulfide bridges 
are not absolutely required (229,230,308). Moreover, to explore whether high 
cationic charge is the only requirement for activity, small, linear peptides 
corresponding to regions of HBD3 were analyzed for their ability to kill different 
pathogens (309). Somewhat surprisingly, the least positively-charged peptides 
proved to be the most active, which suggests that defensins contain inherent subtle 
structural features which come into play upon interaction with the membrane target. 
Previously we reported the discovery of a defensin (Defrl) with five cysteine 
residues expressed in murine heart and testis which had potent antimicrobial activity 
(298). This defensin lacks the first of the conserved six cysteines found in other 
members of the family. Here we explored the effect of this loss on the structural and 
antimicrobial properties of by comparison with its six cysteine analogue Defri Y5C. 
Defrl Y5C has modest, salt-sensitive, antimicrobial activity against a panel of 
microbial pathogens and analysis by electrophoresis and mass spectrometry suggest 
it forms a non-covalently bound dimer in solution. Peptide mass mapping revealed 
that this defensin has Cysl-Cys5, Cys2-Cys4, Cys3-Cys6 disulfide connectivity 
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typical of a 3-defensin. In contrast, Defri has significantly higher antimicrobial 
activity against P. aeruginosa even under raised salt concentrations. High resolution 
mass spectrometry combined with two complementary dissociation techniques 
revealed a dimer containing an intermolecular disulfide bond, a novel structural 
feature not previously observed within the defensin family. Proteolysis and HPLC 
analysis suggest that oxidised Defri is a complex mixture of dimer isoforms varying 
in their intra and intermolecular disulfide connectivities. Recent studies of defensins 
HBD3 and BNB2 have concluded that short linear peptide fragments as well as those 
containing only one intramolecular disulfide could have potential as therapeutic 
agents. Our results demonstrate that defensins containing intermolecular disulfide 
bonds have novel structural and antimicrobial properties and suggest that covalently-
bound dimeric cationic peptides are promising targets for future study. 
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6.1 	Cloning the Defri gene and its derivatives 
One of the factors which hamper studies of defensins has been the lack of large 
quantities of recombinant peptides. To address this issue we undertook a study to 
develop an expression system for defensin production in E. coil. 
For this investigation we overexpressed and purified murine Defri. 
Furthermore, we also overexpressed a derivative of Defri, Defri I cys, which 
contained only a single cysteine residue in the Cys 5 position (the other four 
cysteines were substituted by serine residues, See Appendix I). Upon refolding this 
peptide formed a dimeric molecule containing an intermolecular disulfide bond. 
Functional studies of this peptide have again highlighted that a significant increase in 
antimicrobial activity is linked with the presence of an intermolecular disulfide bond. 
6.1.1 Cloning the Defri gene 
Oligonucleotide primers were designed in order to clone the Defri gene from murine 
cDNA. The primers, Defrl AlwNI For and Defri A1wNI Rev, incorporated an 
AIwNI restriction site and both the 3- and 5-end of the gene. After amplification by 
PCR, the product was first cloned into the PCR2.I vector before digestion with 
AIwNI and ligation into the commercial plasmid pET31b. The resulting construct, 
pFT3lb/Defrl, encoded a 125aa ketosteroid isomerase protein tag (KSI) at the 5-end 
of the defensin gene (Figure 6.1). The DNA sequence between the KSI tag and 
defensin gene contained a unique methionine residue, which would facilitate 
cleavage of the expressed fusion protein by cyanogen bromide. 
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Figure 6.1. Cloning the Defri 
gene. A. Defri was cloned into 
pET 3 1 b using A1wNI restriction 
sites. B. The resulting construct 
included a C-terminal KSI-tag 
and a unique cyanogen bromide 
(CNBr) cleavage site. 
B. 	 CNBr Cleavage 
KSI Tag 	 defri 
13471 Da 	 3788 Da 
6.1.2 Designing the Defri icys gene, a one-cysteine analogue of Defri 
Earlier work using synthetic Defri highlighted the presence of an intermolecular 
disulfide bond (see chapter 5). This unique structural feature had dramatic effects on 
both the structure and antimicrobial activity of the peptide. 
In order to investigate these effects further we planned a strategy for the 
expression of a derivative of Defri which contained only a single cysteine, located in 
the Cys 5 position. Within this analogue of Defri, named Defri icys, the remaining 
cysteine were substituted for serine residues. The construction of the Defri icys gene 
was achieved by recursive PCR using the four overlapping primers- named Defri 
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iCys P1-P4 (310). The gene incorporated A1wN1 sites at the 3'- and 5-ends and was 
designed using codons which were optimised for expression in E. coli. 
The Defri Icys gene was subsequently cloned into pET31b as described in 
section 6.1.1 and the resulting construct was named pET3lb/Defr1 icys. 
6.2 	Overexpression and purification of KSI-defensin fusion protein 
E. coli BL21 Rosetta(DE3)pLysS were used to express both recombinant defensins. 
After induction with ITPG, these competent cells facilitated high level 
overexpression of both constructs as insoluble inclusion bodies. Expression was 
monitored by SDS-PAGE (Figure 6.2). 
The cells were lysed by treatment with lysozyme and freeze-thawing and the 
inclusion bodies were purified by a series of washes as outlined in Materials and 
Methods. Typically, after purification inclusion bodies were 80% pure and the yield 














Figure 6.2. Expression, purification and cleavage of KSI-defensin fusion 
peptide. A. Overexpression of KSI-Defrl. Lane 1, cell extract before induction. 
Lane 2, cell extract after 8 hour induction. B. Cleavage of KSI-Defrl. Lane 1, 
purified KSI-Defrl fusion protein. Lane 2, KSI-Defrl after cyanogen bromide 
cleavage. 
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6.3 	Cyanogen bromide cleavage of KSI-defensin fusion protein 
After purification, the KSI defensin fusion protein was subject to sulfitolysis. This 
procedure protected the free cysteine residues by capping each cysteine thiol with a 
sulfite group. This protection strategy has been successfully used in the expression of 
recombinant insulin (311). The protected fusion protein was then subject to cleavage 
by excess cyanogen bromide. Great care was taken to ensure that the cleavage 
reaction was performed under nitrogen and in the absence of light. The reaction was 
allowed to proceed for 16 hours. Generally, cleavage was achieved in good yield 
(>80%, see figure 6.2B). 
Separation of the cleaved defensin from the KSI tag after cleavage proved 
more problematic. For Defri, this was finally achieved by freeze-drying the cleaved 
mixture and extracting with a minimum amount of 40% acetonitrile/60% 
water/0.01% TFA. The highly hydrophobic KSI is insoluble in this solvent, and the 
protected Defri was extracted in good yield (Figure 6.3). For the cleaved Defri Y5C 




20kDa 	 KSI.Defrl 
9kDa 
*m 	I - 
Figure 6.3. Cleavage and 
separation of Defrl-KSI. Lane], 
Purified KSI Defri fusion protein. 
Lane 2, Cleaved fusion protein after 
treatment with cyanogen bromide. 
Lane 3, soluble fraction after 
treatment with 40% acetonitrile/ 
0.01% TFA consisting of Defri. 
Lane 4, insoluble fraction after 
treatment with 40% acetonitrile/ 
0.01% TFA consisting of KSI. 
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6.4 	Deprotection and refolding recombinant defensins 
6.4.1 Deprotection and refolding Defrl 
Deprotection of Defrl was monitored by LC-MS. Analysis of the protected-Defrl 
revealed a mass of 4188.0 Da, consistent with the mass of Defrl with the addition of 
5 sulfite groups (caic. mass 4183.55 Da). After reduction with TCEP full 
deprotection was observed and the mass of the deprotected recombinant Defrl was 
3788.0 Da, consistent with the mass of fully reduced Defrl (3788.2 Da). 
Refolding Defri proved problematic. Initial attempts at reducing the 
concentration of the denaturing agent guanidine (GuHCI) by rapid dilution and 
dialysis resulted in precipitation of the peptide. The most successful results were 
achieved by dialysing against refolding buffer A at 4°C. However, this procedure still 
resulted in significant precipitation of the peptide (Table 6.1). 
Addition of a small quantity of oxidised and reduced thiols (e.g. 
cysteine/cystine) to refolding buffers has been known to dramatically increase yield 
of refolding proteins containing disulfide bonds- as the thiol additives catalyse 
disulfide bond shuffling within the protein. Indeed, on addition of both oxidised and 
reduced glutathione and cysteine/cystine yields of refolded defensin increased 
dramatically (refolding buffers B and Q. However, LC-MS analysis of the resulting 
oxidised Defri showed no intermolecular-disulfide bound dimer species (Table 6.1). 
Instead the majority of the peptide seemed to have formed two intramolecular 
disulfides, while the fifth cysteine residue was capped with the thiol additive (either 
glutathione or cysteine). 
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Refolding Buffer Yield' Obs. Mass (Da) Assignment 
A 15% 3784.7 2 intramolecular disulfides, I reduced 
cysteine? (CaIc. 3784.2 Da) 
B 80% 4090.0 2 intramolecular disulfides, addition of 
glutathione (CaIc. 4088.3 Da) 
C 80% 3903.0 2 intramolecular disulfides, addition of 
cysteine (CaIc. 3902.4 Da) 
Table 6.1. Refolding of recombinant Defri. Refolding Defri was attempted under 
three different conditions. Unfortunately, no oxidised dimer species was detected. 
a Yield has been approximated. 
6.4.2 Deprotection and refolding Detri icys 
In contrast to Defri, Defri Icys underwent oxidation to form an intermolecular 
disulfide bound dimer in high yield. The mass of the protected peptide was found to 
be 3804.0 Da, in agreement with the calculated value of 3802.9 Da. Defri Icys was 
deprotected by reduction with excess TCEP and LC-MS analysis revealed the 
reduced mass to be 3724.3 Da (Calculated 3723.9 Da). After exhaustive dialysis to 
remove the reducing agent an intermolecular disulfide was formed in high yield 
(>90%) and the resulting Defri Icys covalent dimer was found to have a mass of 
7446.0 Da (calculated 7445.9 Da). As this Defri derivative has only one cysteine 
residue there is only one possible isoform of the dimeric species, and the 
intermolecular disulfide bridge can be assigned as Cys5-Cys5. 
Finally, dimeric Defrl Icys was purified by cation exchange chromatography 
on a Tricorn S column using a linear gradient of 0 to 1M NaCl over 25 column 
volumes. The recombinant protein eluted between 300-350mM NaCl. 
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6.5 	Antimicrobial activity of recombinant detensins 
6.5.1 Antimicrobial activity of recombinant Defri 
Although recombinant Defri could not be folded to form a covalent dimer, enough 
monomeric Defri to perform activity assays was isolated and purified. Defri, which 
had been refolded using refolding buffer B and consequently had one cysteine 
capped with glutathione, was assayed against P. aeruginosa PAO 1. The recombinant 
defensin was dialysed into 0.01% acetic acid and the assay was performed as 
described in sections 5.1 and 7.6. 
Recombinant Defrl did exhibit antimicrobial activity and displayed an MBC 
of 50 tg/ml against PAUl in both oxidised and reduced forms. In comparison with 
synthetic Defri, we noted that the activity of the reduced forms of the peptides 
displayed identical activities. However, the oxidised form of recombinant Defri, 
which we know lacks an intermolecular disulfide, displayed no increased activity. 
Monomeric recombinant Defri seems to display antimicrobial properties similar to 
Defrl YSC, with oxidation state having little effect on activity. These results again 
highlight the importance of the intermolecular S-S bond within dimeric Defri. 
6.5.2 Antimicrobial activity of recombinant Defrl lcys 
In contrast to recombinant Defri, the Defri icys mutant was successfully purified in 
a dimeric state, containing a single intermolecular disulfide bond. The peptide was 
assayed against both Gram negative (P. aeruginosa PAUl and E. coli ATCC 25922) 
and one Gram positive bacterium (MRSA Si 13) as outlined in sections 5.1 and 7.6. 
The activity of oxidised Defri icys was similar to synthetic Defri for all the bacteria 
tested (See Table 6.2). Furthermore, the antimicrobial activity of the recombinant 
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defensin analogue was reduced after reduction of the intermolecular disulfide bond 
with excess DDT. It is also interesting to note that reduced Defri icys seems to be 
significantly more active than reduced Defri. This may be explained by the change 
in the hydrophobic nature of the peptide by the substitution of four cysteine residues 
with serines. These substitutions would have an effect on the hydrophobicity of the 
molecule- a factor which is known to effect antimicrobial activity. This effect 
remains to be investigated in future work. 
Organism  MBC ( gImI)  
Def iCys Ox Def iCys Red Defri Ox Defri Red 
Gram Negative 
P. aeruginosa 6 25 6 50 
E. co/i >3 25 8 >100 
Gram Positive 
S. aureus 6-12 100 10 >100 
Table 6.2. Activity of recombinant Defri icys. The activity of Defri icys was 
determined against three species of bacteria. The peptide was tested in both oxidised 
and reduced forms. The data is displayed with the comparative data from synthetic 
Defri. 
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7.1 	General materials 
7.1.1 General reagents 
Chemicals and solvents were of the appropriate quality and were purchased from 
Amersham Bioscience, Promega, Sigma, Pierce, Biorad, Gibco BRL, Vivascience, 
New England Biolads, Water Micromass, or Invitrogen unless otherwise stated. 
Aqufex aeolicus genomic DNA was a kind gift from Ronald V. Swanson 
(Diversa), Robert Huber and Karl Stetter (University of Regensburg). Synthetic 
defensin peptides were produced using standard solid phase synthetic procedures 
(Albachem). 
7.1.2 Solutions and buffers 
TAE buffer —40 mM Tris-HC1, 20 mM Acetic acid, 1 mM EDTA (pH 8.3). 
Buffer A - 10 mM HEPES (pH 7.5). 
Buffer B - 10 mlvi HEPES, I M NaC1 (pH 7.5). 
6His-Binding Buffer - 20 mlvi Tris-HCI, 0.5 M NaCl, 5 mM imidazole (pH 7.5). 
6His-Charge Buffer - 100 mM NiSO4, 
6His-Elution Buffer - 20 mM Tris-HC1, 0.5 M NaCl, 1 M imidazole (pH 7.5). 
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KSI-Resuspension Buffer - 50 mM Tris-HC1, 25% Sucrose, 1 mM EDTA, 0.1% 
NaAzide, 10 mM DTT (pH 8.0). 
KSI-Lysis Buffer - 50 mM Tris-HC1, 1% Triton X-100, 100 mM NaC1, 0.1% 
NaAzide, 10 mM DTT (pH 8.0). 
KSI-Wash Buffer (with Triton) - 50 mM Tris-HCI,1% Triton X-100, 100 mM 
NaC1, 1 mM EDTA, 0.1% NaAzide, 1 mM DTT (pH 8.0). 
KSI-1 M Guanidine Buffer - 50 mM Tris-HC1, 1% Triton X-100, 100 mM NaC1, 1 
M Guanidine-HC1, 1 mM EDTA, 0.1% NaAzide, 1 mM DTT (pH 8.0). 
KSI-6 M Guanidine Buffer - 50 mM Tris-HC1, 1% Triton X-100, 100 mM NaC1, 6 
M Guanidine-HCI, 1 mM EDTA, 0.1% NaAzide, 1 mlvi DTT (pH 8.0). 
Buffer C- 50 mM Tris-HC1, 8 M Guanidine (pH 8.0). 
Buffer D- 50 mM Tris-HC1, 1 mM EDTA, 6 M guanidine (pH 6.2). 
Buffer E- 50 mM Tris-HC1 (pH 8.2). 
Buffer F- 50 mM Tris-HC1, 1 mlvi EDTA (pH 6.2). 
Buffer G- 50 mM Tris-HC1, 1 mM EDTA, 1 M NaC1 (pH 6.2). 
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Refolding Buffer A- 50 mM Tris-HC1, 20% DMSO (vlv) (pH 7.8). 
Refolding Buffer B- 50 mM Tris-HC1, 1 mM EDTA, 3 mlvi [R] Glutathione, 0.3 
mM [0] Glutathione (pH 7.8). 
Refolding Buffer C- 50 mM Tris-HCI, 1 mM EDTA, 3 mM [R] Cysteine, 0.3 mM 
[0] Cysteine (pH 7.8). 
Chymotrypsin digestion Buffer- 50 mM Tris-HC1, 20 mM CaC12 (pH 8.2) 
Trypsin digestion Buffer- 50 mM Tris-HC1, 0.1% sodium azide, 5 mM EDTA (pH 
6.2). 
7.1.3 Media 
Sterilisation of media - All media was autoclaved at 121 °C for 15 mins at 15 psi 
pnor to use. 
Agar plates - bacto-agar (15 gIl) was added to the specified media to prepare agar 
plates. 
Luria Bertani (LB) - tryptone (10 gIl), yeast extract (5 g/l), sodium chloride (10 
gil); pH adjusted to 7.5 with sodium hydroxide. 
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2YT - tryptone (16 gIl), yeast extract (10 gIl), sodium chloride (5 g/l); pH adjusted to 
7.5 with sodium hydroxide. 
Soc - tryptone (20 gIl), yeast extract (5 gIl), sodium chloride (0.5 gIl), magnesium 
sulfate (5 gIl), glucose (3.2 gIl); pH adjusted to 7.5 with sodium hydroxide. 
Iso-sensitest (IS) - 23.4 gIl (Oxoid Ltd.). 
7.2 	Molecular Biology - DNA manipulation 
7.2.1 Bacterial cell lines 
Strain Genotype Description! 
Applications 
F'mcrA 	D(mrr-hsdRMS-mcrBC) Used 	For 	transforming 
Top IOTM 801acZiM15 	zMacX74 	deoR DNA ligations. 
recAl 	araD 139 (ara-leu)7697 
gal/U gal/K rpsL endAl nupG 
F omp Thsdsb (rB MB-)  gal dcm General 	purpose 
BL21(DE3) (DE3) expression host. 
F omp Thsdsb (r8 m8 ) gal dcm Expression 	host 	for 
Rosetta(DE3)pLysS (DE3) pLysSRARE2 (CamR) expression of mammalian 
genes in E. coli. 
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7.2.2 Oligonucleotide primers 
The following oligonucleotide primers were using in this study. Restriction sites are 
highlighted. 
Name Sequence (5'-3) 
BPL For TTCTTAACCATGGGC11TCAAAAACCTGATCTGG 
BPL Rev TTAAGGATCCTAAGAACGAGACAGGCTGAACTCTCC 
AccB A67 GTAACCATGGGTGAACAGGAAGAA 
AccB Rev GGATCCYI'AAACGTTITGTGTCTATAAG 
AccB Eli 4A CTATGCATTATAGCAGCTCTAAAGGTT 
AccB E 121 A CTAAGGTTATGAACGCGATAGAGAGCGAT 
AccB E 123A ATGAACGAGATAGCGAGCGATGTGAGG 
AccB E 142A GGTGAGACGGTTGCGTACGGACAACGG 
AccB K1 17L GAAGCTCTACTGGTTATGAAC 
AccB ATh CTCGTCGGAACTITTCTACCGCGCCGCAGCACCTCCGTITGTAGAA 
AccB KR I GGAAGAGTGGAGCGTATCCTCGTGG 
AccB KKKRRR 2 CGTCGTACCACGTGTACGT 
Defrl AIwNI For CAGATGCTGATGGATCCAGTAACTTAC 
Defrl AIwNI Rev CAGCATCTGTCACTTGCAGCATTTGAAAGG 
Defrl Icys P1 CAGATGCTGATGGATCCAGTAACTFACATTCGAAACGGAGGCATAAGC 
DefrI I cys P2 ATCYTATGCCTAAGGCCAATGCTCCGATACTGGCTTATGCCTCCGTT 
DefrI Icys P3 CTITAGGCATAAGATTGGAACTTCTGGATCTCCTTTCAAATGCAG 
Defrl I cys P4 CAGCATCTGTCAC1TGCTGCAYFTGAAAGGAGATCC 
7.2.3 Storage of bacterial stocks 
LB or 2YT medium containing the appropriate antibiotics were used for the short 
term storage of E. coli. Colonies of bacteria were stored on inverted agar plates at 4 
°C for up to 28 days. For long term storage strains were frozen (-80 °C) in LB or 
2YT media containing 20% glycerol. 
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7.2.4 Transformation of E. coil competent cells with recombinant 
plasmid DNA 
Competent cells were transformed according to the manufacturers' instructions. 
DNA (up to 40 ng) was added to an aliquot of competent cells and gently mixed. 
This was left on ice for 5 or 30 minutes before the cells were heat shocked (42 °C, 30 
sec). The cells were then grown in 80 or 250 tl SOC medium at 37 °C for 1 hr. 
Finally, the cells were spread to dryness on selective agar plates and incubated at 37 
°C overnight. 
7.2.5 Preparation of plasmid DNA 
Plasmid DNA was prepared using QiAprep® Spin Miniprep Kit (Qiagen) following 
the manufacturer's instructions. 
7.2.6 Digestion of DNA with restriction endonucleases 
The required amount of DNA (0.5-1 .tg) was treated with the appropriate amount of 
endonuclease and buffer and incubated for at least 2 hours at 37 °C. Blue/orange 
loading dye (Promega) was added and the sample was subjected to electrophoresis 
on agarose. The gels were viewed and photographed under UV-light. 
7.2.7 Electrophoresis of DNA 
The required amount of agarose was added to IxTAE buffer (typically 1.2g / lOOml) 
and heated at 100 °C until it dissolved. The solution was allowed to cool to 55 °C 
and ethidium bromide was added to a final concentration of 0.5 j.tg/ml. The gel was 
then poured into the casting mould and allowed to set at room temperature. DNA was 
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loaded and electrophersed using a potential difference of 100 V for an adequate time 
to achieve separation. 
7.2.8 Purification of DNA 
DNA was purified from agarose using QlAquick® Gel Extraction Kit (Qiagen) 
following the manufacturer's instructions. 
7.2.9 Amplification and megaprimer mutagenesis of DNA 
Polymerase chain reactions (PCRs) and sequencing reactions were performed using a 
Perkin Elmer 480 thermal cycler. A typical reaction contained - 2 Ready to Go 
PCR TM beads (Amersham Biosciences), DNA template (1tl), primer I (forward) 
(5tl, lOp.M), primer 2 (reverse) (5pJ, lOj.LM), and distilled water (39 t1). Reactions 
were overlayed with oil and cycled 30 times at 95 °C for 1 mm, 54 °C for I min and 
72 °C for 2 mm. Heating at 72 °C for 10 min terminated the reaction. The PCR 
product was then subjected to agarose gel electrophoresis and the required band was 
excised and the DNA purified as described in section 9.11. In mutagenic PCR 
reactions the resulting PCR product (the megaprimer) was used as primer 2 in the 
second reaction. 
7.2.10 Recursive PCR 
The gene assembly technique used was based on the recursive PCR protocol as 
described by Prodromou and Pearl (310). A gene sequence encoding the Defri iCys 
peptide was designed using codons optimised for high level expression in a bacterial 
host. Four oligonucleotide primers were then synthesised spanning the entire 
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sequence (Defri iCys P1-4, see section 9.5), these were 40-50 bp in length and 
consecutive primers overlapped by 10-20 bp. A1wN1 restrictions sites were 
incorporated at the beginning and end of the sequence to facilitate subsequent 
incorporation into the pET3 lb expression vector. A codon encoding a methionine 
residue was also introduced directly before the peptide sequence. 
The recursive PCR (30 cycles; 2 min at 95 °C, 2 min at 56 °C, and 1 min 72 
°C) was performed using a Perkin Elmer 480 thermal cycler. The reaction contained 
20-30 pmol of the outermost primers, 2-3 pmol of the internal primers, 10 pi of 10 x 
Herculase buffer, 5 units of Herculase® polymerase (Stratagene), 4 j.il of Dirnethyl-
sulfoxide (DMSO), 4 tl of 100 iiM of each dinucleotide triphosphates (dNTPs: 
dATP, dCTP, dGTP, dTTP), and dH2O was added to a final volume of 100 pt The 
PCR product was then subjected to agarose gel electrophoresis and the required band 
was excised and the DNA purified as described in section 9.11. 
7.2.11 Direct cloning of PCR products 
All PCR products were cloned into the pCR 2.1-TOPO vector using the TOPO TA 
Cloning® kit (Version J) using the manufacturer's guidelines. 
7.2.12 DNA sequencing 
Automated DNA sequencing was performed on an ABI prism 377 DNA sequencer 
using the Sanger dideoxy chain termination method. Each sequencing reaction 
typically contained - DNA template (-5 pmol) (2 pi), primer (10 tiM, 1 tl), distilled 
water (13 .tl) and Big Dye 4.1 (4p1; PE Biosystems, UK). The reaction was 
overlayed with oil and cycled 30 times at 96 °C for 30 sec, 45 °C for 15 sec and 60 
131 
Chapter 7: Materials and Methods 
°C for 4 mm. Sequence data was analysed using Contig Express within the Vector 
NIT Advance TM  V9 software package. 
7.2.13 Cloning into plasmid vectors 
The DNA fragment cut with suitable restriction enzymes (13 .tl), the host vector cut 
with suitable restriction enzymes (4 tl), lOx T4 DNA ligase buffer (2 tl), and T4 
DNA ligase (2 j.tl) were gently mixed and incubated overnight at room temperature. 2 
pl of the reaction mixture was used to transform suitable competent cells. 
7.3 	Molecular Biology - Protein Expression & Purification 
7.3.1 Polyacrylamide gel electrophoresis (PAGE) 
SDS-PAGE was used to analyse proteins on the basis of their molecular mass. The 
technique used was the discontinuous buffer system of Laemmeli. Alternatively, 
proteins were analysed on precast 12% Bis-Tris Nu-PAGE gels (Invitrogen) 
according to manufacture's instructions. 
Proteins were analysed in their native form by native gel electrophoresis 
(NGE) using 16% Tricine Nu-PAGE gels (Invitrogen).For NGE, samples were 
mixed with equal volumes of non-reducing Novex Tricine SDS sample buffer. Gels 
were visualised using Comassie blue or GelCode Blue Stain reagent (Pierce). 
7.3.2 Large Scale Expression of A. aeolicus BPL and mutant 
The pET28aJ aaBPL vector was transformed into E. coli BL21(DE3) cells 
(Novagen). A single colony was added to 200 ml LB supplemented with kanamycin 
(30 .tg / ml) and grown overnight at 37 °C and 250 rpm. This seed culture was then 
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used to inoculate 4 litres of fresh growth medium and grown subject to the same 
conditions to A600 = 1.0 before induction with isopropyl-1-thio-3-D-
galactopyranoside (ITPG) to a final concentration of 1.0 mM. After a further 3 hours 
the cells were harvested by centrifugation (5000 rpm for 15 minutes at 4 °C), washed 
buffer A, and stored at -20 °C. 
7.3.3 Purification of A. aeo!icus BPL and mutant 
Cells overexpressing BPL were resuspended in buffer A and disrupted by sonication 
(15 pulses of 30 seconds at 30 second intervals) at 4 °C. The cell debris was removed 
by centrifugation at 15,000 rpm for 20 minutes at 4 °C. One tablet of Complete TM 
Proteinase Inhibitor Cocktail (Roche) was added to the cell lysate before it was 
heated for 20 minutes at 60 °C. The resulting precipitated cellular protein was 
removed by centrifugation at 15,000 rpm for 20 minutes at 4 °C. The supernatant 
was filtered through a 0.45 .tM membrane before it was loaded onto a Resource-S 
cation exchange column (Amersham Biosciences, 20 °C) equilibrated with buffer A. 
The BPL protein was eluted with a linear salt gradient (0-100% buffer B) over 20 
column volumes. Fractions containing BPL were run on either SDS-PAGE or Nu-
PAGE gels and those fractions judged to be 95% pure were pooled and stored in 
buffer A containing 20% glycerol (v/v) at —20°C. Protein concentration was 
determined using the Bio-Rad protein assay kit. The aaBPL K19A mutant was 
expressed and purified in a similar manner. 
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7.3.4 Large scale expression of H1s6-tagged A. aeolicus BCCPA67 
and mutants 
Overexpression of A. aeolicus BCCPA67 was achieved by transforming E. co/i 
BL21(DE3) cells with the plasmid pET6H/aaAccBA67. A single colony was added 
to 200ml 2YT supplemented with ampicillin (100 tg / ml) and grown overnight at 37 
°C and 250 rpm. This seed culture was then used to inoculate 4 litres of fresh growth 
medium and grown subject to the same conditions to A600 = 1.0 before induction with 
ITPG (1.0 mM final concentration). After a further 3 hours the cells were harvested 
by centrifugation (5000 rpm for 15 minutes at 4 °C), washed in binding buffer, and 
stored at -20 °C. 
7.3.5 Purification of His6-tagged A. aeolicus BCCPA67 and mutants 
Cells overexpressing His6-BCCPA67 were resuspended in binding buffer (5 ml per 
gram of wet cell paste) and disrupted by sonication (15 pulses of 30 seconds at 30 
second intervals) at 4 °C. The cell debris was removed by centrifugation at 15,000 
rpm for 20 minutes at 4 °C, after which the supernatant was filtered through a 
0.45 j.tm membrane prior to chromatography. 
The cell lysate was loaded onto a Hitrap®  chelating affinity column 
(Amersham Biosciences, 20°C) previously charged with 6His-charge buffer and 
equilibrated with 6His-binding buffer. The column was then washed with 5 column 
volumes of 6His-binding buffer before bound material was eluted using a linear 
gradient of 0-100% 6His-elution buffer. Fractions were analysed by UV 
spectroscopy and SDS-PAGE, those containing BCCPA67 were pooled and dialysed 
overnight against 4 litres of buffer A at 20°C. 
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Apo- and holo BCCPM7 were separated by applying the BCCPM7-
containing fractions eluted from the nickel column onto a Mono-Q column 
(Amersham Biosciences, 20 °C) pre-equilibrated in buffer A The column was then 
washed with 20 column volumes of Buffer A, before the protein was eluted with a 
salt gradient (0-100% buffer B) over 25 column volumes. The elution was monitored 
by UV spectroscopy and fractions containing apo- and holo-BCCPM7, screened by 
LC-MS, were pooled and stored in buffer A containing 20% glycerol (v/v) at —20°C. 
Due to the low proportion of aromatic residues in BCCP M7, protein concentration 
was evaluated by measuring the absorbance at 280nm and using the molar extinction 
coefficient 3960 M' cm1, calculated using the Vector NTI Advance TM  V9 software. 
The expression and purification of the BCCPL67 mutants were performed 
essentially as above and the resulting protein was stored at the same conditions. 
7.3.6 Overexpression of Defrl-KSI and Defri lCys-KSI fusion protein 
as inclusion bodies 
The pET31b/Defrl vector was transformed into E. coli Rosetta(DE3)pLysS cells 
(Novagen). A single colony was added to 200ml 2YT media supplemented with 
ampicillin (100 p.g / ml) and chloramphenicol (10 .Lg/ ml) and grown overnight at 37 
°C and 250 rpm. This seed culture was then used to inoculate 4 litres of fresh growth 
medium and grown subject to the same conditions to A600 = 0.3 before induction with 
ITPG (1.0 mM final concentration). After a further 5 hours the cells were harvested 
by centrifugation (5000 rpm for 15 minutes at 4 °C). 
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7.3.7 Purification of Defrl-KSI and Defri lCys-KSI fusion protein 
Cells overexpressing KSI-fusion protein were resuspended in KSI-resuspension 
buffer (5 ml per gram of wet cell paste) and disrupted by sonication (4 pulses of 30 
seconds at 30 second intervals, 50% power) at 4 °C. Following sonication 100 pi 
lysozyme (50mg! ml), 250 ii DNAseI (10 mg/ml), and 50 ti MgCl2 (500 mM) were 
added and the sample mixed for 10 seconds using a vortexer. Lysis buffer (5 ml per 
gram of wet cell paste) was then added, the sample mixed, and incubated at room 
temperature for 45 minutes. After the addition of 700 j.il of EDTA (500mM, PH 8.0), 
the mixture was flash-frozen in liquid nitrogen and then thawed at 37 °C for 45 
minutes. 500 tl MgCl2 (500 mM) was subsequently added before the sample was 
incubated at room temperature. After the viscosity of the sample decreased, typically 
30-60 minutes, 7001.ii EDTA (500mM) was added and the sample placed on ice. 
Crude inclusion bodies were collected by centrifugation (11,000 g, 20 minutes, 4 
°C). 
The inclusion bodies were first washed by resuspending in KSI-Wash Buffer 
(lOml/ g original cell pellet), disrupting by sonication (4 pulses of 30 seconds at 30 
second intervals, 50% power) at 4 °C, and harvesting by centrifugation (11,000 g, 20 
minutes, 4 °C). This step was repeated three times. Finally, the inclusion bodies were 
washed twice in KSI-1 M Guanidine Buffer (lOml/ g original cell pellet) and 
collected by centrifugation (11,000 g, 20 minutes, 4 °C). The purity of the inclusion 
bodies after each wash step was monitored by SDS-PAGE. 
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7.3.8 Protection of KSI fusion proteins by sulfite addition 
Washed inclusion bodies were dissolved in KSI-6 M Guanidine Buffer (lOmi/ g 
original cell pellet) and any insoluble debris was removed by centrifugation (30,000 
g, 20 minutes, 4 °C). Sulfitolysis was performed by incubating the protein with 300 
mM sodium sulfite and 60 mM sodium tetrathionate for 16 hours at 20 °C. The 
sample was subsequently precipitated by either addition of an equal volume of 
100mM ZnC12 or by dialysis against 4 litres of water for 2 hours at 20 °C. Finally the 
protected fusion protein was collected by centrifugation (11,000 g, 20 minutes, 4 °C). 
7.3.9 Cleavage and separation of KSI fusion protein 
The protected fusion protein was dissolved in a minimum amount of 80% formic 
acid under nitrogen, and cyanogen bromide was added to a final concentration of 100 
mM. After incubation for 16 hours in the absence of light and under nitrogen the 
sample was freeze dried. 
Defri was separated from the KSI tag by extraction with a minimum amount 
40% acetonitrile! 60% water! 0.01% TFA for 1 hour at 20 °C. In contrast the Defri 
iCys mutant was extracted using 10 ml 10mM sodium phosphate buffer (pH 7.5). 
The resulting suspensions were centrifuged (30,000 g, 20 minutes, 4 °C), and the 
soluble fraction containing the cleaved peptide was further clarified by filtration 
using a 0.22 tm filter. The purity and the cleaved peptide was analysed by SDS-
PAGE and LC-MS. The organic solvent was removed from Defri by freeze-drying 
overnight. 
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7.3.10 Deprotection and refolding Defri 
Defri peptide, dissolved in buffer C, was deprotected by treatment with 10 mM 
TCEP for 4 hours at 20 °C, and monitored by LC-MS. The excess TCEP was 
removed by precipitating the reduced peptide, which was achieved by dialysing 
against water at 20 °C for a further 4 hours. Reduced Defri was finally dissolved in 
buffer D. 
Refolding of Defri was attempted by dialysis against either refolding buffer A, B or 
C. The time and temperature of each dialysis was varied in an attempt to improve 
yield (See section 6.4.1). 
7.3.11 Deprotection and oxidation of Defri iCys 
The Defri iCys peptide was deprotected by treatment with 10 MM TCEP for 4 hours 
at 20 °C and monitored by LC-MS. The sample was oxidised by removal of excess 
TCEP by exhaustive dialysis against buffer E. The formation of the intermolecular 
disulfide bond was monitored by LC-MS. 
7.3.12 Final purification of Defri and Defri iCys 
Both Defri and Defri iCys were dialysed into buffer F and loaded onto a Tricon-S 
cation exchange column (Arnersham Biosciences) equilibrated with buffer F. The 
column was washed with 20 column volumes of buffer F, before the protein was 
eluted with a 0-100% gradient of buffer G over 25 column volumes. The elution was 
monitored using liv spectroscopy, SDS-PAGE and LC-MS. Fractions containing 
pure recombinant defensin were stored at -20°C. 
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7.4 Protein Chemistry 
7.4.1 Assay of A. aeolicus BPL 
BPL activity was assayed by measuring the incorporation of [14C]biotin  into purified 
BCCPA67, in a similar way to that previously described (98). Except where stated 
otherwise, the reaction contained 10 mM HEPES (pH 8.5), 100 jiM ATP, 200 j.tM 
M902, 10 j.tM biotin, 1 jiM [14C]biotin  (specific activity 54mCi/mmol), 0.1 mg/ml 
bovine serum albumin, and 400 tM apo-BCCPL67. The reaction was initiated by the 
addition of purified BPL to a final concentration of 1 jiM, and incubated at 70°C for 
30 mm. The reaction was terminated by the addition of ice-cold trichioroacetic acid 
(final concentration 25% w/v), and incubation on ice for 30 mm. The resulting 
protein precipitate was removed by centrifugation (15,000 rpm for 10 minutes). 
Aliquots of the supernatant were added to 5 ml of scintillation fluid (ICN 
biomedicals), and radioactivity was measured using a Tri-carb 210 OTR liquid 
scintillation counter (Packard). 
For kinetic analysis each of the substrate concentrations (biotin, ATP, BCCP) were 
varied accordingly. Values for Km and Vmax were determined by Michaelis-Menten 
analysis on SigmaPlot 2001 software. In some assays, to obtain sufficiently high 
levels of activity for accurate detection, it was necessary to continue until greater 
than 10% of the limiting substrate had been used. In these instances the data was 
transformed using the method of Lee and Wilson and plotted as transformed values 
s' and v' (312). 
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7.4.2 Limited proteolysis of A. aeolicus BPL 
Proteolysis of apo-BPL and substrate-bound-BPL were investigated using the 
proteases trypsin (Sigma) and chymotrypsin (Promega). Substrate-bound BPL was 
prepared by incubating BPL (15 jiM) for 20 min at 60 °C with saturating amounts of 
biotin (40 jtM), MgATP (2 mM), or both. The samples were then cooled for 10 mm 
before treatment with protease (with a final protease: substrate ratio of 1:20 (w/w)) 
and incubation at 37 °C for 30 mm. Digestion was terminated by the addition of SDS 
sample buffer and boiling for 5 minutes, and the extent of proteolysis was analysed 
by SDS-PAGE. 
7.4.3 Chemical crosslinking of A. aeolicus BPL and BCCPA67 mutants 
Purified BPL (15 jiM) and BCCPA67 mutants (45 jiM) were covalently cross-linked 
using 1-ethyl-3-(dimethylamino-propyl)-carbodiimide (EDC, 10 mM) at 60 °C for 60 
mins. Aliquots were withdrawn at various time intervals, quenched with ammonium 
acetate (40 mM), and analysed by SDS-PAGE. 
The cross-linked complex was prepared on a larger scale and separated from 
BPL and BCCPA67 by gel filtration. To prepare the complex we incubated 5 mg 
each of BPL and BCCP, EDC (10 mM) in a final volume of 5 ml 10 mM HEPES 
(pH 8.5) for 60 min at 60 °C. After incubation the reaction was quenched with 
40mM hydroxylamine and analysed by SDS-PAGE. The mixture was passed through 
a Superdex 75 column (AP-Biotech) equilibrated in 10 mM HEPES (pH 8.5) and 100 
mM NaCl and the purified protein was stored at —20 °C. 
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7.4.4 Chemical Biotinylation 
Chemical biotinylation was performed essentially as previously described (32). 
Briefly, the purified BCCP mutants, BCCPA67zTh and BCCPL67LTh4KR (90 jiM, 
10mM HEPES pH 8.0), were incubated with biotinyol-hydroxy-succinimide (250 
jiM, in DMSO) at room temperature for four hours. The solution was then dialysed 
against 10mM HEPES pH 8.0 overnight with one buffer change; the reaction was 
monitored by LC-MS. The biotinylated product was separated from unreacted apo-
protein by HPLC using a C5 reverse phase column and a gradient of 50-65% 
acetonitrile over 20 minutes. 
7.5 Protein Characterisation 
7.5.1 High performance liquid chromatography (HPLC) 
HPLC was performed using a Beckman System Gold analytical instrument fitted 
with an autosampler and a diode array. Typically, proteins were monitored at 214 
and 280 nm and data was analysed using Beckman Gold software. The instrument 
was a kind gift from Glaxo-Smith-Kline, and was specially customised by Parcel-
Force. 
7.5.2 Liquid chromatography-mass spectrometry (LC-MS) 
LC-MS was performed on a MicroMass Platform II quadrupole mass spectrometer 
equipped with an electrospray ion source. The spectrometer cone voltage was 
ramped from 40 to 70 V and the source temperature set to 140 °C. Protein samples 
were separated with a Waters HPLC 2690 with a Jupiter C5 reverse phase column (5 
lam, 250 x 4.6 mm, Phenomenex) directly connected to the spectrometer. Proteins 
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were eluted from the column with a 5-95% acetonitrile (containing 0.01% TFA) 
gradient at a flow rate of 0.2 ml/min. Peptide samples were separated with a Jupiter 
C18 reverse phase column (5 ltm, 250 x 4.6 mm, Phenomenex). Typically, 
separation was achieved using a 20-50% acidified acetonitrile gradient over 60 mm, 
and a flowrate of I ml/min. The total ion count in the range 500-2000 mlz was 
scanned at 0.1 s intervals. The scans were accumulated, spectra combined and the 
molecular mass determined by the MaxEnt and Transform algorithms of the Mass 
Lynx software (Micromass, U. K.). 
7.5.3 FT-ICR Analysis 
Characterization of the oxidation state of the defensin peptides Defri, and Defri 
Y5C, was performed using the accurate mass capabilities of a 9.4 T FT-ICR mass 
spectrometer (Bruker Daltonics). Using this instrument, two dissociation methods 
were applied to the isolated peptides. For Sustained Off Resonance Collision Induced 
Dissociation (SORI-CID) a given charge state was isolated by sweep excitation and 
subjected to CID with Argon as the collision gas for 500 ms. To perform ECD a 
given charge state was isolated by sweep excitation and subjected to electron 
irradiation for 50 ms using a barium oxide coated high-surface area (5mm diameter) 
dispenser cathode (HeatWave) An experimental pulse sequence which combined 
ECD and SORI-CID was also employed. This work was performed under the 
supervision of Dr. Pedita Barran and with the help of Dr. Nick Polfer. 
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7.5.4 Protease digestion and peptide mass mapping of defensins 
The peptide mass mapping for Defrl and Defrl Y5C was conducted using a 
MALDI-TOF (Tof-Spec 2E, Micromass, U.K.). Enzymatic digestion of Defri (500 
Vg/ml) with trypsin (100 pg/ml) and chymotrypsin (100 pg/ml) was performed at 37 
°C in chymotrypsin digestion buffer and allowed to proceed for four hours, before 
termination by addition of 0.05% TFA. For analysis of the reduced proteolytic digest 
I p1 of the peptide mixture was removed and reduced with 100 mM TCEP. For 
MALDI-MS analysis oxidised and reduced peptide digests were desalted and 
concentrated using C18 ZipTips (Millipore Corp.). I il of analyte and I p1 of matrix 
solution (a saturated solution of a-cyano-4-hydroxycinnamic acid in 50% acetonitrile 
with 0.1% TFA) were mixed, left to air-dry on a MALDI plate and MALD I-MS 
results were obtained in the positive mode. 
For analysis of Defri Y5C, peptide of concentration 500 pg/mi was digested 
with trypsin (100 pg/mI). The reaction was performed in trypsin digestion buffer and 
was allowed to proceed for four hours at 37 °C before termination by addition of 
0.05% TFA. Cleavage products were separated by HPLC using a Phenomenex C18 
Jupiter column (5 gm, 250 x 4.6 mm) and a 10-35% acetonitrile gradient and the two 
major species were collected and freeze-dried. The resulting peptides were 
reconstituted in chymotrypsin digestion buffer and each split into three aliquots. One 
aliquot was analyzed in its oxidised state; the second was reduced with 20 mM 
TCEP; and the third was digested with chymotrypsin (100 Vg/ml) for 4 hrs at 37 °C. 
All samples were purified and concentrated using C18 ZipTips and analyzed by 
MALDI-TOF MS as described above. 
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7.5.5 Collision induced dissociation (CID) of peptides 
CD analysis performed using a Q-TOF tandem mass spectrometer (Micromass, 
U.K.) equipped with a nanospray source. Samples were typically analysed in 50% 
acetonitrile, 0.1% TFA and sprayed from gold/palladium coated tips (Proxeon 
Biosystems). Specific ions were mass selected by the quadrupole MS, subjected to 
CID using argon and the resulting fragments were analyzed in the TOF MS. 
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7.6 Microbiology 
7.6.1 Bacterial isolates 
All bacterial isolates were provided by Prof. John Govan from the Edinburgh Cystic 
Fibrosis Microbiology Laboratory and Strain Repository (ECFML). 
Organism Strain Description 
Gram-negative 
P. aeruginosa PAO1 Type strain 
C3425 Manchester Epidemic Strain 
H183 Liverpool Epidemic Strain 
C4269 Brisbane Epidemic Strain 
C3781 Melbourne Epidemic Strain 
E. coli ATCC 25922 Type strain 
B. cepacia ATCC25416 Type strain 
B. cenocepecia J23151LMG16656 Type strain 
S. maltophilia C1980 Clinical Isolate 
C3625 Clinical Isolate 
C3626 Clinical Isolate 
C3627 Clinical Isolate 
B. bronchoseptica J3083 Clinical Isolate 
picketti C3079 Clinical Isolate 
R. eutropha C30811LMG1199 Clinical Isolate 
Gram-positive 
E. faecalis ATCC 29212 Type strain 
aureus ATCC 25923 Type strain 
S113/ J2918 Clinical Isolate - MRSA 
Fungi 
C. albicans J2922 Clinical Isolate 
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7.6.2 Preparation of defensin for antimicrobial assays 
The synthetic peptides (Albachem, Edinburgh) were lyophilised (in 250 .tg aliquots) 
and kept at —70 T. Prior to use, the peptide was dissolved in 250 il of 0.01% acetic 
acid to give a stock solution with a final concentration of 1 mg/ml. The peptide 
preparations were held at 4°C during use and after which at —70 T. 
Reduction of the peptides was performed by adding 10 mM dithiothreitol (DTT) and 
incubating at room temperature overnight. The oxidation state of each peptide prior 
to performing antimicrobial assays was determined by LC-MS. 
7.6.3 Broth dilution antimicrobial assay of defensins 
Test bacteria were grown to mid-logarithmic phase in ISB (Oxoid) and then diluted 
to 2x106 CFU/ml in 10 mM sodium phosphate containing 1% (v/v) ISB, pH 7.4. The 
bacterial samples were washed three times in buffer to ensure removal of salt. 
Varying concentrations of test peptide (peptide range 1.5 tg/ml to 100 jtg/ml) were 
incubated in 100 j.tl of the bacterial suspension at 37°C for 1 hour. 10-fold serial 
dilutions of the incubation mixture were plated on ISA plates, incubated at 37°C, and 
the number of colony forming units (CFU) determined the following day. The 
minimum bactericidal concentration (MBC) was determined as the concentration of 
peptide where we observed >99.99% killing of the initial inoculum. All assays were 
performed in duplicate and repeated on two independent occasions. The MBC was 
obtained by taking the mean of all the results, and experimental errors were within 
one doubling dilution. Dose-response curves could be determined from surviving 
CFU. 
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7.6.4 Time-kill assay of defensins 
A defensin killing assay using P. aeruginosa PAOI and Defri at 5 x MBC (25 
tg/m1) was performed as described above. Bacterial sample was removed at 30-
minute intervals, and plated on agar to determine the viable count (CFU/ml). 
7.6.5 Salt sensitivity of defensins 
The effect of salt on antimicrobial activity was tested by incubating 100 iI of 1-5 x 
105 CFU of bacteria in 10 mM potassium phosphate, 1% (v/v) Iso-Sensitest, pH 7.4 
which contained various concentrations of NaCl (0-300 mM). The bacteria were then 
challenged with peptide at a concentration four times the MBC. 
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BCCP Biotinylation Domain and Mutants 
(1)1 	10 
kcpD676H (1)MHHHHHHAMGEQE YHV 
bccpD676HEl14A (1)ME-11-1U1-IHHAMGEQE YHV 
bccpD676HEl21A (1)MHHHHHHAMGEQE YHV 
bccpD67 6H El 23A (1)MHHHHHHAMGEQE YHV 
bccpD67 6H El 42A (1)MHHHHHHAMGEQE; YHV 
bccpD676HKl17L (1) MHHHHHHAMGEQE' YHV 
bccpD67Dth6H (1) MHHHHHHAMGEQE YHV 
bccpD67 Dth 6H 4XR (1) MUHHHHHAMGEQEE YHV 
30 	40 	50 
LVGTEYAP PFVEVGDIVSPGQVLCI 
LVGTFY AP PFVEVGDIVSPGQVLCI 
LVGTFY AP PFVEVGDIVSPGQVLCI 
LVGTFY AP PFVEVGDIVSPGQVLCI 
LVGTFY AP PFVEVGDIVSPGQVLCI 
LVGTFY AP PFVEVGDIVSPGQVLCI 
LVGTFYAP --- PFVEVGDIVSPGQVLCI 
LVGTFY 	P---PFVEVGDIVSPGQVLCI 




I SDVRGRVILVENGET YGQPLFLIDTNV 
I SDVRGRVILVENGET YGQPLFLIDTNV 
IASDVRGRVILVENGET YGQPLFLIDTNV 
I SDVRGRVILVENGETVAYGQPLFLIDTNV 
I SDVRGRVILVENGET YGQPLFLIDTNV 
I SDVRGRVILVENGET YGQPLFLIDTNV 
I SDVRGRV 	YGQPLFLIDTNV 
BPL and BPL mutant 
(1) 1 	10 	20 	30 	40 	50 	60 	70 	 80 	90 
BPLaa (1) GPKNLIWLKEVDSTQERLKEWNVSYGTALVADRQTKGRGRLGRKWLSQEGGLYFSFLLNPKEFENLLQLPLVLGLSVSEALEEITEIPFS 
BPLaaK19A (1) GFKNLI1LKEVDSTQERLAEWNVSYGTALVADRQTKGRGRLGRKWLSQEGGLYFSFLLNPKEFENLLQLPLVLGLSVSEALEEITEIPFS 
(91) 91 	100 	110 	120 	130 	140 	150 	160 	170 	180 
BPLaa (91) 
BPLaa k19A (91)LKWPNDVYFQEKKVSGVLRELSKDKLIVGIGINVNQREIPEEIKDRATTLYEITGKDWDRKEVLLKVLKRISENLKKFKEKSFKEFKGKI  




Del ri and Mutants 
(1) 1 	 10 	-- 	20 	 34 
de"() 
iptIRNGGISQYRSIGLRHKIGTSGSPFKCSK
PIRNGGI QY IGLRHKIG GSPFKC K 
defri 1)pIRNGGI QY IGLRHKIG GSPFKC K 
defri'YC (1)pIRNGGI QY IGLRHKIG GSPFKC K 
defr11c,s (1)  
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Biotinylation in the hyperthermoph lie Aquifex aeollcus 
Isolation of a cross-linked BPL:BCCP complex 
David J. Clarke, Joseph Coulson, Ranald Baillie and Dominic J. Campopiano 
School of Chemistry, University of Edinburgh, UK 
Biotin protein ligase (BPL) catalyses the biotinylation of the 
biotin carboxyl carrier protein (BCCP) subunit of acetyl 
CoA carboxylase and this post-translational modification of 
a single lysine residue is exceptionally specific. The exact 
details of the protein—protein interactions involved are 
unclear as a BPL:BCCP complex has not yet been isolated. 
Moreover, detailed information is lacking on the composi-
tion, biosynthesis and role of fatty acids in hyperthermo-
philic organisms. We have cloned, overexpressed and 
purified recombinant BPL and the biotinyl domain of BCCP 
(BCCPA67) from the extreme hyperthermophile Aqufex 
aeolicus. In vitro assays have demonstrated that BPL cata-
lyses biotinylation of lysine 117 on BCCPA67 at tempera-
tures of up to 70 °C. Limited proteolysis of BPL with trypsin 
and chymotrypsin revealed a single protease-sensitive site 
located 44 residues from the N-terminus. This site is adjacent 
to the predicted substrate-binding site and proteolysis of 
BPL is significantly reduced in the presence of MgATP and 
biotin. Chemical crosslinking with l-ethyl-3-(dimethylamino-
propyl)-carbodiimide (EDC) allowed the isolation of a 
BPL:apo-BCCPA67 complex. Furthermore, this complex 
was also formed between BPL and a BCCPA67 mutant 
lacking the lysine residue (BCCPA67 KII7L) however, 
complex formation was considerably reduced using holo-
BCCPA67. These observations provide evidence that addi-
tion of the biotin prosthetic group reduces the ability of 
BCCPA67 to heterodimerize with BPL, and emphasizes that 
a network of interactions between residues on both proteins 
mediates protein recognition. 
Keywords: biotin protein ligase; Aqui/x aeolicus; biotinyla-
tion; protein recognition; chemical crosslinking. 
The enzymes of bacterial fatty acid biosynthesis have been 
suggested as good targets for the development of novel 
antibacterial agents since several natural product and 
synthetic inhibitors of this pathway are already known [1]. 
Moreover, significant differences in fatty acid biosynthesis 
between bacteria and mammals should allow selective 
inhibition of the microbial enzymes. The first committed 
step of bacterial fatty acid biosynthesis is catalysed by a 
multisubunit acetyl-CoA carboxylase [2]. This biotin 
-dependent complex is composed of biotin carboxylase, 
carboxyltransferase and biotin carboxyl carrier protein 
(BCCP) subunits, the exact composition of which is 
species-specific. The Escherichia co/i acetyl-CoA carboxy-
lase has been intensively studied, because the subunits can 
be separated or expressed individually in an active form. 
Biotin is covalently bound to a specific lysine residue in the 
BCCP subunit [3,4]. Biotinylated enzymes transfer cardon 
Correspondence to D. Cainpopiano, School of Chemistry. University 
of Edinburgh, West Mains Road, Edinburgh, EH9 3JJ, UK. 
Fax: + 44 131 650 4743, Tel.: + 44 131 650 4712, 
E-mail: Dominic.Cainpopianocd.ac.uk 
Abbreviations: BPL, biotin protein ligase; BCCP, biotin carboxyl 
carrier protein; IPTG, isopropyl thio-3-u-galactoside; EDC, 
1-ethyl-3-(dirnethylamino-propyl)-carbodiiniide. HCS, 
holocarboxylase synthase. 
Enzyme: Biotin protein ligase or holocarboxylase synthase 
(EC 6.3.4.10). 
(Received 26 November 2002. revised 18 January 2003, 
accepted 29 January 2003) 
dioxide from bicarbonate to organic acids to form cellular 
metabolites, using the biotin prosthetic group as a mobile 
carboxyl carrier [5]. Biotin protein ligase (BPL), also known 
as holocarboxylase synthase (HCS, EC 6.3.4.10) catalyses 
this post-translational attachment via a two-step reaction 
(Scheme 1 [6]). 
Biotin + MgATP 	 Biotinyl-5'-AMP + PPi 
Biotinyl-5-AMP + apo-BCCP 	Biotinylated-BCCP + AMP 
Scheme 1. 
Genes encoding BPLs have been identified in a number of 
organisms, but the best-characterized BPL is the 35.3 kDa 
BirA protein from E. co/i [7,8]. BirA is a bifunctional protein 
that can act as both an enzyme and a DNA-binding protein; 
it catalyses protein biotinylation when in vivo biotin 
concentrations are low, but becomes a repressor of the 
expression of biotin biosynthetic enzymes when biotin 
concentrations are increased. The crystal structure of the 
biotin-bound protein, determined at 2.3 A resolution, 
shows the enzyme has three domains [9,10]; an N-terminal 
domain that contains a helix-turn-helix fold for DNA 
binding; a central catalytic domain, which contains a highly 
conserved GRGRRG motif shown to be involved in biotin 
binding [11]; and a small C-terminal domain which has been 
postulated to mediate dimerization with apo-BCCP [12]. 
The recent determination of the structure of a BirA dimer in 
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the absence of DNA provides insight into how the 
N-terminal DNA-binding domain interacts with the 40 bp 
biotin operator sequence [12]. The structure of the apo- and 
holo-forms of the biotinylation domain of E. coli BCCP 
(known as BCCP-87) have been determined by X-ray 
crystallography and NMR [13-15]. The BCCP domain is a 
barrel consisting of two antiparallel 13-sheets each containing 
four strands. The N- and C-termini are close together at one 
end, and the biotinylated lysine is exposed on a tight 13-turn 
at the opposite face of the molecule. Surprisingly, the 
structures of the apo- and holo- forms are remarkably 
similar suggesting that biotinylation causes few significant 
changes in the domain tertiary fold. 
To gain further insight into the detailed protein—protein 
interactions that control biotin transfer we have analysed 
the reaction between BPL and apo-BCCP from the 
hyperthermophilic organism Aquifex aeolicus [16]. This 
bacteria grows optimally at 95 °C on hydrogen, oxygen, 
carbon dioxide and mineral salts. Enzymes from extremo-
philes (extremozymes) are offering new opportunities for 
biocatalysis as a result of their extreme stability [17,18]. 
Analysis of the A. aeolicus genome identified BirA and 
BCCP homologues; the predicted BPL is from the group I 
class (which also includes M. tuberculosis) which lack the 
N-terminal DNA-binding domain found in E. coli BirA 
[19]. In E. coil, we have expressed active A. aeolicus BPL, 
the biotin-binding domain of A. aeolicus BCCP as a His6 
N-terminal fusion (BCCPA67) as well as an A. aeolicus 
BCCP mutant lacking the active lysine residue (Kll7L). 
Biotinylation of apo-BCCPA67 by BPL was most efficient 
at 70 °C and we have carried out kinetic analyses and 
proteolysis experiments at this temperature. Furthermore, 
we describe the isolation of a chemically crosslinked 
BPL:BCCPA67 complex for the first time. This study is 
the first characterization of post-translational modification 
complex from a hyperthermophilic organism. 
Experimental procedures 
Materials 
All chemicals used in the preparation of buffers were at least 
of reagent grade. Nu-PAGE gels were obtained from 
Invitrogen; restriction endonucleases were purchased from 
New England Biolabs; [14C]biotin (54 mCimmol) was 
from Amersham Biosciences; and 1 -ethyl-3-(dimethylamino-
propyl)-carbodiimide (EDC) was from Sigma. PCR was 
performed using Ready To Go PCRTM  beads (Amersham 
Biosciences). 
Oligonucleotide primers were purchased from Sigma-
Genosys. The primer details are as follows (restriction sites 
are indicated by underlining and mutagenic changes are 
shown in bold). BPL-for, 5'-TTCTFAACCATGG 
GCTFCAAAAACCTGAT-CTGG-3'; BPL-rev, 5'-TTAA 
GATCCIAAGAACGAGACAGGCTGAACTCfCC-3'; 
BCCPA67, 5'-GTAACCATGGGTGAACAGGAAGA 
A-3'; BCCP-rev, 5'-GGATCCTI'AAACGTTTGTGTC 
TATAAG-3'; BCCP K1 17L, 5'-GAAGCTCTACTG 
GTI'ATGAAC-3'. 
DNA was isolated from agarose using a QlAquick® Gel 
Extraction Kit, and plasmid DNA was purified using a 
QlAprep® Spin Miniprep Kit (both Qiagen). A. aeolicus  
genomic DNA was a kind gift from R. V. Swanson 
(Diversa, San Diego, USA), R. Huber and K. Stetter 
(University of Regensburg, Germany). All growth media 
were prepared following standard procedures [20]. 
Nucleic acid manipulations 
DNA manipulations were performed using standard pro-
tocols [20]. Standard conditions were used for restriction 
endonuclease digestions, agarose gel electrophoresis and 
DNA ligation reactions, according to the manufacturer's 
instructions. All nucleic acid constructs were confirmed by 
commercial DNA sequencing (MWG Biotech). 
Cloning of BPL, BCCPA67 and BCCPA67 K177L 
from A. aeolicus 
The A. aeolicus bpi and bcqx67 genes were amplified from 
A. aeolicus genomic DNA template by polymerase chain 
reaction using primers BPL-for and BPL-rev; and 
BCCPA67 and BCCP-rev, respectively. The PCR products 
were cloned into plasmid pCR2. I (Invitrogen) using stand-
ard TOPO cloning procedures, yielding the plasmids 
pCR2. l/BPL and pCR2. l/BccpM7. Positive clones were 
sequenced to confirm the fidelity of the insert and a 
restriction digest was performed on the pCR2.1/BPL 
plasmid using the restriction endonucleases NcoI and 
BamHI. The isolated 723 bp fragment containing the 
A. aeolicus BPL gene was cloned in NcoI/BarnHI-digested 
pET28a (Novagen), producing the expression vector 
pET28a/BPL. An NcoI/BamHI digest was performed on 
plasmid pCR2. 1/Bccpt\67 and the resulting 259 bp frag-
ment containing the truncated Bccp gene was ligated in a 
NcoI/BarnHI-digested pET derivative (Novagen). The 
resulting expression vector, pET6H/BccpA67, produced a 
His6 fusion at the N-terminus of bccpA67. 
A hccpA67 mutant gene encoding a mutation of the 
active site lysine to a leucine residue (KI17L) was 
produced by the PCR megaprimer method [21]. The 
primers used were BCCPA67, BCCP-rev and BCCPA67 
K1I7L and the plasmid pCR2.1/BccpM7 was used as the 
PCR template. The mutant gene PCR product was cloned 
into pCR2. 1 and the resulting plasmid was named 
pCR2.1/BccpA67 K117L. To express the mutant bccpLx67 
with an N-terminal His6-tag, pET6H/BccpA67 K 11 7L, 
was produced in the same fashion as described for the 
wild-type protein. 
Expression and purification of A. aeolicus BPL 
The pET28a/BPL vector was used to transform E. coil 
BL21(DE3) cells (Novagen). A single colony was used to 
inoculate 200 mL LB broth supplemented with kanamycin 
(30 tginL) and grown overnight at 37 °C and 250 r.p.m. 
This seed culture was then used to inoculate 4 L of fresh 
growth medium and grown at 37 °C to D 0 = 1.0 before 
induction with 1.0 mm isopropyl thio-13-D-galactoside 
(IPTG). After a further 3 h growth the cells were harvested 
by centrifugation (4000 g for 15 min at 4 °C) and washed 
with 10 mm Hepes (pH 7.5). The cells were resuspended in 
10 mm Hepes buffer (pH 7.5) and disrupted by sonication 
(15 pulses of 30 s at 30-second intervals) at 4 °C. The cell 
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debris was removed by centrifugation at 27 000 g for 
20 min at 4 °C. 
One tablet of CompleteTM Proteinase Inhibitor Cocktail 
(Roche) was added to the cell lysate before it was incubated 
at 60 °C for 20 mm. Precipitated cellular debris was 
removed by centrifugation at 27 000 g for 20 min at 4 °C. 
The supernatant was filtered through a 0.45-pm membrane 
before it was loaded onto a 6-mL Resource-S cation 
exchange column (Amersham Biosciences) equilibrated 
with 10 mm Hepes (pH 7.5) at room temperatutre. The 
BPL protein was eluted with a linear salt gradient (0-1 M 
NaCl in 10 mm Hepes, pH 7.5) over 20 column volumes 
(120 mL). Fractions containing BPL (eluting at 200 mm 
NaCl) were analysed by SDS/PAGE and those fractions 
judged to be 95% pure were pooled and stored in 10 mm 
Hepes (pH 7.5) containing 20% glycerol (v/v) at -20 °C. 
Protein concentration was determined using the Bio-Rad 
protein assay kit. 
Expression and purification of Apo-BCCPA67 and 
BCCPA67 K1 171 from A. aeolicus 
Overexpression of A. aeolicus BCCPA67 was achieved by 
transforming E. co/i BL2 1 (DE3) cells with the plasmid 
pET6H/BccpA67. A single colony was used to inoculate 
200 mL 2YT supplemented with ampicillin (100 tgmL) 
and grown overnight at 37 °C and 250 r.p.m. This seed 
culture was then used to inoculate 4 L of fresh growth 
medium and grown at 37 °C to D600 = 1.0 before induction 
with IPTG (1.0 mm final concentration). After a further 3 h 
the cells were harvested by centrifugation (4000 g for 
15 min at 4 °C) and washed in binding buffer (20 mm 
Tris/HC1, pH 7.5, 0.5 M NaCl, 5 mm imidazole). The cells 
were resuspended in binding buffer (5 mL per gram of wet 
cell paste) and disrupted by sonication (15 pulses of 30 s at 
30-second intervals) at 4 °C. The cell debris was removed by 
centrifugation at 27 000 g for 20 min at 4 °C, after which 
the supernatant was filtered through a 0.45-lim membrane 
prior to chromatography. 
The cell lysate was applied to a Hitrap® chelating affinity 
column (Amersham Biosciences) previously loaded with 
charge buffer (100 mm NiSO4) and equilibrated with binding 
buffer at room temperature. The column was then washed 
with 5 column volumes of binding buffer before bound 
material was eluted using a linear gradient of 0-100% 
elution buffer (20 mrvi Tris/HC1, pH 7.5, 0.5 M NaCl, 1 M 
imidazole). Fractions were analysed by SDS/PAGE and 
those containing BCCPA67 were pooled and dialysed 
overnight against 4 L of 10 mrvi Hepes (pH 7.5) at 20 °C. 
Apo-BCCPA67 and holo-BCCPA67 were separated by 
applying the BCCPA67-containing fractions eluted from the 
nickel column onto a 1-mL Mono-Q column (Amersham 
Biosciences) pre-equilibrated with 10 mm Hepes (pH 7.5) at 
room temperature. The column was then washed with 20 
column volumes of 10 mm Hepes (pH 7.5), before the 
protein was eluted with a salt gradient (0-100% 10 mm 
Hepes, 1 M NaCl, pH 7.5) over 25 column volumes. 
Fractions containing apo-BCCPA67 (confirmed by LC-
MS analysis) were pooled and stored in 10 mrvi Hepes 
(pH 7.5) containing 20% glycerol (v/v) at -20 °C. Due to 
the low proportion of aromatic residues in BCCPA67, 
protein concentration was evaluated by measuring the  
absorbance at 280 nm and using the conversion factor 
calculated using VECTOR NTIS software. 
The expression and purification of the BCCPA67 K II 7L 
mutant was performed in a similar way to the wild type 
protein. Elution from the Mono-Q column produced a 
single, apo-form peak. 
Mass spectrometry characterization of proteins 
Mass spectrometry was performed on a MicroMass Plat-
form 11 quadrupole mass spectrometer equipped with an 
electrospray ion source. The spectrometer cone voltage was 
ramped from 40 to 70 V and the source temperature set to 
140 °C. Protein samples were separated with a Waters 
HPLC 2690 with a Phenomenex CS reverse phase column 
directly connected to the spectrometer. The proteins were 
eluted from the column with a 5-95% acetonitrile (contain-
ing 0.01% trifluoroacetic acid) gradient at a flow rate of 
0.4 mL-min-1. The total ion count in the range 500-2000 rn/z 
was scanned at 0. 1 s intervals. The scans were accumulated 
and spectra combined and the molecular mass determined by 
the MAXENT AND TRANSFORM algorithms of the MASS LYNX 
software (MicroMass). 
Assay of A. aeolicus BPL 
BPL activity was assayed by measuring the incorporation of 
[14C]biotin into purified BCCPA67, in a similar way to that 
described previously [22]. Except where stated otherwise, the 
reaction contained 10 mm Hepes (pH 8.5), 100 llM  ATP, 
200 IM MgCl,, 10 ltM biotin, 1 sM [14C]biotin (specific 
activity 54 mCimmor1 ), 0.1 mg-mL-1  bovine serum albu-
min, and 400 lAM apo-BCCPA67. The reaction was initiated 
by the addition of purified BPL to a final concentration of 
I ltI, and incubated at 70 °C for 30 mm. The reaction was 
terminated by the addition of ice-cold trichloroacetic acid 
(final concentration 25% w/v), and incubation on ice for 
30 mm. The resulting protein precipitate was removed by 
centrifugation (27 000 g for 10 mm). Aliquots of the 
supernatant were added to 5 mL of scintillation fluid 
(ICN biomedicals), and radioactivity was measured using a 
Tri-carb 210 OTR liquid scintillation counter (Packard). 
The extent of BCCPA67 biotinylation was deduced from the 
decrease in {14C]biotin in the supernatant. 
For kinetic analysis each of the substrate concentrations 
(biotin, ATP, BCCP) was varied accordingly. Values for Km 
and Vmax were determined by Michaelis-Menten analysis 
on SIGMAPLOT 2001 software. In some assays, to obtain 
sufficiently high levels of activity for accurate detection, it 
was necessary to continue until more than 10% of the 
limiting substrate had been used. In these instances the data 
was transformed using the method of Lee and Wilson and 
plotted as transformed values s' and v' [23]. 
To demonstrate the formation of the reaction interme-
diate, biotinyl-5'-AMP, we employed a streptavidin-binding 
assay. Briefly, the reaction contained 10 mrvi Hepes 
(pH 8.5), 10 1cM biotin, 100 lAM  [8-14C]ATP (specific activity 
50-62 rnCimmol t), 200 IIM MgCl2 and 0.1 mg-mL-1  
bovine serum albumin. The reaction was initiated by the 
addition of purified BPL to a final concentration of 5 lAM, 
and incubated at 70 °C for 30 mm. Ice-cold trichloroacetic 
acid (final concentration 10% w/v) was used to terminate 
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the reaction and the resulting precipitate of BPL was 
removed by centrifugation. Aliquots of the assay were then 
spotted onto a single SAM® Biotin Capture Membrane 
(Promega). Unreacted [0e-14C]ATP was removed by washing 
each membrane four times in 2 M NaCl, four times in 2 M 
NaCl in 1% l-13PO4, and twice in water. Finally the 
membrane was added to 5 mL of scintillation fluid (ICN 
biomedicals), and the radioactivity of the retained, bound 
biotinyl-5'-[-14C]AMP was measured using a Tri-carb 210 
OTR liquid scintillation counter (Packard). 
Limited proteolysis of BPL 
Proteolysis of apo-BPL and substrate-bound-BPL were 
investigated using the proteases trypsin (Sigma) and chy-
motrypsin (Promega). Substrate-bound BPL was prepared 
by incubating BPL (15 VIM) for 20 min at 60 °C with 
saturating amounts of biotin (40 pm), MgATP (2 mm), or 
both. The samples were then cooled for 10 min before 
treatment with protease, with a final protease/substrate 
ratio of 1: 20 (w/w), and incubation at 37 °C for 30 mm. 
Digestion was terminated by the addition of SDS sample 
buffer and boiling for 5 mm. The extent of proteolysis was 
analysed by SDS/PAGE and densitometry analysis of the 
gel spots was performed using IMAGEMASTER TOTAL LABOR-
ATORY Software (Amersham Biosciences). 
Chemical crosslinking of A. aeolicus BPL 
and Apo-BCCPA67 
Purified BPL (15 jiM) and either apo-BCCPA67, holo-
BCCPLS67 or BCCPA67 K! 17L (45 mm) were covalently 
cross-linked using l-ethyl-3-(dimethylamino-propyl)-carbo-
diimide (EDC, 10 mm) at 60 °C for 60 ruins. Aliquots were 
withdrawn at various time intervals, quenched with ammo-
mum acetate (100 mm), and analysed by SDS/PAGE. 
The cross-linked complex was prepared on a larger scale 
and separated from BPL and BCCPA67 by gel filtration. To 
prepare the complex we incubated 5 mg each of BPL and 
BCCP, EDC (10 mm) in a final volume of 5 mL 10 mm 
Hepes (pH 8.5) for 60mins at 60 °C. The mixture was 
concentrated to 1 mL and then passed through a Super-
dcx 75 column (Amersham Biosciences) equilibrated in 
10 mM Hepes (pH 8.5) and 100 mrvt NaCl. The purified 
protein was stored at —20 °C. 
Results 
Analysis of the A. aeolicus genome 
The complete genome sequence of A. aeolicus consists of 
1512 predicted open reading frames [16]. We performed a 
BLAST search on the complete genome and identified two 
ORFs of 233 aa and 154 aa with high sequence homology 
to E. co/i BirA (20.9% identity, 35.2% similarity) and 
BCCP (33.8% identity, 46.9% similarity), respectively. The 
pairwise sequence alignments generated by CLUSTAL w [24] 
are shown in Fig. I and these enabled us to design PCR 
primers to clone the A. aeolicus BPL and BCCP genes. We 
noted from this initial analysis that the A. aeolicus BPL 
differs from the E. co/i BirA in that it lacks an N-terminal 
DNA-binding domain which places it in the group I class 
Ul 
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Fig. 1. Sequence alignments of BCCP (A) and BPL (B) from E. co/i and 
A. aeo/icus. Pairwise alignment was prepared using CLUSTAL W. (A) 
The start residue of the BCCP-87 domain and the BCCP subtilisin 
fragment are indicated (.1 and V. respectively). The start codon of the 
BCCPA67 domain is shown (1'), and the biotinylated lysine residue is 
indicated (•). Secondary structural elements of the BCCP-87 domain 
are shown and the thumb' region is indicated (*). (B) Pairs of dis-
ordered surface loops which are close in space in the E. co/i BirA 
structure are shown (- and +) The trypsin cleavage sites of A. aeolicus 
BPL are indicated ($) as is the site of subtilisin cleavage of E. coil BirA 
(6) 
of BPLs along with those from Mvcobacteriwn tuberculosis 
and Therinotoga ni.aritinsa [19]. 
Previous studies on full-length E. co/i BCCP (156 aa) 
revealed that the protein forms a tight complex with the 
biotin carboxylase (BC) subunit in solution, which compli-
cates biochemical studies [25]. In most cases, the biotin 
carrier domain of biotin-containing enzymes is located at 
the C-terminal end of the carboxylase, with the biotinyl-
lysine about 35 residues from the C-terminus. Structural 
studies revealed that a 65-70 amino acid fragment of BCCP, 
previously suggested by deletion mutagenesis, is required to 
form a minimal structured biotin domain [26]. Various 
truncated forms of the E. co/i BCCP have been used in 
biochemical and structural studies, containing between 80 
and 87 residues from the C-tenninus of the protein. Here we 
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expressed A. aeolicus BCCP lacking 67 residues from the 
N-terminus (BCCPA67, Fig. 1) with an N-terminal His6-tag 
(total length 96 aa). The homology scores between 
A. aeolicus BCCPA67 and E. co/i BCCP-87 (a domain 
containing 87 C-terminal amino acids) are 51.9% identity 
and 69.6% similarity (Fig. I). 
Cloning, expression and purification of BPL 
The A. aeolicus bp/ gene was amplified by PCR using 
A. aeolicus genomic DNA as a template and cloned into 
plasmid pCR2. 1. DNA sequencing confirmed the previ-
ously published gene sequence, with the exception of a single 
base change at position 325 (T-4C), which results in the 
substitution of a cysteine residue with an arginine. Subse-
quently the bp/ gene was cloned into a pET expression 
vector for expression in various E. co/i cells (DE3 lysogens); 
we found optimum recovery of protein using the 
BL2I(DE3) strain. Cells were grown in shake flasks at 
37 °C and expression induced with 1 mm IPTG (see 
Experimental procedures). 
The predicted p1 of the A. aeolicus BPL is 9.1 and as the 
enzyme contains a high proportion of positively charged 
residues, cation-echange chromatography was used to 
purify it in a single step (Fig. 2, lanes 2-4). Initially the 
crude lysate was incubated at 60 °C which resulted in the 
precipitation of a significant quantity of E. co/i proteins. It 
was then necessary to dialyse the sample overnight (20 °C) 
against 10 mm Hepes (pH 7.5) as immediate loading of an 
untreated extract onto a ResourceS column resulted in very 
poor binding (< 5%). It is unclear why this step was 
necessary, but after dialysis binding to the cation-exchange 
column approached 100%. BPL eluted from the column at 
200 mrvt NaCl and we obtained the enzyme with a purity of 
greater than 95% (as determined by SDS/PAGE). Electro-
spray mass spectrometry analysis gave the molecular mass 








Fig. 2. Purification of A. aeolicus BPL, BCCPA67 and BCCPA67 
K117L. Protein purification was analysed by SDS/PAGE under 
reducing conditions. Lanes 1, 5 and 9, low molecular mass marker; 
lane 2, BPL cell lysate; lane 3. BPL cell lysate after heat purifica-
tion; lane 4, BPL after ResourseS purification; lane 6, BCCPA67 cell 
lysate; lane 7. BCCPA67 after Ni-affinity purification; lane 8. apo-
BCCPA67 after Mono-Q purification; lane 10, BCCPA67 KI 17L cell 
lysate; lane 11. BCCPA67 KI 17L after Ni-affinity purification; lane 12. 
BCCPA67 KI 17L after Mono-Q purification. 
of the protein as 26636.8 + 2.3 Da, consistent with the 
post-translational removal of the N-terminal methionine 
residue, and accurate to within experimental error of the 
predicted value of 26634.6 Da. The final yield of BPL using 
this method was > 10 mg per litre of cell culture and this 
protein was used for all subsequent kinetic and cross linking 
analysis. 
Cloning, expression and purification of BCCPA67 
We designed primers to clone a truncated domain of the 
A. aeolicus hccp gene missing the first 201 bp, which encode 
the N-terminal 67 amino acids of A. aeolicus BCCP (Fig. 1). 
The truncated gene was amplified from genomic DNA 
using PCR and cloned into the pCR2.1 vector. DNA 
sequencing confirmed the expected gene sequence, and the 
bccpA67 gene was subsequently cloned into a pET-derived 
expression vector with an N-terminal His6-tag. E. co/i 
BL2I(DE3) competent cells were used for recombinant 
expression (described under Experimental procedures) and 
the BCCPA67 cell lysate was first purified by nickel-affinity 
chromatography (Fig. 2, lanes 6-8). The protein eluted with 
200 mm imidazole and, as precipitation had been observed 
at high concentrations of this eluant, it was immediately 
diluted 1: 1 with 10 mrvi Hepes (pH 7.5) and dialysed 
against this buffer. SDS/PAGE analysis indicated 
BCCPA67 to be > 90% pure but electrospray mass spectro-
metry revealed the presence of two distinct species. The first, 
of molecular mass 10740.1 ± 1.1 Da, corresponded to the 
predicted mass of apo-BCCPA67 (10739.6 Da) while the 
second corresponding to the holo-form (biotinyated), with a 
mass increase of 226.1 Da (10965.4 Da; predicted mass 
10965.7 Da). This confirmed that the A. aeolicus BCCPA67 
domain folded correctly, and was recognized and biotinyl-
ated by the host E. co/i BirA. To separate the apo- and 
holo-forms of BCCPA67 we employed anion exchange 
chromatography in a similar way to that used for E. co/i 
BCCP-87 [27]. Fractions from the column were analysed by 
electrospray mass spectrometry and the apo-protein eluted 
at a slightly lower salt concentration than the holo-form 
(160-240 mm NaCl vs. 240-320 ma NaCl). Approximately 
80% of the apo-BCCPA67 was resolved from the holo-form 
by collecting only the leading fractions of the protein peak. 
The final yield of apo-BCCPA67 was 5-10 mg per litre of 
cell culture and 1 mg per litre of the holo-form. 
Cloning, expression and purification of BCCPA67 Ki 1 7L 
mutant 
A mutant of the truncated bccpA67 gene, with the active 
lysine residue (KI 17) replaced by a leucine residue, was 
produced using the megaprimer method [21]. The mutation 
was confirmed by DNA sequencing before the gene was 
cloned into a pET-derived expression vector with an 
N-terminal His6-tag and the resulting construct was then 
transformed into E. co/i BL2 I (DE3) cells for expression (as 
described in Experimental procedures). The BCCPA67 
K 11 7L protein was purified using nickel-affinity chroma-
tography and the protein eluted with 200 mtvi imidazole 
(Fig. 2, lanes 10-12). Protein-containing fractions were 
immediately dialysed against 10 mtst Hepes (pH 7.5). Fur-
ther purification on anion-exchange chromatography gave a 
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single species with a mass of 10724.8 + 1.1 Da, consistent 
with the predicted mass of apo-BCCPA67 KI17L of 
10724.6 Da. A species was not present at +226 Da, an 
indication that in vivo biotinylation had not occurred. The 
yield of the apo-BCCPA67 K  17L mutant was 15 mg of 
protein per litre of cell culture. 
Biochemical properties of BPL 
Activity assays were performed with BPL by measuring 
the incorporation of [ 14C]biotin into the purified apo-
BCCPA67 biotin-accepting domain [22]. In initial experi-
ments we observed optimal enzyme activity at pH 8.5, 
and magnesium ions, ATP, biotin and apo-BCCPA67 
were all required for activity. The activity of the enzyme 
was also measured at varying temperatures, with optimal 
activity at 70 °C. Activity was seen to decrease by 
roughly 50% for every 10 °C drop in temperature, and 
increasing the temperature above 70 °C resulted in 
enzyme precipitation, together with a dramatic loss in 
activity (data not shown). The tolerance of BPL for 
other nucleotide sources was measured by replacing ATP 
with UTP, GTP or CTP. No BPL activity was detected 
for any of these three substrates, suggesting that the 
enzyme is completely dependent on ATP for its nucleo-
tide supply (data not shown). 
In assays performed with BCCPA67 K  17L as the biotin 
acceptor no biotinylation was observed, verifying Ki 17 as 
the active residue and demonstrating the specificity of the 
BPL catalysed reaction. 
Kinetic analysis of BPL 
The kinetic constants for D-biotin, MgATP and apo-
BCCPA67 were determined using steady-state kinetics 
(Fig. 3). The Km for D-biotin was determined to be 
440 + 70 flM. The K 1 values for BPLs from other species 
range from low nanomolar to low micromolar; 67 ± 11 nM 
(Saccharoniyces cerevisiae BPL), 300 nM (E. co/i BirA), 
130 nM (Arabidopsis thaliana HCS) and 3.3 m (chicken 
liver HCS1) [28-31]. The Km for MgATP was 
15.1 ± 1.5 IIM, which is similar to that determined for the 
S. cerevisiae BPL (20.9 ± 3 sat) and A. thaliana HCS 
(4.4 gm). In contrast, the R for MgATP for E. co/i BirA 
is around 300 KIM. It should be noted that the kinetic 
analyses for each BPL were performed under slightly 
different reactions conditions, for example an elevated 
temperature was used in the study presented here. Finally, 
the K13, for apo-BCCPA67 was 160 ± 32 l.IM. A range of 
biotinylation substrates have been used in assays of BPL 
activity with cross-species reactivity frequently observed, 
e.g. S. cerevisiae BPL has a K, of 11.1 ± I mm for E. co/i 
BCCP-87. However, we could not test E. co/i BCCP-87 as a 
substrate for BPL because the rate of biotinylation at 37 °C 
was outside the lower limit of detection in our assay. 
As shown in Scheme 1 the first step in all biotinylation 
reactions studied thus far involves the synthesis of a 
biotinyl-5'-AMP intermediate and the release of PP. This 
molecule is the substrate for biotin transfer to BCCP and is 
also the corepressor of E. co/i BirA. To prove that 
A. aeo/icus BPL synthesises biotinyl-5'-AMP we incubated 
BPL with biotin and [ 14C]MgATP at 70 °C and used 
streptavidin-coated membranes to capture radioactive bio-
tinyl-5'-[14C]AMP (data not shown). Furthermore, we 
noted that biotinylation was inhibited by the addition of 
NaCl in concentrations above 200 mm. 
Proteolysis of BPL 
We subjected BPL to limited proteolysis in the presence and 
absence of biotin and MgATP (Fig. 4). Digestion with both 
trypsin and chymotrypsin resulted in formation of a 
fragment of 21 kDa. Chymotrypsin digestion also pro-
duced an array of smaller peptide fragments. We found that 
only 34% of total BPL remained after trypsin cleavage in 
the absence of substrates. However, preincubation of BPL 
with saturating amounts of biotin or MgATP separately 
increased its resistance to digestion (50% and 63% 
remained, respectively). Moreover, preincubation with both 
substrates dramatically increased the resistance of BPL to 
proteolysis with trypsin (98.9% remained). Comparative 
analysis with chymotrypsin showed that 11% of BPL 
remained intact after digestion. Preincubation of the enzyme 
with MgATP afforded little protection (13% of BPL 
remaining), whereas 34% and 92% BPL remained after 
preincubation with biotin and biotin and ATP. Taken 
together these results suggest that the binding of the 
substrates and/or the formation of the intermediate, 
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Fig. 3. Steady-state kinetic analysis of BPL substrate binding. The activity of A. aeolicus BPL was measured under steady-state conditions at 70 °C. 
Two substrates were kept at constant saturating levels while the concentration of the third substrate was varied over the ranges shown above in the 
graphs. From the curves. K,, values for biotin (A), MgATP (B) and apo-BCCPA67 (C) were determined (see Experimental procedures). 
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Fig. 4. Proteolysis of A. aeolicus BPL. A. aeolicus BPL was treated 
with trypsin or chymotrypsin either with or without equilibrating the 
enzyme with 1 rnm MgATP and/or 50 .iM biotin. Lanes 1-4, Trypsin 
digest; lane I BPL; lane 2, BPL + MgATP; lane 3, BPL + biotin; 
lane 4, BPL + MgATP and biotin. Lanes 5-8 Chymotrypsin digest; 
lane 5, BPL; lane 6, BPL + MgATP; lane 7, BPL + biotin; lane 8, 
BPL + MgATP and biotin. 
LC-MS analysis of the peptide fragment produced from 
BPL after treatment with trypsin revealed the presence of 
two distinct species of mass 215549.5 ± 2.6 Da and 
21678.6 ± 5.9 Da. Primary structure analysis of BPL 
established these masses corresponded to trypsin cleavage 
between R44 and K45, and K45 and W46 adjacent to the 
proposed catalytic centre and biotinyl-5'-AMP binding site. 
Chemical crosslinking of BPL and BCCP 
Although structures of E. co/i BirA and both apo- and holo-
BCCP-87 have been determined, our goal was to isolate a 
BPL:BCCP complex for biochemical and structural studies. 
Previous work in our laboratory used the chemical 
crosslinking agent EDC to isolate an E. co/i flavodoxin—
flavodoxin reductase complex, so we used this reagent to 
crosslink BPL and various forms of BCCPA67 [32]. Initially 
we incubated BPL and apo-BCCPA67 in the presence of 
excess EDC at room temperature with and without 
saturating amounts of biotin and MgATP, but we did not 
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observe any crosslinked species of predicted molecular mass 
36 kDa on SDS/PAGE (data not shown). However, a 
species was observed when the incubation was carried out at 
elevated temperatures, with 60 °C being the optimum 
(Fig. 5A). The presence of the substrates had no observable 
effect on crosslinking. Interestingly, when BPL was incuba-
ted with holo-BCCPA67 and EDC the amount of cross-
linked species generated was significantly reduced compared 
to the apo form (Fig. SB). Moreover, the incubation of BPL 
with the BCCPA67 K  17L mutant led to the formation of 
crosslinked complex in comparable amounts to that using 
apo-BCCPA67 (Fig. SC). Purification of the BPL: 
BCCPA67 complex from unreacted proteins was achieved 
using size exclusion chromatography, which resolved the 
mixture into three peaks (Fig. 6). We noted that both BPL, 
BCCPA67 and the complex eluted from the size exclusion 
column at retention volumes different to that predicted by 
their molecular masses (45, 35 and 70 kDa, respectively). 
However, analysis by SDS/PAGE revealed that the 
BPL:BCCPA67 complex eluted from the column first and 
had a molecular mass of 37 kDa (Fig. 6, inset). Electrospray 
analysis of the complex gave a molecular mass of 
37 200 + 200 Da which agrees well with the predicted 
mass of a 1 1 heterodimer. 
Discussion 
The attachment of biotin to the specific lysine residue of the 
apo- forms of biotin-requiring enzymes is a complex, 
multistep reaction. The BPL enzyme (also known as 
holocarboxylase synthetase, HCS) catalysing this process 
first activates biotin as biotinyl-5'-AMP then transfers the 
biotin to a specific lysine of the BCCP domain. The BPLs 
and BCCPs from a diverse range of organisms including 
E. co/i (BirA), yeast, human and plant have been isolated 
and it has been shown that the BPL from one organism can 
biotinylate the BCCP domain from another [28]. This 
suggests some degree of structural homology between these 
proteins and primary structure analysis reveals there is a 
high degree of amino acid sequence similarity throughout 
the catalytic domain of the BPL family and the biotinyl 
domain of BCCPs [33]. An understanding of the protein— 
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Fig. 5. SDS/PAGE analysis of chemical crosslinking assays. Gel A, crosslinking of BPL and apo-BCCPA67. Gel B, crosslinking of BPL and holo-
BCCPL67. Gel C, crosslinking of BPL and BCCPA67 K II 7L. Lanes 1-5 of each gel, assay after 0, 5. 10,15 and 30 min respectively. Gel A. lanes 6 
and 7, control assays with BCCPA67 alone and BPL alone. 
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Fig. 6. Purification of the chemically crosslinked BPL:apo-BCCPA67 complex by size-exclusion chromatography. The chromatogram above was 
obtained when the cross-linking reaction was applied to a Superdex 75 column. The three peaks correspond to the crosslinked complex (7-8 mL), 
BPL (10 mL) and BCCPA67 (11-12 mL). Insert: SDS/PAGE analysis of the column fractions. Lane I, cross-linking reaction before purification. 
Lane 2-11, 1 mL fractions cluting between 6 and 15 mL. 
protein interactions that mediate this highly specific reaction 
requires three dimensional structures of each of the com-
ponents. The structure of the E. co/i BirA monomer in 
complex with biotinyl-lysine revealed details of the protein—
substrate interactions but several loops within the active site 
were disordered [9]. More recently, the structure of the BirA 
dimer has provided insights into how the ligase also acts as a 
transcriptional repressor by binding to the E. co/i biotin 
operon operator [12]. The structures of the apo- and holo-
forms of E. co/i BCCP-87, determined by X-ray and NMR, 
are virtually identical and showed that the biotinyl-lysine 
residue is located at an exposed j3-turn, flanked by 
important, highly conserved methionine residues [13,15]. 
A more recent NMR study, combined with results from site-
directed and random mutagenesis [29,34,35], allowed mod-
elling of the elusive E. co/i BPL:BCCP-87 complex and it 
appears that its formation is dependent on subtle, compet-
ing protein—protein interactions [36]. 
Analysis of the complete genome of the hyperthermophile 
A. aeolicus revealed the presence of BPL and BCCP 
homologues (Fig. 1). The A. aeolicus BPL enzyme belongs 
to the class I group of BPLs since it lacks the DNA-binding 
domain found in BirA and is the smallest characterized thus 
far. Eukaryotic BPLs also lack predicted DNA-binding 
domains but have large N-terminal extensions with 
unknown functions [33]. The full-length A. aeolicus BCCP 
has a C-terminus showing high sequence homology to the 
biotin domains of biotin-carboxylases and contains the 
eight amino acid thumb' motif found in E. co/i BCCP 
[33,37,38]. The N-terminus has a large proportion of 
charged residues, and displays little similarity to any other 
BCCPs. 
Using recombinant proteins isolated from E. co/i we have 
characterized the full-length BPL and BCCP biotinylation 
domain BCCPA67 (with a His6 N-terminal tag) from a 
hyperthermophile. We have gained insight into this 
extremely specific post-translational modification reaction 
at high temperatures and used features of the two A. aeo-
licus proteins to capture a BPL:BCCP complex. We found 
A. aeolicus BPL to be monomeric, and thus competing 
hornodimerization interactions found in E. co/i BirA are 
not present. We isolated a mixture of apo- and holo-forms 
of A. aeolicus BCCPA67 and so conclude that it must be a 
substrate for E. coli BPL in vivo. Biotinylation in hyper-
thermophiles proceeds via the two-step reaction sequence 
found in other organisms (Scheme 1). Isolated A. aeolicus 
BPL could biotinylate apo-BCCPA67 at temperatures up to 
70 °C albeit at a slow rate. It is interesting to compare the 
A. aeolicus BPL:BCCPA67 biotinylation reaction with that 
of a mutant E. co/i BirA lacking the N-terminal DNA 
binding domain (BirA65-321) and E. co/i BCCP-87. The 
BirA65-32 I mutant could synthesize biotinyl-5'-AMP and 
transfer biotin to apo-BCCP-87 at the same rate as wild-
type BirA. However, the affinity of BirA65-32 1 mutant for 
biotin and biotmyl-5'-AMP was decreased 100-fold and 
1000-fold, respectively [39]. This suggested that in BirA, the 
N-terminal domain is somehow involved in tight-binding of 
the two ligands. In future, it would be interesting to study a 
BPL:BirA chimera by fusing the DNA-binding domain at 
the N-terminus of A. aeolicus BPL. 
Substrate Km values for BPLs from a number of species 
have been shown to range from the low nanomolar to low 
millimolar. In steady-state kinetic assays at 70 °C, the 
A. aeolicus BPL bound biotin, MgATP and apo-BCCPA67 
with affinites of 440 rim, 15.1 tIM and 160 p, respectively. 
The kinetic constant for MgATP suggests that A. aeolicu.s 
BPL resembles those from eukaryotic biotin auxotrophs 
(low micromolar). In contrast, E. co/i BirA binds MgATP 
with a Km in the low millimolar range which reflects its dual 
function as both repressor of biotin biosynthesis and biotin 
ligase. It is interesting to note that A. aeolicus contains all 
the genes required to convert pimelate to biotin (bloW, bioF, 
bioA, bioD and bioB) suggesting it can synthesize this 
vitamin but the in vivo concentration within A. aeolicus cells 
is unknown. The Km for the apo-BCCPA67 domain used in 
this study is high compared to others but this may reflect the 
fact that the first 67 amino acid residues, which contain a 
high number of charged residues, could play an important 
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role in tight binding to BPL. Most biochemical studies use 
these truncated BCCP domains and future work using full 
length BCCPs should elucidate the role of the N-terminal 
interaction with BPL. It is also possible that the addition of 
the His6-tag to the protein has altered its kinetic properties 
and may contribute to the abnormally high Km for 
BCCPA67. The calculated kmt/Km for biotin of 
1.7 ± 0.1 x 10 M s 1 is 300-, 100- and 35-fold smaller 
than the E. co/i BirA, yeast and A. tha/iana BPL enzymes, 
respectively [28,30,40] but reflects the fact that the A. aeo-
licus BPL kcat is low at 70 °C (çí. Á. aeolicus grows 
optimally at 95 °C). 
Limited proteolysis with trypsin produced two fragments 
of 	20 kDa, differing in length by only one residue (Fig. 4). 
Mass spectrometry revealed that cleavage had occurred 
after residues R44 and K45 which, by comparison with 
E. co/i BirA, are predicted to lie near the putative inter-
mediate binding site (Fig. 1). Treatment of BPL with trypsin 
and chymotrypsin in the presence of biotin or MgATP 
decreased the susceptibility to cleavage by a small but 
noticeable amount. However, incubation of the enzyme in 
the presence of both substrates rendered A. aeolicus BPL 
protease-resistant. The same region is protease-sensitive in 
S. cerevisiae BPL and is also protected by incubation with 
both biotin and MgATP [28]. The E. co/i BirA structure 
contains five surface loops, four of which are in the central 
domain with loop regions (110-128, 212-233) and (140-146, 
193-199) close together in three-dimensional space [6]. The 
region containing 110-128 in E. co/i BirA is highly analog-
ous to residues 32-50 in A. aeolicus BPL whereas the other 
loop regions have low pairwise sequence homology. A 
protease-sensitive site has been reported between residues 
217 and 218 of BirA. In contrast, A. aeolicus BPL is not 
cleaved at this site but is cleaved in the adjacent loop region 
(32-50). This suggests that this highly conserved region 
forms an exposed loop near the biotinyl-5'-AMP binding 
site (Fig. 1). These flexible, unstructured regions are also 
involved in BCCP binding and are believed to become more 
rigid upon substrate-binding [6,34]. 
A recent combined mutagenesis/biological selection 
approach identified two single glutamate residues E119 
and E147 of E. co/i BCCP-87 that appear to interact with 
BPL [22]. A BCCP-87 El 19K mutant is inactive as a 
substrate for BirA, whereas the E147K protein could be 
biotinylated, albeit poorly. It is presumed that these acidic 
BCCP-87 residues interact with basic BirA counterparts and 
mutation of BirA residues K277 and R317 were found to 
effect biotinylation and ATP-binding, respectively. This 
surprising result suggested that the C-terminal domain of 
BirA, which had been ascribed no biochemical function, 
also plays a significant role in apo-BCCP and substrate 
recognition [29]. 
It has been shown that ion pair networks are a common 
feature in heat-resistant proteins and are believed to play 
important roles in their increased thermal stability [17,41]. 
As both the A. aeolicus BPL and BCCP contain a large 
number of charged residues and we observed inhibition of 
biotinylation at high salt concentrations, we presume that 
ionic interactions are involved in the formation of the 
hyperthermophilic BPL:BCCPA67 complex. To investigate 
the formation of the BPL:BCCPA67 heterodimer we used 
the chemical cross-linking agent EDC to capture a 
BPL:BCCP complex for the first time. The zero-length 
EDC reagent activates acidic residues on one protein to 
form an unstable urea derivative [42]. This derivative then 
reacts with a nucleophile (such as lysine) on another protein 
to form an amide link between the two proteins. Incubation 
of BPL and apo-BCCPA67 in the presence of EDC led to 
the time-dependent appearance of a species of 37 kDa on 
SDS/PAGE gels (Fig. 5A), which is in agreement with the 
predicted mass of a I : I complex of BPL and apo-
BCCPA67. We noticed that BPL, BCCPA67 and the 
complex eluted earlier than predicted from the size-exclu-
sion column. Future studies will analyse the proteins by 
equilibrium sedimentation experiments in a similar way to 
that described for the BCCP-87 and BCCP [25]. Neverthe-
less, the complex was easily separated from the unreacted 
proteins using this procedure (Fig. 6) and allowed us to 
confirm its mass by electrospray mass spectrometry. Inter-
estingly, the complex was not formed between BPL and 
holo-BCCPA67 (Fig. SB) suggesting that biotinylation had 
either caused a conformational change in BCCPA67 such 
that it no longer bound to BPL or that the biotin moiety had 
somehow blocked residues that react with the EDC reagent. 
Furthermore, a complex was formed between the BCCPA67 
KI 17L mutant and BPL both in the absence and presence 
of saturating amounts of biotin and MgATP (Fig. SC). This 
demonstrates that the active lysine residue does not take 
part in the cross-linking reaction and saturating amounts of 
both substrates do not inhibit complex formation. 
Although the published 3D structures of the apo- and 
holo- forms of BCCP-87 show no major structural differ-
ences, some structural studies (both NMR and X-ray) have 
concluded that the lack of any major differences between 
them might not be wholly reflected in their behaviour in 
solution [15]. NMR titration experiments were carried out 
with BirA and apo-BCCP-87 and, in light of our data, it 
would be interesting to repeat this work with BirA and holo-
BCCP-87 to determine if any differences arise. Recent 
elegant studies by Cronan and Solbiati ci a/. highlight a 
difference in the stability of apo-BCCP-87 and holo-BCCP-
87 to proteolysis and stress the importance of the essential 
so-called 'thumb' domain of BCCP-87 (residues 91-100) 
which had previously been shown to interact with the ureido 
ring of the attached biotin moiety [37,43]. Studies using 
chemically biotinylated BCCP-87 recently confirmed that 
this increased stability is an inherent property of holo-
BCCP-87 and not due to a conformational change imparted 
by BPL. Furthermore, thumbless holo-BCCP-87 mutants 
exhibit little increased stability over their apo- counterparts, 
implying the majority of this increased stability is due to the 
thumb—biotin interaction. The authors conclude that the 
more protease sensitive apo- BCCP has a more dynamic 
form than the holo- protein. The A. aeolicus BCCPA67 also 
contains a well-conserved thumb domain (Fig. 1) and we 
are currently producing thumbless BCCPA67 mutants for 
analysis by EDC cross-linking with BPL (D. Clarke and 
D. Campopiano, unpublished results). 
A recent study suggested that the C-terminal domain of 
BirA is essential for the catalytic activity of the enzyme and 
plays a role in ATP and BCCP binding [29]. Also, a model 
of the E. co/i BirA:holo-BCCP-87 complex has been 
suggested based upon structural studies, sequence analysis, 
mutagenesis and limited proteolysis experiments [36]. The 
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model (PDB code 1K67) was built using the coordinates of 
the BirA dimer in the presence of biotin (PDB code I HXD) 
and holo-BCCP-87 (PDB IBIA). Residues in both E. coli 
proteins thought to be responsible for BirA:BCCP-87 
complex formation are conserved in A. aeolicus BPL and 
BCCPA67 (Fig. 1). A current goal is to identify the charged 
residues taking part in the EDC-mediated crosslinking 
reaction and A. aeolicus BPL and BCCPM7 mutants are 
currently being studied using high-temperature in vitro 
biotinylation and chemical crosslinking assays. 
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Defensins are cationic antimicrobial peptides that 
have a characteristic six-cysteine motif and are impor-
tant components of the innate immune system. We re-
cently described a -defensin-related peptide (Defrl) 
that had potent antimicrobial activity despite having 
only five cysteines. Here we report a relationship be-
tween the structure and activity of Defrl through a com-
parative study with its six cysteine-containing analogue 
(Defrl Y50. Against a panel of pathogens, we found that 
oxidized Defrl had significantly higher activity than its 
reduced form and the oxidized and reduced forms of 
Defrl Y5C. Furthermore, Defrl displayed activity 
against Pseudomonas aeruginosa in the presence of 150 
mm NaCl, whereas Defrl Y5C was inactive. By using 
nondenaturing gel electrophoresis and Fourier trans-
form ion cyclotron resonance mass spectrometry, we 
observed Defrl and Defrl Y5C dimers. Two complemen-
tary fragmentation techniques (collision-induced disso-
ciation and electron capture dissociation) revealed that 
Defrl Y5C dimers form by noncovalent, weak associa-
tion of monomers that contain three intramolecular di-
sulfide bonds. In contrast, Defrl dimers are resistant to 
collision-induced dissociation and are only dissociated 
into monomers by reduction using electron capture. 
This is indicative of Defrl dimerization being mediated 
by an intermolecular disulfide bond. Proteolysis and 
peptide mass mapping revealed that Defri Y5C mono-
mers have 13-defensin disulfide bond connectivity, 
whereas oxidized Defrl is a complex mixture of dimeric 
isoforms with as yet unknown inter- and intramolecular 
connectivities. Each isoform contains one intermolecu-
lar and four intramolecular disulfide bonds, but because 
we were unable to resolve the isoforms by reverse phase 
chromatography, we could not assign each isoform with 
a specific antimicrobial activity. We conclude that the 
enhanced activity and stability of this mixture of Defrl 
dimeric isoforms are due to the presence of an intermo-
lecular disulfide bond. This first description of a co-
valently cross-linked member of the defensin family pro-
vides further evidence that the antimicrobial activity of 
a defensin is linked to its ability to form stable higher 
order structures. 
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13-Defensins are members of the antimicrobial peptide family 
that are important components of the mammalian innate im- 
mune response (1, 2). In addition to potent bactericidal activity, 
they can also act upon T lymphocytes and immature dendritic 
cells thus playing key roles in adaptive immunity (3). They are 
produced as prepropeptides and are processed to a mature se-
creted peptide, which have six canonical cysteine residues with 
spacing and intramolecular disulfide bridge connectivity (Cys'— 
Cys5, Cys2—Cys4, and Cys3—Cys6) distinct from the similar a-de-
fensins (4). A recent bioinformatic analysis of the human and 
mouse genomes revealed a significantly higher number of 13-de-
fensin genes than previously thought, although the function of 
each individual defensin has still to be determined in vivo (5). 
Two strong lines of evidence have demonstrated the signifi-
cance of the antimicrobial activity of defensins in vivo. First, it 
was demonstrated that deleting the gene that encodes the en-
zyme matrilysin, which processes n-defensins in gut paneth cells, 
resulted in mice where orally administered bacteria survived in 
greater numbers and were more virulent (6). Second, a human 
ca-defensin gene expressed in mice resulted in transgenic animals 
that were markedly resistant to oral challenge with the virulent 
Salmonella typhimurium (7). In addition, mice that are deficient 
in the 13-defensin 1 gene have a phenotype consistent with a 
defect in microbial resistance (8). The mature peptides of de- 
fensins are 30-45 amino acids in length and are amphipathic, i.e. 
they have discrete cationic and hydrophobic patches. Their net 
positive surface charge implies an initial electrostatic interaction 
between the peptide and negatively charged components of the 
bacterial cell wall, e.g. lipopolysaccharide or teichoic acid (9). 
Indeed, reduction of the negative charge of these molecules by 
enzymatic covalent modification has been observed in antimicro-
bial peptide-resistant bacterial strains (10). The exact mecha- 
nism of how defensins bind and disrupt the bacteria membrane is 
still the subject of intensive study, but it appears that active 
peptides must display an appropriate balance of hydrophobicity 
and net positive charge (11, 12). It has been proposed that the 
conserved disulfide bridges impart a structural core, and noncon- 
served residues on the surface are under selective pressure 
against rapidly evolving bacteria (13, 14). In direct contrast to 
this perceived structure-function relationship, Wu et al. (15) have 
recently demonstrated that the antimicrobial activity of human 
13-defensin 3 (HBD3)' is independent of disulfide bridging. How- 
'The abbreviations used are: HBD, human 0-defensin; Defrl, defensin-
related peptide 1; Pr-ICR, Fourier transform ion cyclotron resonance; 
CID, collision-induced dissociation; ECD, electron-capture dissociation; 
SORI, sustained off resonance irradiation; MALDI, matrix-associated la-
ser desorption ionization; ESI-MS, electrospray ionization mass spectrom-
etry; Q-TOF, quadrupole time of flight; MBC, minimum bactericidal con-
centration; CPU, colony-forming units; HPLC, high performance liquid 
chromatography; DTI', dithiothreitol; TCEP, tris-carboxyethylphosphine; 
Tricine, N- [2-hydroxy-1, l-bis(hy- droxymethyl)ethyllglycine. 
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1 	2 	3 	 4 	56 
flafri 	DPVTYI RNGGICQYRCIGLRHKTGTCGSPFKCCK 
Defrl Y5C DPVTCIRNC.GICQYRCIGLRI-IKIGTCGSPF'KCCK 
FIG. 1. Sequence of Defrl and Defr Y5C. Numbering corresponds 
to the six conserved cysteines found in 13-defensins. 
ever, chemotactic properties of this peptide are dependent on 
disulfide bond formation. In another study, Nagaraj and co-work-
ers (16) showed peptide fragments of bovine neutrophil /3-defen- 
sin BNBD-2 had antibacterial activities that were independent of 
the number and location of the disulfide bridges. 
Subdivision of the defensin family into the well known a- and 
/3-classifications is based on gene organization, cysteine spac- 
ing, and disulfide bond connectivity (17, 18). It was hoped that 
structural studies would provide explanations for their diverse 
cellular properties, and over 10 years ago a crystallographic 
study of the human cs-defensin hNP3 revealed that it forms a 
dimer containing a six-stranded /3-sheet region (19). The first 
human /3-defensin crystal structure was recently determined 
from two crystallographic forms of HBD2 (20). The monomer in 
each form had a central, three-stranded /3-sheet fold, similar to 
the a-defensins, as well as a small a-helix at the N terminus. In 
one crystal form, monomers associated noncovalently into 
dimers by interaction of the first /3-sheet of each monomer, and 
in the second form, HBD2 octamers were observed within the 
crystallographic unit cell. In contrast, the x-ray structure of the 
HBD1 monomer was very similar to the HBD2 monomer, but 
there was no evidence of higher order oligomerization (21). It is 
worth noting that in the more dynamic environment posed by 
NMR, there is little indication of HBD1, HBD2, or BNBD-12 
dimers or other higher order aggregate formation (22-24). In 
contrast, the observation of higher order structures of HBD3 by 
native gel electrophoresis coupled with the significant down- 
field NMR chemical shifts of charged residues allowed model- 
ing of an HBD3 dimer mediated by noncovalent electrostatic 
interactions between residues on the second /3-sheet (25). To 
rationalize these observed structural differences across the 
family, we believe it is imperative to explore the effect of 
quaternary structure on the biological activity of /3-defensins. 
We recently described a murine /3-defensin gene in C571316 
mice that encoded a peptide with only five cysteine residues 
(Fig. 1, Defrl) but retained potent antimicrobial activity (26). 
This gene is a variant allele of Defb8 that encodes six cysteines 
and is found in all other inbred murine strains we have tested 
(27). In this study we describe striking differences between the 
antimicrobial properties of Defrl in comparison with its six-
cysteine analogue, Defrl Y5C, against a panel of bacterial 
pathogens. We have attempted to rationalize these observa-
tions by investigating the structure of both peptides by using a 
combination of analytical techniques, and we reveal the pres- 
ence of a novel structural feature in Defrl that has not been 
observed previously in any other defensin. 
EXPERIMENTAL PROCEDURES 
Materials—Defrl and Defri Y5C were chemically synthesized by the 
standard solid phase methodology (Albachem Ltd.) and were refolded 
and oxidized in air as described previously (26). 
Antimicrobial Activity Assays—The strains of microbes used in this 
study are as follows: Escherichia coli ATCC 25922, Pseudomonas 
aeruginosa PAO1, Staphylococcus aureus ATCC 25923, Enterococcus 
faecalis ATCC 29212, and Candida albicans J2922. 
Test organisms were grown to mid-logarithmic phase in Iso-Sensitest 
broth (Oxoid) growth media and then diluted to 1-5 x 10 colony-
forming units (CFU)/ml in 10 mm potassium phosphate containing 1% 
(v/v) Iso-Sensitest broth, pH 7.4. Different concentrations of test peptide 
were incubated in 100 pJ of cells (1-5 x 105 CFU) at 37 'C for 1 h. 
10-Fold serial dilutions of the incubation mixture were plated on Iso-
Sensitest plates, incubated at 37 'C, and the CFU determined the 
following day. The minimum bactericidal concentration (MBC) is the 
concentration of peptide where we observed >99.99% killing of  
the initial inoculum. All assays were performed in duplicate and re-
peated on two independent occasions. The MBC was obtained by taking 
the mean of all the results, and experimental errors were within one 
doubling dilution. 
Reduction of the peptides was performed by adding 10 mm dithio-
threitol (DTT) and incubating at room temperature overnight. The 
oxidation state of each peptide prior to performing antimicrobial assays 
was determined by mass spectrometry. 
The effect of salt on antimicrobial activity was tested by incubating 
100 pl of 1-5 X 10 CFU of bacteria in 10 mm potassium phosphate, 1% 
(v/v) Iso-Sensitest, pH 7.4, which contained various concentrations of 
NaCl (0-300 mm). The bacteria were then challenged with peptide at a 
concentration four times the MBC. 
Native Gel Electrophoresis—Electrophoresis of Defrl and Defrl Y5C 
was performed under reduced and nonreduced conditions. 5 jig of pep- 
tide was dissolved in 10 Al of 0.01% acetic acid and 10 Al of 2X sample 
buffer (NOVEX Tricine/SDS sample buffer LC1676). Reduction of sam-
ples was performed by adding 2 l of 500 mm dithiothreitol (D'I"f) and 
incubating at room temperature for 1 h. The entire sample was loaded 
on a 16% Tricine gel (Invitrogen). The gel was fixed and stained with 
GelCode Blue Stain reagent (Pierce), and quantification of the bands 
was carried out by using ImageMaster TotalLab 1D software on an 
ImageMaster VD5 VD5-CC (Amersham Biosciences). 
Mass Spectrometry—Mass spectrometry analysis was conducted on 
several instruments. Characterization of the oxidation state of the 
synthetic peptides Defrl and Defrl Y5C was performed initially by 
using the accurate mass capabilities of a 9.4 Tesla Fourier transform 
ion cyclotron resonance (FT-ICR) mass spectrometer (Bruker Daltonics, 
Billerica, MA) equipped with a nanospray source. Any minor partially 
reduced species was removed by acetylation and separation. Using this 
instrument, two dissociation methods were applied to isolated peptides. 
For sustained off resonance irradiation collision-induced dissociation 
(SORI-CID), a given charge state was isolated by sweep excitation and 
subjected to CID with argon as the collision gas for 500 ms. For electron 
capture dissociation (ECD), a given charge state was isolated by sweep 
excitation and subjected to electron irradiation for 50 ms using a bar-
ium oxide-coated high surface area (5 mm diameter) dispenser cathode 
(HeatWave, Watsonville, CA) This instrument was also utilized to 
determine the time scale necessary for full reduction of the peptides. 
The electrospray solution and source conditions were the same for 
accurate mass, SORI-CID, and ECD. All peptide samples were made up 
to a concentration of 50 sM with MeOH/H20/CH3COOH (50:49:1 v/v). 
Solutions were ionized by nano-electrospray from gold/palladium-
coated tips (Proxeon Biosystems). Ions were accumulated in a hexapole 
and transferred to the detection cell of the FT-ICR instrument. The 
predicted isotopic abundance was determined using published methods 
within the XMASS software (28). 
Prior to antimicrobial assays, the oxidation state of the peptides was 
confirmed using a Micromass Platform II single quadrapole mass spec- 
trometer equipped with an electrospray ion source. Following our initial 
experiments on the FT-ICR, the platform had sufficient resolution to 
confirm that the peptides were fully oxidized or fully reduced. The 
spectrometer cone voltage was ramped from 40 to 70 V, and the source 
temperature was set to 140 'C. Protein samples were separated with a 
Waters HPLC 2690 with a Phenomenex CS reverse phase column (5 
Am, 250 x 4.6 mm) directly connected to the spectrometer. The proteins 
were eluted from the column with a 5-95% acetonitrile (containing 
0.01% trifluoroacetic acid) gradient at a flow rate of 0.2 ml/min. The 
total ion count in the range 500-2000 mIs was scanned at 0.1-s inter-
vals. The scans were accumulated and spectra combined, and the mo-
lecular mass was determined by the MaxEnt and Transform algorithms 
of the Mass Lynx software (MicroMass). 
Determination of Disulfide Bridges in Defrl and Defrl Y5C—The 
peptide mass mapping for Defrl and Defrl Y5C was conducted by using 
a MALDI-TOF (Tof-Spec 2E, Micromass, UK). Enzymatic digestion of 
Defrl (500 jig/ml) with trypsin (100 sg/ml) and chymotrypsin (100 
pg/mi) was performed at 37 'C in 50 mm Tris-HCl, 20 mm CaCl2,  pH 8.2, 
and allowed to proceed for 4 h before termination by addition of 0.05% 
trifluoroacetic acid. For analysis of the reduced proteolytic digest, 1 Al 
of the peptide mixture was removed and reduced with 100 mm TCEP. 
For MALDI-MS analysis, oxidized and reduced peptide digests were 
desalted and concentrated using C18 ZipTips (Millipore Corp.). 1 ill of 
analyte and 1 Al of matrix solution (a saturated solution of a-cyano-4-
hydroxycinnamic acid in 50% acetonitrile with 0.1% trifluoroacetic acid) 
were mixed and left to air-dry on a MALDI plate, and MALDI-MS 
results were obtained in the positive mode. 
For analysis of Defrl Y5C, peptide of concentration 500 pg/ml was 
digested with trypsin (100 pg/mI). The reaction was performed in 50 inn 




Antimicrobial activity of oxidized and reduced (red) Defrl 
and Defrl Y5C 
MBC" 
Organism 	Strain 	 Defrl 	Defrl 	Defrl Y5C Defrl 	Y5C (red) (red) 
ig/ml 
Gram-negative 
P. aeruginosa PA01 6 50 50 100 
E. coli ATCC 25922 8 100 >100 50 
Gram-positive 
S. aureus ATCC 25923 10 >100 >100 >100 
E. faecalis ATCC 29212 6 100 >100 ND" 
Fungi 
C. albi cans J2922 3 25 25 50 
"MBC values are the minimum concentration required to kill 99.99% 
of initial inoculum. 
"ND, not determined. 
Tris-110, 0.1% sodium azide, 5 mivi EDTA, pH 6.2, and was allowed to 
proceed for 4 h at 37 °C before termination by addition of 0.05% trifluoro-
acetic acid. Cleavage products were separated by HPLC using a Phenome-
nex C18 Jupiter column (5 gm, 250 >< 4.6 mm) and a 10-35% acetonitrile 
gradient, and the two major species were collected and freeze-dried. The 
resulting peptides were reconstituted in 50 mm Tris-HCl, 20 mis CaCl2, 
pH 8.2, and each was split into 3 aliquots. The 1st aliquot was analyzed in 
its oxidized state; the 2nd aliquot was reduced with 20 mrs TCEP; and the 
3rd aliquot was digested with chymotrypsin (100 pg/mI) for 4 h at 37 C. 
All samples were purified and concentrated using C18 ZipTips and ana-
lyzed by MALDI-TOF MS as described above. 
CID sequence analysis of the digested peptides was performed by 
using a Q-TOF tandem mass spectrometer (Micromass, UK) equipped 
with a nanospray source. Specific ions were mass selected by the qua-
drupole MS and subjected to CID using argon, and the resulting frag-
ments were analyzed in the TOF MS. 
HPLC—Analytical HPLC was performed on a Beckman System Gold 
HPLC equipped with a Phenomenex C18 Jupiter column (5 gm, 250 X 
4.6 mm). The solvents used were water containing 0.1% trifluoroacetic 
acid (solvent A) and acetonitrile containing 0.1% trifluoroacetic acid 
(solvent B) at 1 ml/min. Both oxidized and reduced Defrl and Defrl Y5C 
were analyzed using a linear gradient of 20-35% solvent B developed 
over 40 mm. Peptides were detected at 215 and 280 nm. 
RESULTS AND DISCUSSION 
Antimicrobial Properties—In a previous study we showed 
that despite having only five cysteine residues, murine Defrl 
displayed antimicrobial activity at nanomolar concentrations 
(26). Here we synthesized the six-cysteine analogue, Defrl 
Y5C, and have determined the minimum bactericidal concen-
trations (MBCs) of the oxidized and reduced forms of both 
peptides against a diverse panel of clinically relevant microbes 
(Table I). Numerous methods have been used in various labo-
ratories to determine the antimicrobial activities of defensins 
(for example see Refs. 9, 15, and 16). Typically, the test orga-
nism is exposed to the peptide (0-24 h), followed by growth on 
liquid or solid media and subsequent determination of optical 
densities and/or counting of surviving colonies relative to a 
control. Antimicrobial activities (jcglml) are quoted as minimal 
inhibitory concentrations, MBCs, and LD50 or LD90 values 
(dose required to kill 50 or 90% bacteria). At the outset we 
incubated P. aeruginosa PAO1 with peptides for 0, 1, 4 and 24 h 
and noted that the MBCs (99.99% bacteria killed) were the 
same for each time point, indicating that the peptides killed 
within an hour of administration. We therefore carried all the 
reported assays with a 1-h incubation time. 
Defrl exhibited broad spectrum antimicrobial activity, with 
MBCs ranging from 3 to 10 ig/m1 against all organisms tested. 
These included the Gram-negative bacteria P. aeruginosa and 
E. coli as well as the Gram-positives S. aureus and E. faecalis. 
Defrl also displayed antifungal activity against C. albicans. In 
contrast, the six-cysteine analogue Defrl Y5C displayed MBCs in 
Fm. 2. Effect of NaCl concentration on the antimicrobial ac-
tivity of Defrl and Defrl Y5C. P. aeruginosa PA01 cells (1 X 10 
CFU in 100 jzl) were resuspended in 10 mm sodium phosphate buffer, 
0.1% Iso-Sensitest broth, pH 7.4, containing 0, 25 50, 150, and 300 mm 
NaCl. Bacteria were challenged with defensin at 4)< MBC (24 Ag/ml for 
Defrl and 200 pg/ml Defrl Y5C) for 1 h at 37 °C before serial dilutions 
of the assay mixture were plated on ISA plates and grown overnight at 
37 C. CFUs were counted, and the percentage bacteria killed was 
determined. 
the range 50-100 jig/ml against Gram-negative bacteria, ~100 
pg/ml against Gram-positive bacteria, and 25 jig/ml antifungal 
activity. The increased MBCs of Defrl Y5C compared with Defrl 
highlight a significant increase in potency for the five-cysteine 
variant. Recent work by Wu et al. (15) has demonstrated that the 
activity of HBD3 is independent of the number and connectivity 
of disulfide bridges within the molecule. To test this hypothesis 
we repeated the antimicrobial assays with both peptides after 
complete reduction with excess DTr. Reduced Defrl Y5C had 
similar MBCs to its oxidized form, supporting the hypothesis that 
its activity is independent of the presence of disulfide bonds. 
However, the MBCs of reduced Defrl were significantly higher 
than its oxidized form and similar to the MBCs for Defrl Y5C. 
Thus, in this instance, it appears that the presence of disulfide 
bonds does influence the antimicrobial activity of the five-cys-
teine containing peptide. 
For further comparison we also analyzed the effect of high 
salt concentrations on the antimicrobial activities of Defrl and 
Defrl Y5C against P. aeruginosa (Fig. 2). The activity of Defrl 
Y5C was extremely salt-sensitive, killing only 10% of 1 X iO 
bacteria in the presence of 25 mm NaCl and being completely 
inactive at 50 mm NaCl. In contrast, Defrl displayed 100% 
killing at 25 and 50 mrs NaCl, 84% killing at 150 mm NaCl, and 
28% killing even at 300 nirs NaCl. These salt sensitivity results 
further highlight the significant differences between the anti- 
microbial activity of the six-cysteine and the five-cysteine Defrl 
peptides. 
Structural Analysis—To rationalize the striking differences 
that we observed in antimicrobial activity between Defrl and 
Defrl Y5C, we investigated the structure of the two peptides by 
a combination of native gel electrophoresis, high resolution 
mass spectrometry, and reverse phase chromatography. One 
advantage of using FT-ICR MS for studying defensin structure 
is that only microgram amounts of each peptide are required 
for analysis in contrast to both NMR and x-ray crystallography. 
Native Gel Electrophoresis—To analyze the structure of 
Defrl and Defrl Y5C, they were subjected to nondenaturing 
electrophoresis on 16% Tricine gels (Fig. 3). In their oxidized 
forms, the predominant forms of both peptides migrated with 
apparent molecular masses of -7 kIa, which suggests that 
they can dimerize under these conditions. Reduction of both 
peptides with excess DTT increased their apparent mobility to 
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-4 kDa, which indicates they are present as monomers and 
that disulfide bonds are involved in maintaining their tertiary 
structure. Densitometry analysis of the stained gel gave the 
following monomer/dimer ratios for each of the peptides: Defrl-
reduced (Fig. 3, lane 1), monomer/dimer (2:1); Defrl-oxidized 
(lane 2), monomer/dimer (1:5); Defrl Y5C reduced (Fig. 3, lane 
monomer/dimer (>100:1); Defrl Y5C-oxidized (Fig. 3, lane 
monomer/dimer (1:6). It is interesting to note the observa-
tion of significant amounts of Defrl dimer even after incuba-
tion with DTT, which suggests increased stability of the Defrl 
dimer over the Defrl Y5C dimer under reducing conditions. 
Previous studies on various antimicrobial peptides have re-
vealed that some, but not all, can dimerize. For example, HBD3 
is a potent antimicrobial peptide isolated from human skin, 
which has been the subject of intensive structural and func-
tional studies (29). By native gel electrophoresis, dimeric HBD3 
was observed under oxidizing conditions, whereas monomeric 
HBD3 was detected after reduction (25). Modeling studies pre-
dict that the dimer is formed through a combination of electro-
static salt bridges and H-bonding between amino side chains. 
Octomers, formed by amide backbone interactions, have also 
been observed in the crystal lattice of HBD2 (20). The forma-
tion of higher order aggregates of antimicrobial peptides has 
been proposed as one factor that contributes to their ability to 
disrupt bacterial membranes (11). Because oxidized Defrl and 
Defrl Y5C behave in a similar manner by gel electrophoresis, 




FIG. 3. Colloidal Coomassie-stained nondenaturing 16% 
Tricine gel of oxidized and reduced Defrl and Defrl Y5C. Lane 1, 
Defri reduced; lane 2, Defrl oxidized; lane 3, Defrl Y5C reduced; lane 
4, Defrl Y5C oxidized. Mass markers in kDa are indicated.  
1.01 A 
FIG. 4. Defrl Y5C FT-ICR isotopic 
envelope. The deconvoluted isotopic en- 0.5 
velope from FT-ICR nanospray analysis 
of oxidized Defrl Y5C is shown. A, trian-
gles correspond to the isotopic envelope ca 
expected from a Defrl Y5C monomer with 
0.0 all cysteines oxidized, i.e. contains three  
disulfides. B shows the equivalent spectra < 	3715 
for the dimeric form of Defrl Y5C. Again w 
the triangles represent the isotopic enve- 0.161 B 
lope expected from a dimer with all cys- 
teines oxidized, i.e. six disulfide bonds. 
The elemental composition of oxidized 
Defrl Y5C monomer with three disulfides 0.08 
is C157H254N50043S6, average mass 3722. 
4490 Da; and a Defrl Y5C dimer with six 
disulfide 	bonds 	is C314H508N100086S12, 
and the average mass is 7444.898 Da. 0.00 
7435 
dimerization alone cannot explain the significant differences 
we observed in their antimicrobial activity. 
Characterization of the Nature of Dimerization by Mass Spec-
trometry—To identify the structural differences between Defrl 
and Defrl Y5C, which could account for the increased antimi-
crobial activity of the five cysteine-containing defensin, we 
used high resolution FT-ICR mass spectrometry. The resolving 
power and accuracy of this instrument allows the determina-
tion of the mass and isotopic distribution of large biomolecules. 
A comparison of experimentally observed values to those pre-
dicted based on the empirical formula for the oxidized and 
reduced forms of both defensins can then be used to determine 
the number of disulfide bonds in each species. 
Analysis of the ion envelope and deconvolution for Defrl Y5C 
suggested the presence of two species (Fig. 4, A and B). The 
isotopic distributions and masses fit very well to those pre-
dicted for a Defrl Y5C monomer containing three disulfide 
bonds (elemental composition, C157H254N50043S6; average 
mass, 3722.4490 Da; see Fig. 4A) and to a dimeric Defrl Y5C 
with six disulfide bonds (C314H508N100086S12 and average 
mass 7444.898 Da, Fig. 4B). Artificial dimerization and forma-
tion of higher order aggregates have been observed for proteins 
under the conditions used in ESI (30). However, we do not 
believe the dimer to be an artifact because it was also observed 
by native gel electrophoresis in a 6-fold excess over the mono-
mer. Nevertheless, because the dimer peak displays 16% rela-
tive abundance compared with the monomer, it is clear that the 
dimer is not stable to the electrospray process suggesting dimer 
formation by weak, noncovalent interactions. 
FT-ICR analysis on oxidized Defrl produced the mass spec-
trum, which upon deconvolution gave rise to one major species 
(Fig. 5) whose isotopic distribution matched that expected for a 
fully oxidized dimer containing five disulfide bonds (elemental 
composition for Defrl dimer, C32611518N100088S ; average 
mass, 7566.9761 Da). Most interestingly, there was no peak 
corresponding to Deft monomer. In contrast to that observed 
for Defrl Y5C, the Defrl dimer remains intact under electro-
spray conditions, which implies a strong interaction between 
monomers. Because a Defrl dimer contains 10 cysteine resi-
dues, and a fully oxidized isoform has five disulfide bonds, 
dimerization can only occur through formation of at least one 
intermolecular disulfide bridge. 
Dissociation of Defensin Dimers—CID and ECD are powerful 
mass spectrometry techniques used for analyzing protein struc- 
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ture, which complement traditional methods (31-33). These 
fragmentation techniques were employed to characterize the 
protein-protein interactions mediating dimerization in Defri 
Y5C and Defri. 
For CID analysis of the Defri Y5C dimer, a peak correspond-
ing exclusively to the +5 charge state of the dimer (m/z 1490) 
was isolated and subjected to dissociation (Fig. 6). The +5 ion 
readily dissociates into two monomers with +3 (m/z 1242) and 
+2 (m/z 1862) charge states (Fig. 6, inset). Dissociation of the 
dimer occurs without fragmentation of the peptide backbone, 
demonstrating that the Defri Y5C dimer is unstable and 
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FIG. 5. Defri FT-ICR isotopic envelope. High resolution mass 
spectrum of oxidized Defri dimeric isoforms. The triangles correspond 
to the isotopic envelope calculated from the Defri amino acid sequence 
containing five disulfide bonds. The elemental composition for Defrl 
dimer is C326H518N100055S10, and the average mass is 7566.9761 Da.  
thereby supporting our hypothesis that dimerization is medi-
ated through noncovalent interactions. 
In stark contrast, the Defri dimer was stable to the same 
CID conditions used for Defri Y5C and gave rise to the most 
abundant ion corresponding to the -F 7 charge state of the Defri 
dimer (m/z 1082) (Fig. 7). When this stable dimeric ion was 
isolated and subjected to dissociation, no significant monomeric 
"daughter" fragments were observed. Increasing the amount of 
gas into the collision cell still did not dissociate the dimer, but 
it did allow us to partially sequence the peptide because it gave 
rise to a distinct b-type fragment series from the N termini up 
to the location of the first cysteine (b2—bl0) and a y-type 
fragment resulting from the loss of a C-terminal lysine (Fig. 7, 
inset). Such stability under CID conditions indicates the Defrl 
dimer is held together by covalent bonding. 
These observations are complimented by ECD, where cleav-
age of Cys—Cys disulfide bridges is known to be a favored 
process (34). When the isolated +7 charge state of the Defri 
dimer was subjected to ECD, the molecule readily dissociated 
into monomers with charge states +2, +3, and +4 (m/z 1893, 
1262, and 949, respectively (Fig. 8). On closer inspection (Fig. 8, 
inset), we observed low intensity species with masses ± 16 Da 
on either side of the +2 monomer peak, which indicate the 
gain/loss of a sulfur atom. We can explain the appearance of 
these species only if the Defri dimer is formed by a covalent 
intermolecular disulfide bond. Here the ECD process has 
cleaved the dimer into monomers by two mechanisms. First, 
symmetric cleavage of the S—S bond gave a monomer signal 
with m/z 1892.5. The second pathway involves asymmetric 
cleavage of the C—S bond of the intermolecular disulfide bridge 
to give rise to two monomers: one with a persulfide SH at mix 
1909 and its corresponding partner having lost S at mix 1876.5. 
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FIG. 6. CID spectra of Defri Y5C. The ion envelope for nanospray FT-ICR analysis of Defri Y5C is shown with each ion annotated as 
monomeric [MI or dimeric [D]. Inset, the dimer D5 ion with m/z 1488.905 (monoisotopic mass) was subjected to CID and gave rise to monomeric 
fragment ions with +3 and +2 charge states. 
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FIG. 7. CID of Defri. The +7 charge state (m/z 1081.401, monoisotopic mass) generated by nanospray FT-ICR MS was isolated and subjected 
to collisional activation with argon for 40 ms prior to detection. Fragments arising from activation are labeled. The Defri species remains intact, 
but CID produces b and y ions arising from the cleavage of the amide backbone. The inset shows magnification of the y ions at mfz 1200-1300. 
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FIG. 8. ECD of Defri. Defrl was subjected to nanospray FT-ICR MS, and the [D]7' dimer ion (m/z 1081.401) was isolated and irradiated with 
electrons for 50 ms. This caused the +7 ion to fragment into +5, +4, +3, and +2 monomers. We show a magnification of the +2 monomer ion series 
that results from both symmetric and asymmetric cleavage of the intermolecular S—S bond. 
analogous to those observed previously by CID (35). We are the difference between Defri Y5C and Defri and for the first 
currently using SORI-CID and ECD to carry out a ff11 "top- time has identified a defensin dimer containing an intermolec-
down" sequence analysis of various defensins, which is out with ular disulfide bond. 
the scope of this present study. The use of high resolution 	Reverse Phase Liquid Chromatography—HPLC on a C18 re- 
FT-ICR, coupled with two dissociation techniques, has revealed verse phase column was used to investigate structural differ- 




Determination of the disulfide bond connectivity of oxidized Defrl Y5C 
Trypsin digest of the peptide produced two fragments that were separated by RP-HPLC. The purified peptides (fragment 1 and fragment 2) were 
analyzed by MALDI-TOF. Each fragment was digested separately with chymotrypsin, and the masses of the fragments were determined to remove 
any ambiguity from peptides with similar masses. 
	
Calculated 	 Calculated mass 	Observed 
Assignment 	 mass Observed mass" 	chymotrypsin mass 	 Disulfide bridge (+ 1)" (+ 1) 	chymotrypsin"  
Fragment 1 (Asp'-Arg7) + (Cys'6-Arg20) 	1711.84 	1711.87 	1711.84 	1711.55 	Cys'-Cys5 Cys'-Cys6 or Cys'.-Cys6 
+ (Cys32-Lys34) 	 and Cys3-Cys5  
Fragment 2 (Asn5-Arg'5) + (11e23-Lys31) 1816.86 	1817.54 	1532.66 	1532.70 	Cys2-Cys4 
"Calculated and observed masses of tryptic fragments (in Da). 
Calculated and observed masses of fragments after proteolysis with chymotrypsin (in Da). 
Assignment of S-S connectivity for fragment 1 was determined to be Cys1-Cys5 and Cys3-Cys6 using CID (see text) 
ences between the oxidized and reduced forms of both peptides. 
Oxidized Defri Y5C eluted as a single sharp peak at 26.8 mm 
on a 20-35% acetonitrile gradient. This species had a mass of 
3722.0 Da by ESI-MS in good agreement with the predicted 
value of 3722.3 Da for Defrl Y5C with the loss of six hydrogens. 
Upon incubation with excess DTT, the single peak eluted ear-
lier in the gradient at 23.6 mm, and this shift in retention time 
suggested that reduction of the disulfide bonds caused a change 
in the structure of the defensin (the mass of this species is 
3728.1 Da). It is thus apparent that Defrl Y5C folds to give a 
single species. Upon refolding from a denatured state, we 
would normally expect a shift to shorter retention time on a 
reverse phase column resulting from burial of hydrophobic 
residues. The refolding mechanism of defensins is not well 
understood but appears to be governed by the formation of the 
disulfide bonds. Because defensins are amphipathic and con-
tain surface-exposed hydrophobic and cationic patches, these 
properties can be postulated to explain this unusual chromato-
graphic behavior, which has also been observed for the oxida-
tive folding of HBD2 (15). 
In contrast, oxidized Defrl eluted as a broad peak between 
22 and 24 mm, which we were unable to resolve despite trying 
a range of conditions (under ESI conditions Defrl 7566.0 Da in 
agreement with a dimer with the loss of 10 protons). Upon 
reduction with excess DTT, Defrl eluted as a single sharp peak 
at 21.8 mm (mass 3788.0 Da, predicted mass for fully reduced 
3788.2 Da). These data suggest that during oxidative refolding 
Defrl has formed a number of different species all of which are 
dimeric. This phenomenon has been observed for HBD3, which 
was shown to form several different oxidized isoforms from a 
single reduced precursor (15). The differences in the chromato-
graphic behavior of Defrl and Defrl Y5C again suggest that 
their structures are dissimilar. 
Determination of Disulfide Connectivity-To determine their 
S-S connectivities, both defensins were subjected to protease 
cleavage and analysis of the resulting peptide fragments by 
MALDI-TOF and Q-TOF mass spectrometry. Trypsin cleavage 
of Defrl Y5C produced two major fragments that were easily 
separated by HPLC (Table II). Fragment 1 had a mass of 
1711.87 Da and was unmodified by treatment with chymotryp-
sin, consistent with the species (Asp'-Arg7) -- (Cysle_Argso) + 
(Cys82-Lys34) containing two disulfide bonds (calculated mass 
1711.84 Da). Because (Cys32-Lys34) contains two adjacent cys-
teines (Cys5 and Cys6), these data alone cannot be used to 
assign the absolute connectivity. However, from the mass of the 
first fragment we can assign the connectivity as either Cys'-
Cys5 and Cys3-Cys6 or Cysi_Cyse  and Cys3-Cys5. The second 
tryptic fragment had a mass of 1817.54 Da and was susceptible 
to chymotrypsin producing a species with mass 1532.70 Da. 
These results are consistent with the second tryptic fragment 
being (Asn8-Arg'5) + (11e23-Lys31) containing 1 disulfide bond 
(calculated mass 1816.86 Da), and its chymotrypsin derivative  
being (Asn8-Tyr'4) + (11e28-Phe30) (calculated mass 1532.66 
Da), allowing the assignment of a disulfide bond between Cys2-
Cys4. To distinguish between Cys5 and Cys6 in fragment 1, we 
used a Q-TOF tandem mass spectrometer and CID to sequence 
the peptides. Dissociation of the +3 charge state of fragment 1 
resulted predominantly in the sequential loss of residues from 
the N terminus of the fragment (Asp'-Arg7). However, a +2 
species was observed with mlz 404.96 Da (deconvoluted mass 
807.92 Da), which we attribute to (Cys'6-Arg20) + (Cys33-
Lys34) (calculated mass 807.41 Da), which allows the assign-
ment of the disulfide bridge between Cys3 and Cyse  and thus, 
by elimination, Cys'-Cys°. In summary, oxidized Defrl Y5C 
monomers contain the typical 13-defensin S-S connectivity 
(Cys1-Cys5, Cys2-Cys4, and Cys3-Cys6). It is worth noting that 
the NMR structure of mBD-8 (NEPVSCIRNGGICQYRCIGL-
RHKIGTCGSPFKCCK) has been determined (Protein Data 
Bank accession code 1E4R) (23). This defensin is very similar to 
Defrl Y5C, the only differences being at the N terminus 
(NEPVS of mBD-8 replaces DPVT of Defrl Y5C). Because the 
sequences of mBD-8 and Defrl Y5C are highly similar and they 
both display 13-defensin connectivities, we suggest that mBD-8 
is a good model for the three-dimensional structure of Defrl 
Y5C. 
In contrast to its six-cysteine analogue, cleavage of oxidized 
Defrl with a combination of trypsin and chymotrypsin pro-
duced a complex mixture of peptide products that proved im-
practical to separate by HPLC. Instead, the unfractionated 
mixture was analyzed by MALDI-TOF MS. The mass spectra 
obtained from analysis of the reduced peptide products re-
vealed that proteolysis had been incomplete, and many pep-
tides were present that contained uncleaved, internal proteol-
ysis sites (see Table III). Analysis of the oxidized tryptic digest 
peptide products enabled the assignment of disulfide connec-
tivities (see Table 1V). Peaks were observed with masses con-
sistent with peptide fragments with Cys2-Cys3, Cys2-Cys4, 
Cys3-Cys4, and Cys4-Cys4 disulfide bonds. To confirm the ini-
tial assignment of these masses and identify potential disulfide 
bonds, we again carried out N-terminal sequencing of selected 
peptides by CID. This allowed us to confirm the identity of the 
N-terminal fragment (Asp'-Arg7), and peptides containing di-
sulfide bridges between Cys2-Cys3 and Cys2-Cys4. 
Our analysis revealed Defrl has S-S connectivities not typ-
ical of either a- or 13-defensins. It appears from our proteolysis/ 
mass mapping data that certain cysteine residues (e.g. Cys2) 
can form disulfide bonds with more than one other cysteine. 
This can only be explained if Defri is a mixture of topologically 
different dimeric isoforms, rather than a single species with a 
defined connectivity. The HPLC analysis also supports the 
unusual nature of Defrl. The broad peak resulting from re-
verse phase-HPLC analysis of oxidized Defrl again suggests 
that Defrl is heterogeneous. The high resolution FT-ICR data 
prove that all of these isoforms are dimeric connected by an 
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TABLE III 
Determination of the disulfide bond connectivity of oxidized Defri 
Oxidized Defri was digested with trypsin and chymotrypsin, and the peptide fragments were analyzed by MALDI-TOF. The peptide mixture 
from the digest was reduced with TCEP, and the masses were assigned accordingly. 
Assignment Calculated mass (+1) 	 Observed mass Relative abundance 
Asp'-Arg7 863.46 	 863.71 72 
11e6-Tyr14 1023.50 1023.98 91 
11e6-Arg15 1179.60 	 1179.92 11 
His21-Phe30 104650 1046.95 67 
Asn8-Arg2°  1452.71 	 1452.72 26 
Cys16-Phe30 1588.80 1588.67 20 
Arg'5-Phe3°  1744.90 	 1744.54 100 
Cys16-Lys54 2051.01 2051.21 13 
TABLE IV 
Determination of the disulfide bond connectivity of oxidized Defri 
Oxidized Defri was digested with trypsin and chymotrypsin, and the peptide fragments were analyzed by MALDI-TOF. MALDI-TOF analysis 
of the peptide digest was without reduction and assignment of disulfide bonds. Assignments were confirmed by N-terminal sequencing by CID 
peptide mass mapping where indicated. 
Assignment Calculated mass (-1) Observed mass Relative abundance N-terminal sequencing Disulfide bridge 
Asp'-Arg7 863.46 863.36 72 DPVTY 
Asn8-Argi°  1450.70 1450.83 100 NGGI Cys2-Cys3  
Ile6-Arg2°  1719.88 1719.66 58 Cys2-Cys3  
Arg15.-Arg20 + His21-Phe5°  1760.90 1760.61 87 HKI Cys 3-Cys4 
Ile'-Tyr 14 + IlesaPhe m 1801.83 1801.50 47 Cys2-Cys4 
Ile'-Tyr 14 + His"-Phe3°  2066.98 2067.31 48 Cys2-Cys4 
His`-Phe3° + His21 Phe50 2089.99 2090.28 6 Cys4-Cys4 
Ile'-Tyr" + His21-Lys34 2527.18 2526.82 11 
N-terminal sequencing data were collected using CID to resolve peptides that could not be unambiguously assigned (see text) 
intermolecular disulfide bridge. However, it appears that the 
intermolecular disulfide bond is not formed exclusively be-
tween two equivalent cysteine residues from each monomer, 
e.g. Cys5'-Cys5 or Cys4'-Cys4. Rather, our proteolysis and 
chromatography data suggest that the Defri dimer can be 
formed via any two cysteine residues from each monomer from 
15 possible combinations, e.g. Cys2'-Cys3. Recent work on syn-
thetic HBD3 led to the surprising discovery that it did not fold 
into a single isoform with typical /3-defensin disulfide connec-
tivity in vitro (15). Instead, at least seven topologically distinct 
isoforms were isolated with unusual intramolecular connectivi-
ties, all of which displayed similar antimicrobial activity. It is 
noteworthy that the S-S connectivity of native HBD3 purified 
from human skin has not been determined (29). Most interest-
ingly, none of these isoforms contained an intermolecular di-
sulfide bond. The authors were unable to determine the indi-
vidual connectivity of these isoforms, so they devised a 
synthetic protocol that allowed the control of disulfide bond 
formation. We are currently exploring whether this strategy 
can be used to control the formation of a specific intermolecular 
disulfide bond in Defri. 
Conclusions--Defensins are characterized by having six 
conserved cysteines that are oxidized to form three disulfide 
bonds. It was assumed that these were required for antimicro-
bial activity, but several recent studies have begun to explore 
their structural and functional roles. Analogues of bovine 13-de-
fensin BNBD-12 containing one, two, and three disulfide 
bridges, synthetic peptides corresponding to the C-terminal 
segment of bovine f3-defensin BNBD-2, and a cysteine-free, 
full-length analogue of HBD3 all displayed antimicrobial activ-
ity suggesting that the three disulfide bridges are not abso-
lutely required (15, 16, 36). Moreover, to explore whether high 
cationic charge is the only requirement for activity, small lin-
ear peptides corresponding to regions of HBD3 were analyzed 
for their ability to kill different pathogens (37). Somewhat 
surprisingly, the least positively charged peptides proved to be 
the most active, which suggests that defensins contain inher- 
ent subtle structural features that come into play upon inter-
action with the membrane target. 
Previously we reported the discovery of a defensin (Defri) 
with five cysteine residues expressed in murine heart and 
testis that had potent antimicrobial activity (26). This defensin 
lacks the first of the conserved six cysteines found in other 
members of the family. Here we explored the effect of this loss 
on the structural and antimicrobial properties by comparison 
with its six-cysteine analogue Defri Y5C. Defri Y5C has mod-
est, salt-sensitive antimicrobial activity against a panel of mi-
crobial pathogens, and analysis by electrophoresis and mass 
spectrometry suggest it forms a noncovalently bound dimer in 
solution. Peptide mass mapping revealed that this defensin has 
Cys1-Cys5, Cys2-Cys4, and Cys3-Cys6 disulfide connectivity 
typical of a 13-defensin. In contrast, Defri has significantly 
higher antimicrobial activity against P. aeruginosa even under 
raised salt concentrations. High resolution mass spectrometry 
combined with two complementary dissociation techniques re-
vealed a dimer containing an intermolecular disulfide bond, a 
novel structural feature not previously observed within the 
defensin family. Proteolysis and HPLC analysis suggest that 
oxidized Defri is a complex mixture of dimer isoforms varying 
in their intra- and intermolecular disulfide connectivities. Re-
cent studies of defensins HBD3 and BNB2 have concluded that 
short linear peptide fragments as well as those containing only 
one intramolecular disulfide could have potential as therapeu-
tic agents. Our results demonstrate that defensins containing 
intermolecular disulfide bonds have novel structural and anti-
microbial properties and suggest that covalently bound dimeric 
cationic peptides are promising targets for future study. 
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Abstract 
Recent developments in sample introduction of biologically relevant molecules have heralded a new era for gas-phase methods of structural 
determination. One of the biggest challenges is to relate gas-phase structures, often measured in the absence of water and counter ions, with 
in vivo biologically active structures. An advantage of gas-phase based techniques is that a given peptide can be analysed in a variety of 
different forms, for example, as a function of charge state, or with additional water molecules. Molecular modelling can provide insight into 
experimental findings and help elucidate the differences between structural forms. Combining experiment and theory provides a thorough 
interrogation of candidate conformations. Here two important naturally occurring peptide systems have been examined in detail and results 
are assessed in terms of their biological significance. 
The first of these is gonadotropin-releasing hormone (GnRH), a decapeptide which is the central regulator of the reproductive system in 
vertebrates. We have examined several naturally occurring variants of this peptide using Ion Mobility Mass Spectrometry and Electron Capture 
Dissociation (ECD) in conjunction with Fourier Transform Ion Cyclotron Mass Spectrometry (FT-ICR-MS). Candidate conformations are 
modelled using the AMBER force field. Single amino acid changes, for example (iIy6 —). A1a6, or Ala6 --* D-A1a6, have observable effects 
on the gas phase structure of GnRH. It has been shown that evolutionary primary sequence variations are key to the biological activity of 
GnRH, and it is thought that this is due to different binding affinities at target receptors. This work provides strong evidence that this activity 
is structurally based. The second system examined is the relationship between the quaternary structure and activity of two novel 3-defensins. 
FT-ICR mass spectrometry has been employed to characterize di-sulphide bridging and dissociation based experiments utilised to investigate 
their structural core. Defri, with five cysteines, exists as a covalently bound disulphide linked dimer; Defri YSC with six cysteines also is 
observed as a dimer, but non-covalently bound, suggesting that this defensin has a tendency to aggregate. The activity of Defri is 10 times 
higher than that ofDefrl Y5C when tested against the pathogen Pseudomonas aeruginosa. The results from these studies could inform future 
design of novel GnRH type ligands and anti-microbial agents, and illustrate the power of gas-phase based techniques for solving peptide 
structures. 
© 2004 Elsevier B.V. All rights reserved. 
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1. Introduction 
* Corresponding author. Tel.:--44 131 6507533:fax:±44 131 650 7533. 
E-mail address: perdita.barran@ed.ac.uk (P.E. Barran). 
Present address: FOM Institute for Plasma Physics Rijnhuizen', Edis-
onbaan 14, 3430 BE Nieuwegein, The Netherlands. 
1387-3806/$ - see front matter © 2004 Elsevier B.V. All rights reserved. 
doi: 10.101 6/j.ijms.2004.09.0 13 
Advances in proteomic technologies, coupled with the 
sequencing of the human genome have resulted in vast 
numbers of peptide ions being 'measured' daily in mass 
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spectrometers across the world [1]. Determination of the pri-
mary sequences of proteins expressed from cells is providing 
many research groups with a wealth of information. How-
ever, these high-throughput gas-phase techniques which anal-
yse small proteolytic peptide fragments, do not yet provide 
information about secondary or tertiary structure. Clemmer 
and co-workers [2] have made some advances in that direc-
tion by employing ion mobility mass spectrometry, coupled 
with LC-analysis. This approach generates very large three-
dimensional (3D) data sets which contain elution time, mass 
to charge ratios and drift times, where peptides that may 
exhibit homogeneous properties in one dimension, are dis-
tinguishable in another [3]. In order to relate the drift time 
to structure(s), it is necessary to perform calculations and 
compare the cross-sections of minimised low energy struc-
tures to those measured experimentally [4], which often can 
become a rate limiting step in such measurements. Unfortu-
nately, information about the structure of these enzymatically 
digested fragments has little biological relevance. What is po-
tentially more meaningful is to use gas-phase technologies, 
albeit at a lower throughput, to determine secondary and ter-
tiary structures of peptides [5]. As with larger proteins, three-
dimensional structures of small peptides are traditionally 
deduced either by such techniques as X-ray diffraction and 
nuclear magnetic resonance (NMR) or by theoretical predic-
tion methods. Because of their size, the interplay between 
solvent/solute and internal interactions enables peptides to 
be more flexible than proteins. Nevertheless, the secondary 
structure(s) of peptides, arising in part from this conforma-
tional flexibility, are important. Significantly different phar-
macological ligandlreceptor activities testify for single-point 
mutations of peptides [6]. NMR and crystallography are no-
toriously difficult to apply to small peptide systems due to 
their inherent flexibility. Hence, active form(s) are often dif-
ficult to isolate. Computational approaches are gaining mo-
mentum as viable methods to determine tertiary structures 
[7]. However, much effort has been (rightly) directed to 
model systems [8], and only a handful of small real pep-
tide systems have been solved using solely in silico tech-
niques which then rely on comparison to experimental data 
[9,10]. 
The gas-phase offers a different environment for study-
ing the conformations of peptide molecules. Time scales 
available for study are several magnitudes smaller than those 
present in NMR, and the ability to alter the energy available 
to the isolated gas phase ion means that conformational flex-
ibility may be examined in great detail. Furthermore since 
the dielectric constant of a vacuum (Evacuum = 1) is more sim-
ilar to the immediate environment of a membrane receptor 
(Speptjde/prote jn  = 2-4) than for water (Swater = 80), [11] the gas-
phase is an appropriate 'medium' in which to study the struc-
tures of peptides which in their active form are bound to a 
receptor located in a membrane. We present results here on 
two important naturally occurring peptide systems using a 
variety of gas-phase techniques; our data is interpreted with 
reference to its biological significance. 
The gonadotropin-releasing hormone (GnRH) peptides 
are a family of decapeptides also known as luteinizing hor-
mone releasing hormone (LHRH). They play a key physio-
logical role as a mediator of neuroendocrine regulation in the 
mammalian reproductive system [12,13]. Of the 23 naturally 
occurring structural variants of GnRH thus far identified, the 
N-terminal residues (pGlu-His-Trp-Ser) and the C-terminal 
residues (Pro-Gly-NH2) are conserved with a few exceptions 
[14]. In mammalian GnRH, residues 5-8 are believed to adopt 
a type II' 13  turn conformation which allows interaction with 
GnRH type I receptors [15]. The identity of residue 6 plays 
a particular role in determining whether this 11113  turn con-
for -nation is adopted or not [16]. Since single amino acid 
variations in the primary sequence of GnRH peptides have a 
significant effect on their interactions with the GnRH recep-
tor [6], we have employed Ion Mobility Mass Spectrometry 
and Electron Capture Dissociation (ECD) to investigate gas 
phase conformations of GnRH and three structural variants. 
Molecular dynamics is used to model their structures such 
that comparisons may be made to the trends observed exper-
imentally. 
The second peptide systems described in this paper are 
3-defensins. These are members of the antimicrobial pep-
tide family which form an important component of the 
mammalian innate immune response [17,18]. They possess 
potent broad-spectrum antimicrobial activity and are pre-
dominately expressed at epithelial surfaces. Mature peptides 
sequences are 30-45 amino acids in length and are both 
amphipathic and cationic. This net positive surface charge 
implies an initial electrostatic interaction between the pep-
tide and negatively-charged components of the bacterial cell 
wall, e.g., lipopolysaccahride (LPS) [18]. 13-Defensins ex-
hibit exceptionally low sequence homologies save for con-
served cysteines, which form disulfide bridges with specific 
connectivity (Cys 1-5, Cys 2-4, Cys 3-6). It has been pro-
posed that the disulfide bridges impart a structural core and 
non-conserved residues on the surface are under selective 
pressure against rapidly evolving bacteria [19,20]. In direct 
contrast to this perceived structure-function relationship, Wu 
et al. [21] have recently demonstrated that the antimicrobial 
activity of human 13-defensin 3 (}{BD3) is independent of 
disulfide bridging whilst the peptide's chemotactic proper-
ties do depend on it. 
Over 10 years ago a crystallographic study of the human 
a-defensin hNP3 revealed that it forms a dimer containing 
a six-stranded 13-sheet region [22]. More recent work by 
Lubkowski and co-workers [23] shows a dimeric form of hu-
man j3-defensin 2 (HBD2), which is present in a quaternary 
arrangement in the crystal unit cell. These findings provide 
evidence for the stability of defensin dimers, but can only 
fuel speculation about the active forms adopted by this class 
of compounds. It is worth noting that in the more dynamic 
environment posed by NMR there is little indication of dimer 
or other higher order aggregate formation [24]. Our work has 
focused on exploring the effect of oligomerisation on the ac-
tivity of 3-defensins [25]. In this paper we will summarise our 
P.E. Barran et at. / International Journal of Mass Spectrometry 240 (2005) 273-284 
	
275 
mass spectrometry findings on these two important classes of 
peptides. 
2. Experimental 
2.1. Mass spectrometry 
Mammalian GnRH used in this study was obtained 
from Sigma-Aldrich. Cional variants were synthesised by 
conventional solid phase methodology and purified by 
HPLC. All GnRH peptides were examined without fur-
ther purification and made up at a concentration of 20 i.M 
(H20:MeOH:CH3COOH, 0.49:0.49:0.02) for ECD and at 
100 .M under the same solution conditions for ion mobility. 
3-Defensins were obtained from Albachem (UK) and used 
without further purification. Electrospray solution and source 
conditions were the same for accurate mass, SORI-CID and 
ECD. Defensins were sprayed at a concentration of 50 i.M 
(MeOH:H20:CH3COOH, 50:49:1). Dirneric signal was still 
observed for Defrl Y5C peptide on ten fold dilution. So-
lutions were ionised by electrospray and nano-electrospray, 
from gold/palladium coated tips (Proxeon Biosystems). 
Analysis was conducted on two instruments. Ion mobility 
experiments were conducted on an instrument in the labora-
tory at UCSB which has been described in detail elsewhere 
[26]. Ions drift through a cell pressured to 5 Torr with he-
lium at room temperature and are mass selected prior to de-
tection. Arrival time distributions (ATDs) were collected at 
room temperature over no more than 5 min for each GnRH 
variant. AIDs were converted to collision cross sections ac-
cording to transport theory [27] for comparison with values 
obtained from modelled peptides structures. 
Characterization of the oxidation state of the defensin 
peptides Defrl, and Defrl YSC, was performed using the 
accurate mass capabilities of a 9.4 T FT-ICR mass spectrom-
eter (Bruker Daltonics) at the University of Edinburgh. Using 
this instrument, two dissociation methods were applied to the 
isolated peptides. For Sustained Off Resonance Collision In-
duced Dissociation (SORI-CID) a given charge state was iso-
lated by sweep excitation and subjected to CID with Argon 
as the collision gas for 500 ms. To perform ECD on both the 
GnRH peptides and the defensins, a given charge state was 
isolated by sweep excitation and subjected to electron irradi-
ation for 50 ms using a barium oxide coated high-surface area 
(5 mm diameter) dispenser cathode (HeatWave) An experi-
mental pulse sequence which combined ECD and SORI-CID 
was also employed.  
namics at decreasing temperatures according to an exponen-
tial cooling curve. At OK the candidate structure is subjected 
to minimisation using a steepest descent approach followed 
by a conjugate gradient algorithm. The minimised structure 
was then used as the seed for the next run of high temperature 
dynamics. Three hundred candidate structures were gener-
ated of each GnRH variant. Calculations were performed on 
an Alpha Server Compaq DS20e which forms part of the 
EPIC bio-computing facility [29]. The two lowest energy 
structures obtained were then subjected to molecular mechan-
ics for I ns at 300 K, to determine the conformational flexi-
bility of the minimised structures. Representative snapshots 
of co-ordinates obtained during this run are those discussed 
within the text. These structures were viewed and analysed 
using VMD [30]. An orientation averaged projection cross 
section is calculated from each candidate structure geome-
try, which is scaled according to the temperature dependent 
helium interaction potential [31]. 
3. Results and discussion 
3.1. GnRH—gonadotropin releasing hormone 
3.1.1. Jon mobility studies on mammalian GnRH and 
Cional structural variants 
Results of the measurements made and comparison with 
model geometries are shown in Table 1. The four peptides 
here are mammalian GnRH and three structural variants, one 
of which is the naturally occurring form for the lower non-
vertebrate Cional (a type of sea squirt). The other two are 
mutants of Cional where the sixth residue (shown in bold) 
has been substituted Ala -->. Gly and Ala -* D-Ala. Primary 
sequences for the two naturally occurring peptides are shown 
below: 
Mammalian GnRH: pGlu-His-Trp-Ser-Tyr-GIy-Leu-Arg-Pro-Gly-NH2 
Cional: pGlu-I-lis-Trp-Ser-Tyr-AIa-Leu-Ser-Pro-Gly-NH2 
There is good agreement between experiment and theory 
for all peptides examined with differences within expected 
experimental error. The number in brackets indicates that a 
Table I 
Measured and calculated cross sections for four GnRH variants 
GnRH 	[M+H] (A2 ) 	 [M±2H]2 (A2) 
Experimental Calculated Experimental Calculated 
Mammalian 246.2 249.5(6) 252.3 253.3 (6) 
2.2. Molecular modelling using the AMBER forcefield 	Cional 256.8 257.5(9) 252.1 254.3 (11) 
1281 	 Ciona DAla(6) 249.9 249.8 (5) 245.8 246.2(9) 
Ciona Gly(6) 247.7 247.6(8) 243.7 242.4(3) 
The GnRH peptides were built using X-Leap [28]. All 
amino acids were held at their physiological ionization states. 
A simulated annealing procedure was employed wherein high 
temperature dynamics is performed at 800 K, followed by dy- 
Results are shown forboth singly and doubly charged ions. Calculated values 
are an average of the cross sections obtained from candidate geometries 
which, when all 100 structures are sorted by relative energy occur in the 
lowest 20%. The numbers in brackets are the standard deviations from this 
central value. 
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Fig. I. Representative low energy structures of singly charged GnRH peptides (M+ H) from molecular dynamics performed at 300K. (A) Mammalian GnRH, 
(B) Cional, (C) CionalDA1a6 and (D) CionalGly6. The blue dotted lines indicate hydrogen bonds formed for that conformation. For each peptide, three 
residues have been depicted in CPK format, for the Ciona I peptides these are His2, Ala6/DAIa6/G1y6 and the amidated C terminus, for mammalian GnRH 
these are G1y6, Arg8 and the amidated C terminus. 
(C 
range of cross sections are found for low energy structures, 
however, the mean value is close to that found experimentally 
in each case. 
Two major trends are apparent in this data: the first is 
that the Cional singly charged peptides have slightly larger 
cross sections than their doubly charged equivalents, but for 
the mammalian form the reverse is true. The second is that 
the size order of cross sections obtained for all the forms of 
GnRH both singly and doubly charged is found to be: 
Mammalian GnRH < Ciona 1 Gly6 Cional DAIa6 < Cional 
These trends are best discussed with reference to the molec-
ular models obtained. 
3.1.2. Molecular modelling—the structures 
For gas phase peptide ions the amino acid which has the 
highest gas phase basicity is presumed the first to protonate 
[32]. Considering the peptides studied here, it is most likely 
to be Arg 8 for the mammalian form and His2 for the Cional 
variants. To assign a second proton to the [M+ 2H]21 ions we 
assume that His2 will also protonate in mammalian GnRH. In 
the absence of a second basic amino acid for the Cional vari-
ants the next most basic site is the C terminal amide group. 
These assignments are used in modelling to obtain low en-
ergy structures whose calculated cross sections appear in the 
second and fourth columns of Table 1. In all force field cal-
culations sites of protonation are fixed at the start of mea-
surements however experimentally, and particularly on col-
lisional activation, protons on less basic sites are potentially 
mobile [33]. The relevance to this study will be discussed 
later, although the good correlation between experimental 
and calculated cross sections, suggests that it is not a signif-
icant problem with the ion mobility measurements of these 
structures. 
Figs. 1 and 2 illustrate representative structures obtained 
for structures of the [M+ Hl' and [M+ 2H]2 GnRH peptide 
ions from molecular dynamics runs at 300K. In all cases the 
backbone forms a loop which is stabilised by the presence 
of hydrogen bonds predominantly from side chain groups to 
backbone carbonyls. With mammalian GnRH Arg8 provides 
an excellent 'cap' to the peptide backbone (Fig. 1A). In the 
Cional variants, this role is taken by His2 (Fig. IB—D). The 
presence of the second protonation site at the amidated C ter-
minal glycine allows for additional H bond fonTnation, with 
carbonyl groups along the polypeptide chain. This bonding 
is analogous to an effect which occurs from C terminal ly-
sine groups [34]. The effect of these cross chain hydrogen 
bonds is to tighten the structure, which accounts for the de-
crease in size from [M+HJ to [M+2H]21. The capping of 
the polypeptide backbone can be seen in Fig. 2 for all the 
Cional peptides. The protonated histidine residue in partic-
ular with Ciona 1 G1y6 (C) and DAla6 (D) is able to interact 
with groups situated on the opposite face of the polypeptide 
chain. There is a play off here with columbic repulsion that 
would occur between the two charged groups, and might be 
expected to increase the cross section of the doubly proto-
nated ions. However, the Cional decapeptide systems orien-
tate themselves such that coulombic repulsion is not domi-
nant, consistent with the slight decrease in cross section from 
single to doubly protonated ions. 
The difference in the cross sections obtained for the single 
and doubly protonated forms of the mammalian form follows 
an opposite trend. Here the protonated guanidinium group 
forms hydrogen bonds to backbone carbonyl groups as can 
be seen in Fig. IA. This bonding fixes the structure and sub-
sequent protonation of the bulky histidine side chain results 
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Fig. 2. Representative low energy structures of doubly charged GnRH peptides (M+ 2H)21  from molecular dynamics performed at 300K. (A) Mammalian 
GnRH, (B) Cional, (C) Cional DAIa6 and (D) CionalGly6. The same residues as for the singly protonated peptides are again depicted in CPK format. 
the peptide, providing a slight increase in the cross section 
for the [M+ 2H]21  ion. 
As stated above, for the Cional peptides conformations 
obtained via simulated annealing are similar. The natural 
Cional GnRH is somewhat larger than its chiral analogue 
CionalDAla. Cross sections for this DAla6 variant in both 
charge states are similar to those for the G1y6 variant. This 
implies that the presence of the D amino acid at residue 6 
allows a for a slightly more compact structure which can 
form a Il l P type turn, as with the achiral glycine residue. 
It appears that the LAla isoform introduces steric hindrance 
which yields a more open polypeptide than that found in 
either the DAIa or the Gly form. This is supported by molec-
ular dynamics calculations. Fig. 3 illustrates this for Cional 
and CionalGly6. It can be seen that the distance between 
residues 3 and 7 (Trp and Leu) is significantly greater in 
the Cional peptide over the course of a 1 ns dynamics run 
than that for CionalGly6. Across this defined co-ordinate, 
which effectively is the diameter of the quasi circular form 
taken by these peptides, the CionalLGIy6 [M+H]*  pep-
tide exhibits somewhat higher conformational flexibility than 
Cional. The cross-peptide distance obtained for CionalDAla 
averages at 6.3 A which falls midway between that seen here 
for CionalGly6 and Cional. 
3.1.3. ECD of mammalian GnRH 
The use of relative fragmentation intensities to determine 
gas-phase stability has been employed by many researchers. 
When examining small molecular systems insights obtained 
from collision or photo induced dissociation are used with 
electronic structure calculations, in order to confirm proposed  
ionic conformations [35,36]. Such approaches rely on accu-
rate knowledge of the process by which fragmentation pro-
ceeds. ECD is a relatively new technique, which has princi-
pally been applied to determination of primary structures of 
peptide and proteins [37,38]. Since the precise mechanism 
of the electron capture and subsequent dissociation process 
is not yet known, it is difficult to interpret results in terms of 
the secondary structures of the ions involved. However, we 
believe that this technique can provide information on gas 
phase conformations. Polfer [39] has obtained exceptionally 
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Fig. 3. Co-ordinate plots from molecular dynamics performed on Ciona I 
and CionalGly6. Shown here is the distance between the alpha carbons of 
residues 4 and 7 over the course of 1 ns of dynamics at 300 K. 
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Fig. 4. Relative intensities of ECD fragment ions for Cional, Cional DAM 
and Ciona I Gly6, each taken from spectra comprising 100 time-domain tran-
sients, with 50 ms electron irradiation. The relative intensities are calculated 
by dividing individual peak intensities by the surn of all the c fragments. 
Xxx represents A1a6, DAla6 or Gly6. 
on a series of GnRH variants. In addition Zuberev and co-
workers [40] present evidence for the structural selectivity of 
ECD by comparing spectra taken from a peptide with a single 
chiral substitution such as we consider here. 
For this study ECD was performed on each of the Cional 
peptides listed in Table 1. Each peptide yielded partial se- 
quence information from ions corresponding to 	type frag- 
ments, for 2 < n < 7. Relative fragmentation efficiencies ob-
tained from each peptide are shown in Fig. 4. For each of the 
fragments assigned to C3 and C4 ions we also observe ions 
at masses 1.017Da lower. These c odd electron ions (first 
reported by Zuberev et al. [41]) occur at intensities which are 
100% of the corresponding c ion. For this purpose of this 
study, c and c fragments have been summed (Fig. 4). The 
Cional peptides produced no z-type fragment ions, which 
implies that charge is retained on the N terminal section of 
the peptide, presumably due to the higher gas phase basicity 
of the His2 side chain than that of the C terminal amidated 
glycine. 
Each Cional variant presents a slightly different fragmen-
tation pattern. Error bars, which are not included on this Fig-
ure, are within the size of the dots. Both CionalDAla6 and 
Cional Gly6, have a lower fragmentation intensity for the C4 
channel, than that for Cional. This effect is reversed for the 
C6' channel. This is a significant result. Switching the chi-
rality of the alpha carbon at this residue from Ala --> DA1a 
and substitution of the achiral Gly residue yields an increased 
preference for this fragmentation channel. This strongly sug-
gests that there is a difference in the gas phase structures of 
these ions, and that the presence of glycine favours capture 
and cleavage at this position on the polypeptide backbone. 
A similar effect is seen for the production of the c7  frag-
ment. As might be expected from peptides where 9 out of 
10 amino acids are the same, there are also some compa- 
rable features. For example, the c2 and c5 product chan-
nels appearing at similarly low abundances for each GnRH 
variant. 
Quantitative analysis of this data with reference to gas 
phase conformation(s) of these peptides is not conclusive. If 
the ECD mechanism proceeds via electron capture at a pro-
ton which is hydrogen bonded to a backbone carbonyl, then 
it appears that the presence of LA1a reduces the formation 
of such a bond, although two out of the 10 low energy struc-
tures examined did show such a bond. Since there is still some 
fragmentation here for the Cional peptide, it may simply be 
that the opening of the peptide backbone lessens the likeli-
hood for hydrogen bond formation at this point. The use of 
force fields to provide gas phase structures is limited by the 
absence of a parameterised mobile proton. Our calculations 
have all employed the amidated N terminus as the second 
protonation site. This choice introduces some flexibility and 
as can be seen in Fig. 213—D, where the protonated amidated 
glycine forms hydrogen bonds to several backbone carbonyls. 
Whilst our ion mobility measurements support this structure, 
it is possible that on collisional activation (for example in 
the transfer hexapole of the FT-ICR) such a proton would be 
mobile prior to ECD. A proper comparison of ECD data to 
gas phase structures must consider this. 
3.1.4. Biological significance 
Many thousand synthetic analogues of GnRH have been 
made and so the significance of each amino acid in this pep-
tide towards binding at the receptors in the anterior pituitary 
has been well established in this intense research field [6]. 
What is clear from earlier work is that the presence of a chi-
ral amino acid at residue 6 significantly reduces binding at 
the mammalian GnRH I receptor [6,42]. This is presumed 
to be due to the inability of peptides to form the tight type 
jjl 	turn which preconfigures the ligand prior to receptor 
binding and activation. The structures shown in Fig. I  and 
C taken in parallel with the ion mobility results illustrate 
that the Cional peptide has a looser conformation than the 
DAla6 or Gly6 structural variants. Some low energy struc-
tures for both the mammalian GnRH and the DAla6 and 
Gly6 Cional peptides do exhibit such a turn at or around 
residue 6. Data obtained from the [M+ 2H]21  ions is less rel-
evant here, since the C terminal glycine is probably not pro-
tonated in vivo, however our preliminary ECD results also 
imply a different gas phase conformation for these peptide 
ions, which also reflects the influence that single amino acid 
changes can have on structure. The binding affinity of the 
Cional peptides will be the subject of a future communication 
[43]. 
3.2. 3-Defensins 
3.2.1. High resolution mass spectrometry of defensins 
The sequences of the two defensins examined here are 
below. They differ by just one amino acid, the substitution of 
Tyr --> Cys forming Defrl-Y5C which contains six cysteines, 
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Fig. 5. (A) High resolution mass spectrum of oxidized Defrl dimeric iso-
fonns. The triangles correspond to the isotopic envelope calculated from the 
Defrl amino acid sequence containing five disulfide bonds [46]. (B) Dc-
convoluted isotopic envelope from FT-ICR nanospray analysis of oxidized 
Defri Y5C. The triangles correspond to the isotopic envelope expected from 
a Defrl Y5C monomer with all cysteines oxidized, i.e containing three disul-
fides. (C) Equivalent spectra for the dimeric form of Defrl Y5C, here the 
triangles represent the isotopic envelope expected from a dimer with all 
cysteines oxidized, i.e., six disulfide bonds [46]. 
from the five-cystine containing murine defensin Defrl. 
12 
	3 	 4 	56 
Defrl 	DPVT V IRNGGI C QYR C IGLRHKIGT C GSPFK CC K 
Defrl Y5C DPVTCIRNGGICQYRCIGLRHKIGTCGSPFKCCK 
Using FT-ICR mass spectrometry we have been able to 
unambiguously define the number of cross-linked cysteine 
residues in each peptide, by comparing the measured iso-
topic distribution to that expected for a fully or partially 
reduced species. Since it is possible to reduce cysteine in 
the electrospray process, accurate mass was performed on 
defrl pre-incubated with iodoacetamide. After this treatment, 
the deconvoluted signal seen from the Defrl dimer fits the 
isotopic abundances predicted from its primary sequence 
(Fig. 5A). In this spectrum the isotopic envelope matches 
extremely closely to that expected for fully oxidized Defrl, 
ruling out anomalous gain or loss of hydrogen's during the 
electrospray process, and supports the accurate mass assign-
ment we have made. Interestingly there was no peak corre-
sponding to the monomer of Derfi + idoacetamide (region  
not shown), suggesting that no monomer is present in so-
lution prior to mass spectrometric analysis. This strongly 
implies that DefrI exists as a dimer linked by an inter-
molecular disulfide bridge, and that if there is some par-
tially reduced defensin in solution it will be at cysteines 
which are not involved in the intermolecular disulphide 
bridge. In short this peptide is dimeric with five disulphide 
bridges. To further characterize this we employed dissocia-
tion techniques including reduction of disulphide by ECD 
to probe the stability of the defensin peptides in the gas 
phase. 
For Defrl Y5C the isotopic distribution obtained fits 
well to that predicted for a fully oxidized monomeric pep-
tide, so we can conclude that this peptide contains three in-
tramolecular disulphide bonds (Fig. 513). We also observed 
a Defrl Y5C dimer which appears to be composed of two 
non-covalently associated monomers, with all six disulphide 
bonds formed (Figs. 5C and 6B). Since this mass spec-
trum was acquired under denaturing acidic nano-spray con-
ditions, and in the harsh desolvation conditions of the Bruker 
Apex III source, we presume that Defrl Y5C must form a 
dimer due to favourable non-covalent interactions, which is 
the conclusion of others on observation of oligenneric pep-
tides via MS [44]. On lowering the concentration to 5 p.M 
we still observe the dimeric form of this peptide. This ten-
dency to aggregate is also bourn out by gel electrophore-
sis, which has also revealed a dimeric form of Defrl Y5C 
[25]. 
3.2.2. Determination of the structural core via CID and 
ECD 
CID of the Defrl dimer gives rise to b-type fragments from 
the N terminus up to the location of the first cysteine (b2-b10) 
and a y-type fragment resulting from the loss of the C-
terminal lysine, indicating a distinct structural core (Fig. 6A). 
Some very low intensity species are apparent with masses 
±32 arising from monomer units formed by cleavage of the 
C-S bond of the intermolecular cysteine bridge. The lack 
of any significant monomeric 'daughter' fragments, demon-
strates that the dimer is covalently bound. These findings 
are further supported by ECD where cleavage of Cys-Cys 
disulphide bridges is a favoured process [41]. Here this ap-
pears to occur preferentially at the intermolecular disulphide 
bridge leading directly to two monomers (Fig. 7). We can 
conclude from this, that the intermolecular bridge is accessi-
ble for cleavage, at least when this dimer exists as a gas phase 
ion. 
We also performed CID on the Defrl Y5C dimer and 
in contrast to Defri it readily dissociated into monomers 
(Fig. 613 and C), supporting the conclusion of the accurate 
mass work above that this is a non-covalently bound dimer. 
b2..4 fragment ions were observed, corresponding to loss of 
the shorter N terminal section of this peptide, but as for Defrl, 
the disulphide bridged core resisted collision induced disso-
ciation. 
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Fig. 6. (A) SORI-CID spectra of DefrI. Charge state +7 (mlz= 1081.401) was isolated and subjected to collisional activation with argon for 40 ms prior to 
detection. Fragments arising from activation are labeled. (B) Nanospray mass spectrum of Defrl Y5C taken in acidic conditions. The peak due to the +5 charge 
state of the non-covalently bound dimer occurring at rn/:= 1488.905 (monoisotopic mass) is indicated, as are the peaks arising from the monomer charge state 
series. (C) SORI-CID spectra of the Defrl Y5C dimer. The peak at 1488.905 was isolated and subjected to collisional activation. This dissociates readily into 
two monomeric halves with charge states +2 and +3 as indicated. 
3.2.3. Determination of disulphide connectivity's via 	 CID to dissociate the peptide. If sustained ECD alone is 
'top-down sequencing and peptide mass mapping used, it is possible to sequence almost the entire peptide 
A combination of two dissociation techniques were em- 	however connectivity information is not always forthcoming 
ployed to attempt to discern the disulphide bridging ofDefrl: [45]. The low energy nature of the ECD process employed 
ECD to cleave (selectively) the cysteine bridges and SORI- 	here, means that for low charge states, even on backbone 
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frl, here the [D]7 dimer ion (m/z= 108 1.401) was isolated and irradiated with electrons for 50 ms. The +7 ion underwent fragmentation 
i +2 monomers. Shown is an expansion of the +2 monomer ion series which results from both symmetric and asymmetric cleavage of the 
S bond. 
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Fig. 8. Strategy for assigning disulphide connectivity using ECD and SORI-CAD. 
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Fig. 9. ECD SORI-CID spectra of Defrl obtained according to the strategy shown in Fig. 4. Charge states z= 9 to :=4 of DefrI were irradiated with electrons 
for 50 ins. Then charge state 7 (1081.401 Da) was isolated and subjected to collisional activation with argon for 40 ms prior to detection. Fragments arising 
from activation are labeled. Peaks 1-3 correspond to internal fragment ions which are described in the text and in Table 2. 
cleavage, dissociation into measurable fragment ions does not 
occur, since non-covalent interactions preserve the gas-phase 
complex [45]. As stated above, with CID alone cleavage of 
disulphide bridges is unfavourable and N terminal sequenc-
ing to the first cystine only limits the analysis. The strategy 
which combines ECD and collisional activation is illustrated 
in Fig. 8. 
On isolating the dimeric ion at 1082.797 (z=7) and 
subjecting it to ECD followed by SORI-CID several frag-
mentation channels are apparent (Fig. 9). A series of y-type 
ions ensue from the loss of N terminal amino acids, which 
are accompanied by water loss peaks. A dominant channel 
is reduction of the dimer via cleavage of the intermolecular-
disulphide bridge, forming monomer ions as described above. 
Although this also proceeds via cleavage at the thiol ether 
bond, resulting in signature satellite peaks —32 Da and 
+33 Da around the dimer. This provides a useful diagnos-
tic of peaks which arise from the dissociation of the dimeric  
peptide or, of internal disulphide bridges. Table 2 illustrates 
some of the internal fragment ions which were observed. Iso-
lation and fragmentation of a dimeric ion gives rise to two 
strong y-type ions which correspond to the loss of CK+ S 
and to CCK from a monomer defensin mass. These peaks 
are not present if a monomer ion is isolated post ECD and 
subjected to CID. This indicates that they arise from ECD 
fragmentation of the dimer ion, into a monomer followed 
by CID possibly assisted by the location of the Lysine side 
chain, such that both CID and ECD are directed by the inter-
action of a protonated site with the peptide backbone [33,37]. 
The fact that we observe this loss of CK+ S only from the 
dimer, suggests that this arises from a metastable precursor 
which contains a cleaved thiol—ether bond, and indeed we see 
such ions (Figs. 7 and 9). The fact that this loss channel is 
opened to produce the b32 + S ion with greater intensity that 
the b32 - S ion indicates a greater stability for the monomer-S 
species and that is certainly what we see (Fig. 7). Subsequent 
Table 2 
Internal fragment ions arising from ECD followed by CID, the numbering scheme corresponds to peaks in Fig. 9 
Peak number 	ECD/CID fragment residue 	Disulphide bridge 	Satellite S 	Calculated mass 	Observed mass (Da) 
in Fig. 5 	 numbers 	 species (M+H) (Da) 
23-3 1' and/or 15-1831-34 	4-5 and/or 3-6 	Yes 	 892.44 	 892.49 
2 	 6-1223-31 and 14-2532-33 2-4 and/or 3-6 Yes 1637.80 819.9217 (2+) 
3 15-2033-34 	 3-6 	 No 	 791.41 	 791.4440 
a Unlikely to be this internal fragment due to the existence of the satellite S peaks which point to the inclusion of an additional cleaved Cys. 
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fragmentation gives the b31 ion shown by Fig. 5 to be a dom-
inant product. These findings suggest that the intermolecular 
disulphide bridge is formed between 5Cys-5Cys. This bond 
is cleaved in some cases asymmetrically which can lead to 
CID fragment ions which sequence from the C terminus. This 
process is also dependent on prior cleavage of an internal 
3Cys-6Cys bond. 
The peaks listed in Table 2 provide evidence for the ex-
istence of the internal disulphide bonds 2Cys-4Cys (peaks 
1 and 2) and of the internal 3Cys-6Cys bond (peak 3) 
where no evidence for asymmetric cleavage is found. El-
egant though this technique is, we cannot be certain that 
these are the only connectivities available. An alterna-
tive route was taken whereby the two defensins were 
subjected to proteolytic cleavage, and subsequent pep-
tide mass mapping and sequencing [25]. Data obtained 
from Defrl Y5C proved that this six cysteine contain-
ing peptide possesses typical 13-defensin S—S connectivity 
(Cysl—Cys5, Cys2—Cys4, Cys3—Cys6). In contrast on di-
gestion, oxidized Defrl yielded a complex mixture of pep-
tide products. Ions were obtained with masses correlating 
to Cys2—Cys3, Cys2—Cys4, Cys3—Cys4 and Cys4—Cys4 
disulfide bonds, several of which were confirmed by tan-
dem MS sequencing. In short, disulphide connectivity's 
present in Defrl are not soley typical of either ce or 13  
defensins. Cys2 in particular appears able to form S—S 
bonds with other cysteine than Cys4. Our conclusion is 
that Defrl presents a mixture of topologically different iso-
forms, rather than a single species with a defined connectiv-
ity.  
4. Conclusions 
The work presented here demonstrates the power of gas-
phase techniques in determining peptide structures. Several 
complimentary methodologies have been applied in order 
to probe conformational variations in two important peptide 
systems which arise from single amino acid changes in pri-
mary sequences. We have shown how structural variants of 
GnRH can be elucidated by both ion mobility mass spectrom-
etry and the use of ECD. Molecular modelling has generated 
structures with cross sections that correspond to those found 
experimentally. The presence of achiral glycine at residue 6 
enables the formation of a tighter structure which assists the 
binding affinity of this peptide to the mammalian GnRH I re-
ceptor. The fact that the gas phase structure can be related to 
a biologically active form is not entirely surprising, given the 
lower dielectric medium experienced by a ligand as it binds 
to a membrane bound protein. 
Employing the high resolution capabilities of FT-ICR we 
have determined the oxidation state of the covalently bound 
13-defensin dimer Defrl, and developed a strategy which com-
bines ECD and SORT-CAD to map out its disulphide bridg-
ing pattern. We have linked the oligomerisation state of a 
defensin with its antimicrobial activity and these findings 
imply that there is a critical concentration of this naturally 
occurring peptide that is necessary to kill bacteria, which 
is enhanced tenfold by the formation of an intra-molecular 
disulphide bridge. These findings which have been inspired 
by collaborations with bio-medical researchers illustrate the 
potential for solving real biological problems in the gas phase. 
3.2.4. Biological relevance 
The activity of these f3-defensins against Pseudomonas 
aeruginosa PAO 1 was assessed to determine their minimum 
inhibitory concentrations (MICs) [25]. The MICs were also 
determined in the presence of the reducing agent dithio-
threitol (DTT, 10mM). The results from our killing assays 
when taken in tandem with the MS data are remarkable. 
Defrl Y5C has identical activity in its oxidized and re-
duced states supporting the recent conclusions of Wu et al. 
[21] with HBD3 that disulfide-bonds are not required for 
13-defensin antimicrobial activity. However, Defrl is an or-
der of magnitude more active in its oxidized form. This 
demonstrates that this 10 cysteine containing interrnolecu-
lar, covalently-linked dimer is a significantly more potent 
form of this peptide. Defensins are found in high concentra-
tions at cell surfaces [18], and here we have demonstrated 
the activity of a preformed dimeric species. It is possible 
that this provides a more effective seed for the formation of 
higher order aggregates than a monomeric or even a reduced 
6 cysteine defensin. Alternatively the presence of the Un-
tethered N terminal section of Defrl may be assisting initial 
interactions with cell membranes. These observations have 
implications for the future design of novel anti-microbial 
agents. 
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1. Introduction 
Single-stranded DNA-binding (SSB) proteins 
have been shown to play an essential role in 
many aspects of DNA metabolism (Chase & 
Williams, 1986). They preferentially bind and 
protect vulnerable single-stranded DNA 
(ssDNA), which is formed transiently during 
DNA replication, recombination and repair. 
SSB proteins are characterized by the presence 
of a conserved OB-fold motif (oligonucleotide/ 
oligosaccharide/oligopeptide-binding 	fold), 
which is typically 100 amino acids in length 
(Murzin, 1993). 
SSB proteins can be divided into two distinct 
groups based on their quaternary structure. 
Eukaryotic SSB proteins, known as replication 
protein A (RPA), are exemplified by human 
RPA, which has a heterotrimeric structure 
comprising three subunits: RPA70. RPA32 and 
RPA14 (of molecular weights 70, 32 and 
14 kDa, respectively: Wold. 1997). The RPA 
complex contains six OB folds, four of which 
bind DNA: three on RPA70 and one on RPA32 
(Bastin-Shanower & Brill, 2001). An N-term-
inal domain on RPA70 has also been shown to 
be involved in protein—protein interactions 
(Jacobs et al., 1999). In contrast, bacterial SSB 
proteins form homotetramers, with each 
subunit containing one DNA-binding domain 
(Raghunathan et al., 1997). These DNA-
binding domains are located at the N-termini 
of the individual SSB protein subunits and  
form the characteristic OB folds. While the 
N-terminus of each subunit binds ssDNA and 
contains the homotetramer interface, it is 
thought that the C-terminal domain is involved 
in interactions with other protein components 
of DNA metabolism. The C-terminal domain 
of bacterial SSB proteins exhibits low sequence 
homology across species, with the exception of 
the terminal six residues, which form a highly 
conserved negatively charged DDDIPF motif. 
This motif is essential for the function of 
Escherichia coli SSB protein in vivo (Curth et 
al., 1996) and has been shown to interact 
directly with the 3-5' ssDNA-degrading 
exonuclease I (Genschel et al., 2000). The tails 
of both the E. coli and the Sulfolobus solfa-
taricus SSB proteins are not involved in DNA 
binding, but are thought to play roles in 
mediating protein—protein interactions with 
other subunits within the DNA polymerase 
complex (Bruck et al.. 2002). There is also 
evidence that a mutually exclusive interaction 
between the C-terminal domain of E. coli SSB 
protein, DNA polymerase and primase is 
utilized as a three-point switch to initiate the 
exchange of places of these two proteins on 
DNA (Yuzhakov et al., 1999). Furthermore, a 
recent report suggests that the interaction 
between the DNA polymerase and SSB from 
RB69 (a T4-like bacteriophage) results in an 
increase in the overall affinity of the SSB 
protein for ssDNA (Sun & Shamoo, 2003). 
Finally, Gulbis and coworkers have recently 
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proposed a positively charged patch on the x 
subunit of Pol III holoenzyme which may 
interact with the C-terminal acidic region of 
SSB (Gulbis et al., 2004). 
The DNA-binding domains and OB folds 
from SSB proteins have been well studied 
and structural information is available from 
a variety of organisms spanning all three 
kingdoms of life (Bochkareva et al., 2001; 
Bochkarev et al., 1997, 1999; Webster et al., 
1997; Raghunathan et al., 2000; Yang et al., 
1997; Kerr et al., 2003). However, crystal-
lization of a full-length bacterial protein has 
proved problematic and most studies have 
used proteolytic N-terminal fragments of 
SSB proteins; consequently, little is known 
about the structure of its C-terminal domain. 
Efforts to crystallize the intact E. coli SSB 
tetramer resulted in autolysis during crys-
tallization and the structure determination 
omitted 30 amino acids from the C-terminus 
(Matsumoto et al., 2000). It has been postu-
lated that the C-terminal domain of the 
E. co/i SSB is cleaved to decrease unfa-
vourable interactions for crystallization 
which result from its high glutamine content. 
The most recent crystallographic study by 
Kerr and coworkers presents a 1.2 A struc-
ture of a trypsin-cleaved fragment of the 
SSB from the crenarcheote S. so/fararicus, 
missing some 28 amino-acid residues from 
the C-terminal tail (Fig. 1). 
Extensive investigations of the binding 
mode for ssDNA to SSB have revealed a 
complex series of protein—protein and 
protein—DNA interactions (Lohman & 
Ferrari, 1994; Raghunathan et al., 2000). 
Different binding modes [referred to as 
(SSB)35 and (SSB)55] and cooperativities 
have been observed that are dependent 
upon oligonucelotide length, salt and 
protein concentration. For example, E. co/i 
(SSB)35 binds about 35 nucleotides and in 
this case only two of the four subunits in the 
tetramer bind to the DNA. In contrast, in 
the (SSB)65 binding mode all four subunits 
of the tetramer are involved in DNA 
binding, although it appears that there is a 
'limited' type of intertetramer cooperativity. 
Thus, using dT(pT)59 various combinations 
with ratios of one SSB subunit binding 
to one or two DNA oligomers or two 
SSB subunits to one DNA are possible 
depending on the conditions. However, the 
use of a high (>0.2 M NaCI) salt concentra-
tion appears to favour formation of one SSB 
tetramer binding to one dT(pT)69. 
To investigate the structure of a full-
length SSB. we report here the cloning, 
overexpression, crystallization and initial 
data collection for crystals of the SSB 
protein (147 amino acids; Mr 17 131.20; 
Fig. 1) from the hyperthermophilic 
bacterium A. aeo!icus (SSB Aae) in both the 
free and the DNA-bound forms. In contrast 
to E. co/i SSB, primary structure analysis of 
the SSB Aae reveals a polyglutamic acid 
region at its C-terminus and a EDEIPF 
motif (Fig. 1). We hope that the crystal 
structure of the A. aeo!icus SSB protein will 
facilitate the study of the complex protein—
protein interactions mediated through the 
C-terminus of bacterial SSB proteins and the 
data may also reveal the structural basis for 
the increased stability of this SSB at 
elevated temperatures. Further, the DNA-
bound structure may reveal details of the 
(SSB)6.5 binding mode. 
2. Cloning, expression and purification 
The ssb gene was identified from the 
complete A. aeo!icus genome sequence 
(Deckert et a/., 1998), amplified by poly-
merase chain reaction and the resulting 
451 bp fragment was subsequently inserted 
into the pET-23a expression vector 
(Novagen) using NdeI/HindIII restriction 
sites. The fidelity of the construct, pET23a/ 
ssb, was verified by DNA sequencing before 
transformation of E. co/i BL2I(DE3)/pLysS 
(Novagen). Cells were grown in 2YT growth 
media supplemented with ampicillin 
(100 pg ml-1) in shake flasks at 310 K and 
250 rev min' to OD 0 = 0.8 prior to 
induction with 1.0 mM isopropyl-1-thio--o-
galactopyranoside (IPTG). After a further 
4 h of growth, cells were collected by 
centrifugation and stored at 253 K. 
The cell pellet was resuspended in 10 ml 
buffer A (50 mM Tris—HCI pH 7.0) per gram  
of cell paste, disrupted by sonication 
(15 pulses of 30 s at 30 s intervals) at 277 K 
and the cell lysate was centrifuged (30 mm, 
35 000g). The supernatant was filtered 
(0.45 sM) before being applied to a 26/10 
Q-Sepharose anion-exchange column 
(Amersham Biosciences) and eluted with a 
linear NaCl gradient (0-1.0 M) in the same 
buffer. SDS—PAGE analysis revealed that 
SSB eluted between 460 and 510 mM NaCl. 
It is interesting to note that the protein 
migrates with an apparent weight of 23 kDa 
on SDS—PAGE compared with its theor-
etical weight of 17.1 kDa, an anomaly which 
could be a consequence of the high number 
of acidic residues in the C-terminus, also 
observed by Bruck et al. (2002) (Fig. 1 and 
inset in Fig. 2). Fractions containing SSB 
were pooled and concentrated to 5 ml by 
ultrafiltration (Vivaspin) using a 10 kDa 
cutoff membrane (Vivascience). 
The concentrated sample was further 
purified by size-exclusion chromatography 
using a previously calibrated Hiload 26/60 
Superdex 200 column (Amersham Bio-
sciences) equilibrated and eluted in buffer C 
(50 mM Tris—HCI, 100 mM NaCl pH 7.0). 
The SSB protein had a retention time similar 
to that of bovine serum albumin (66 kDa), 
suggesting that the 17.1 kDa protein forms a 
stable homotetramer in solution: a property 
characteristic of bacterial SSB proteins. The 
purity of the SSB protein preparation was 
judged to be >98% by SDS—PAGE and this 
optimized protocol consistently yielded 10-
15 mg of purified protein per litre of cell 
culture. The purified protein was a single 
species of 17 131.0 ± 1.50 Da by ESI mass 
spectrometry, which is in agreement with the 
SSB As. 	(1) --- MLNKVFIIGRLTGDPVITYLPSGTPVVEFTLAYNRRYKNQN-GEFQE (46) 
SSB Eco (1) ASRGVNKVILVGNLGQDPEVRYMPNGGAVANITLATSESWRDKATGEMKE (50) 
SSB Sao 	(1) - - - - t4EEKVGNLKPNMESVNVTVRVLEASEARQIQTKNGVRTISEAIVGD (46) 
SSB Aae 	(47) ESHFFDVKAYGKMAEDWATRFSKGYLVLVEGRLSQEKWEKEGKKFSKVRI (96) 
SSB Eco (51) QTEWHRVVLFGKLAEVASEYLRKGSQVYIEGQLRTRKWTDQSGQDRYTTE (100) 
SSB Sao 	(47) ETGRVKLTLWGKHAGSIKE ---- GQVVKIENAWTTAFKGQVQLNAGSKTK (92) 
SSB Aae 	(97) IAENVR--------------------LINRPKGAELQAEEEEEVPP-IEE (125) 
SSB Eco (101) VWNVGGTMQMLGGRQGGGAPAGGNIGGGQPQGGWGQPQQPQGGNQ-FSG (149) 
SSB Sao 	(93) IAEASEDGFP-----E----------SSQIPENTPTAPQQMRGGGRGFRG (127) 
* 	 $ 	# + 
SSB As. (126) EIEKLGKE------EEKPFTDEEDEIPF 	(147) 
SSB Eco (150) GAQSRPQQSAPAPSNEPPMDFDDDIPF (177) 
SSB Sso (128) GGRRYGRRGG ---- RRQENEEGEEE--- 	(148) 
Figure 1 
Sequence alignment of the SSB proteins from A. aeolicus (SSB Aac), E. co/i (SSB Eco) and S. so/fataricus (SSB 
Sso). The asterix (5)  under residue L112 of E. co/i SSB (SSB Eco) denotes the limit of the resolution of 
chymotryptic fragment (SSBc. residues 1-135, represented by a $ sign under W135) used to determine the 
structure of the native and DNA-bound SSB complex described by Raghunathan etal. (1997. 2000) (PBD codes 
ikaw and Icyg, respectively). The hash symbol (a) under residue RI 19 indicates the C-terminus of the tryptic 
fragment ofS. solfataricus SSB (SSB Sso) crystallized by Kerr et at (2003) (residues 1-119: PBD code lo7i). The 
addition sign (*) under N145 of SSB Eco denotes the limit of structure determination from the autolytic fragment 
crystallized by Matsumoto etal. (2000) (residues 1-145; PBD code lqvc). Notice the glutamate-rich C-terminus of 
SSB Aae in comparison to the glutamine-rich tail of SSB Eco. 
2010 	Clarke etal. 	Single-stranded DNA-binding protein 	 Ada Cryst. (2004). D60, 2009-2012 
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theoretical weight of full-length A. aeolicus 
SSB protein (17 131.2 Da). 
Crystallization 
Initial crystals were obtained using Mole-
cular Dimensions Structure Screens 1 and 2 
and the sitting-drop vapour-diffusion 
method at 290 K. The drop consisted of 5 j.tl 
protein solution (7 mg m1' in buffer C) and 
5 .tl precipitant. Over two weeks, small 
crystals of native protein were observed 
under three different conditions, with the 
best quality obtained using 100 mM HEPES 
pH 7.5, 2%(v/v) PEG 400, 2.0 M (NH4)2SO4 
pH 7.5 as the precipitant. After refining the 
crystallization conditions, larger crystals 
were obtained after four weeks using the 
same precipitant at a pH of 7.0. Co-crystal-
lization of the DNA-bound protein was 
achieved by mixing 7.5 mg ml protein in a 
1:1 molar ratio (tetramer:5sDNA) with 
69-mer dT(pT)68 (MWG Biotech). The 
complex was incubated on ice for 60 min and 
centrifuged (10 mm, 35 000g) prior to crys-
tallizations being set up. Each crystallization 
drop comprised 1.5 .tI protein in 50 mM Tris 
pH 7.0, 0.1 M NaCl and 1.5 hI precipitant. 
All were set up at 290 K. Crystals grew 
within one week; the best quality crystals 
were obtained using 100mM HEPES pH 
7.5, 2.3 M (NH4)2SO4. 
Data collection and processing 
MOLREP (Vagin & Teplyakov, 1997). The 
search molecule was trimmed of its flexible 
loops and amino-acid side chains to produce 
a tetrameric polyalanine structure. The top 
rotation-function solution produced a satis-
factory translation-function solution that 
was then used to aid location of the second 
tetramer. No solution was obtained using 
the S. solfataricus structure as a search 
model. For the DNA-bound SSB, a multi-
copy search with MOLREP using the 
partially refined SSB Aae dimer (R = 0.272, 
Rir 	= 0.308) provided solutions, the best of 
which contained two dimers per asymmetric 
Table 1 
Data-collection and reduction statistics. 
Values in parentheses are for the highest resolution shell. 
Data collection Home source 
Oscillation range ( ) IsO x I 
Space group P2 
Unit-cell parameters 
a (A) 80.97 
6 (A) 73.40 
(A) 109.76 
/1(A) 95.11 
lètramers per AU 2 
VM (A1 Da) 2.37 
Resolution limits 70-2.92 (3.08-2.92) 
No. observations 100835 (12811) 
No. unique reflections 27790 (3680) 
I/a(I) 9.2 (3.5) 
Completeness (%) 98.9 (98.9) 
11.057 (11.212) 
MOLREP R factor 0.567 
MOLREP correlation coefficient 0.359 
Restrained refinement R factor 0.425 
Restrained refinement R, 0.487 
unit in each of the three space groups. 20 
cycles of rigid-body refinement were 
followed by ten cycles of restrained refine-
ment. The statistics for this process are also 
shown in Table 1. Refinement of both crystal 
forms is currently in progress while attempts 
are being made to improve the diffraction 
quality of the crystals. 
To ensure that no autolysis of the protein 
had occurred, a single crystal of DNA-bound 
SSB was dissolved in 10 mM HEPES pH 8.1 
and analysed by SDS-PAGE and ESI-MS, 
which revealed no significant degradation of 
the protein. SDS-PAGE analysis produced a 
SRS Dareshury 
120 x I 





I I I 
l.86t lOt 1.876 
78.28-2.80 (2.95-2.80) 79.06-2.80 (2.95-2.80) 
79739 (676) 79012 (11550) 
15953 (2324) 164112 (2368) 
7.5 (1.4) 7.9(l.4) 
99.9 (99.9) 99.7 (99,7) 
0.056 (0.525) 11.053 (0.541) 
0.560 0.520 0.517 
0.316 0.471 0.471 
0.401 0.396 0400 
0.507 0.471 0.488 
Protein 	 Native 	 DNA-bound 
Crystals of native protein of approximate 
dimensions 0.1 x 0.2 x 0.2 mm were flash-
cooled in a 20% glycerol well solution and 
X-ray data for the native SSB were collected 
at 100 K (Cryostream cooler; Oxford Cryo-
systems, Oxford, England) on a MAR 
Research 345 imaging plate mounted on 
an Enraf-Nonius FR591 rotating-anode 
generator, A = 1.5418 A, fitted with Osmic 
mirrors and operating at 40 kV, 110 mA. 
Crystals of similar dimensions were obtained 
for the DNA-bound form and data were also 
collected at 100 K on station 14.2 (A = 
0.978 A) at the SRS, CLRC Daresbury 
Laboratory. Analysis of the diffraction data 
for both crystals using MOSFLMISCALA 
(Leslie, 1992; Collaborative Computational 
Project Number 4, 1994) produced the data 
shown in Table 1 and allowed the assignment 
of the native crystals to space group P21 . For 
the DNA-bound data, similar processing 
statistics were obtained with space groups 
1222, 1212121 and 141. 
For the native SSB data set, a model of 
the SSB from Escherichia co/i (PDB code 
lqvc; Matsumoto et al., 2000) was used to 
search for an initial solution using 
16700 1690(1 16900 17000 17100 172110 17300 17400 17 500 17600 17700 17800 17 900 18000 (,,,Ir) 
Figure 2 
Analysis of the crystallized DNA-bound SSB protein by ESI-MS. The main figure shows the dcconvoluled mass 
of 17 127.3 (obtained using Transform software; Micromass UK), consistent with the theoretical value of 
17131.2; right inset, ion envelope of crystallized SSB protein; left inset. SDS-PAGE analysis of crystallized SSB 
protein results in a single band running at an anomalous weight of -23 kDa. 
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single band around 23 kDa in keeping with 
the observed anomalous mobility of the 
native SSB. Only one major species was 
observed by ESI-MS with a mass of 17 127.3 
± 2.7 (Fig. 2), in good agreement with the 
predicted weight. No LCMS data could be 
obtained from the dissolved native SSB 
crystal. 
5. Discussion 
It is clear from the sequence alignment of 
the SSB proteins that the A. aeolicus and the 
E. CO/i proteins are more closely related to 
each other than either is to S. so/ftuaricus 
SSB (Fig. 1). This is borne out by the fact 
that a molecular-replacement solution using 
the E. co/i structure was obtained relatively 
easily, whilst no satisfactory solution could 
be obtained with the S. solfataricus struc-
ture. The very high resolution of S. solfa-
taricus SSB reveals why this should be so in 
that the actual molecular structure is much 
more closely related to the eukaryotic SSB 
fold than that of E. co/i SSB (Kerr et al., 
2003). Consequently, despite a modest 
sequence identity, the Structures are distinct. 
For the DNA-bound crystals reported 
here, there is an ambiguity as regards the 
space group. Given an SSB tetramer in the 
asymmetric unit, using the monomer Mr of 
17 100 and that of the DNA as 20 927, the 
VM can be calculated to be 2.43, 2.11, 1.86 or 
1.51 A3 Da' for zero, 0.5, one or two bound 
DNA 69-mers per tetramer. The expected 
1:1 complex requiring one DNA oligomer 
per asymmetric unit corresponds to a VM of 
1.86 A3 Da 1 , which is within the range 
found by Matthews (1968), albeit quite close 
to the lower limit. The physiological 
tetramer as observed in the native structure 
sits on a crystallographic dyad in both 141  
and 1222, whereas the tetramer sits on a 
screw dyad axis in 1222. It is impossible for 
there to be exact twofold symmetry for the 
SSB tetramer with a single DNA oligomer 
bound, although a pseudo-twofold arrange-
ment is possible. Given the limited resolu-
tion of the present X-ray data and the 
current state of the refinement, such a 
situation cannot yet be ruled out. However, 
if the DNA oligomer is shared between two 
tetramers in some fashion, this could permit  
the DNA-bound tetramer to lie upon a 
crystallographic dyad, while maintaining 
four subunits and a single DNA molecule in 
the asymmetric unit (Ferrari et al., 1994). 
The initial electron-density maps in each of 
the three space groups all show extra elec-
tron density near regions of the protein 
expected to bind DNA (Raghunathan etal., 
2000). Examination of the maps together 
with the statistics shown in Table 1 leads us 
to prefer 1222 as the space group, but we are 
continuing to refine all three possibilities. 
These refinements should clarify this uncer-
tainty and also allow us to estimate the 
occupancy of the DNA. 
In summary, our expression and purifica-
tion strategy has produced full-length SSB 
from the hyperthermophile A. aeolicus with 
no autolysis observed by mass spectrometry 
and SDS-PAGE. The flexible C-terminal tail 
is present in the crystals reported here, 
unlike the truncated SSB used in both the 
E. co/i and S. solfataricus structure deter-
minations. Our initial refinement of the 
structures of both forms has allowed the 
clear assignment of the electron density to 
residues 1-38 and 41-108 and we are 
currently refining the models in an effort to 
distinguish the C-terminal residues. 
Note added in proof: During the proces-
sing of this manuscript a report has been 
published describing the crystallization of 
full-length E. cot! SSB (Savvides etal., 2004). 
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